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Abstract
Background
Pulmonary arterial hypertension (PAH) is a rare, progressive fatal disease 
characterised hy persistent vasoconstriction and vascular remodelling of the small 
pulmonary arteries. 1) The endogenous peptide human urotensin II (hU-II) has 
recently been found to be a potent vasoconstrictor of the rat main pulmonary artery 
and the response was reported to be augmented in the clnonically hypoxic rat 
model of PAH. 2) Increased basal Ca^ "^  sensitivity and enhanced contractile 
responses to 5-HT, have been reported to be augmented in the chronically hypoxic 
rat model of PAH. Additionally expression of the 5-HT transporter, 5-HTT, has 
been reported to be enhanced following exposure to clironic hypoxia and its over­
expression linked to PAH. These reports are controversial.
Aims
1) To profile the vasoconstrictor and vasodilator responses to hU-II along the 
C57BL/6xCBA mouse and Wistar rat pulmonaiy arterial trees (extra/intra-lobar) 
and determine if the contractile activity of hU-II is augmented in rodent models of 
PAH. 2) To determine if basal Ca^ "^  sensitivity in the Wistar rat small pulmonary 
artery is augmented following exposure to chronic hypoxia. 3) To determine the 
influence of 5-HT and 5-HTT over-expression on Ca^  ^sensitivity in Wistar rat, and 
C57BL/6xCBA mouse, small pulmonary arteries respectively.
Results
hU-II caused a potent but low efficacy contractile response in Wistar rat extra-lobar 
(Main pulmonary artery: pECso; 8.64 ± 0.17, Emax: 19 ± 4% of the response to 
50mM KCl 11=9, 1®‘ branch: pECso; 8.57 ± 0.16, Emax: 9 ± 2%, n=13) and
generation intra-lobar (pECso 8.54 ± 0.19, Emax: 13 ± 3%, n=14) vessels but had 
essentially no action on the smaller pulmonary arteries. hU-II failed to dilate any 
pre-constricted rat vessel tested and the contractile responses to hU-II were not 
augmented in rat models of PAH. Furthermore, hU-II had no effect on any mouse 
pulmonary vessel tested. 2) Basal sensitivity in j3-escin pemieabilised, Wistar 
rat small pulmonary arteries was found to be slightly attenuated (pECso: Control; 
6.33 ± 0.02 vs CH; 6.24 ± 0.02, n=10-ll) following exposure to 2weeks chionic 
hypoxia, consistent with a decrease in Rho Kinase activity/Rho A expression. 
Neither 5-HT, nor 5-HTT over-expression augmented Ca^ "^  sensitivity.
Conclusion
hU-II can increase pulmonary vascular tone in the normal Wistar rat but the data 
was not consistent with a role in the pathogenesis of PAH in rodents. Altered Ca^ "^  
sensitivity was not found to be responsible for the persistent elevated basal tone of 
the chronically hypoxic rat model of PAH. Furthermore 5-HT and 5-HTT over­
expression did not exert their effects on vasomotor tone through altered Ca^  ^
sensitivity.
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Chapter 1
General Introduction
The Pulmonary Circulation in Health and
Disease
1.1 The pulmonary circulation
All but the simplest multi-cellular animals require a mechanism to distribute oxygen, 
nutrients and hormones to the respiring tissues and to collect from them the products of 
metabolism. In vertebrates, this task is the responsibility o f the cardiovascular system. 
The cardiovascular system comprises a muscular pump, the heart, and two continuous 
systems o f tubular vessels, the systemic and pulmonary circulations (Bloom and Fawcett, 
1975). Whilst the primary job o f the systemic circulation is one o f delivery and removal 
of the blood to and from the respiring tissues, the primary job o f the pulmonary 
circulation is recycling, thus ensuring the correct composition o f the blood being 
delivered (Fig 1.1).
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Figure 1.1 Graphic depiction of the relationship between the pulmonary and systemic 
circulations (Adapted from Berne and Levy, 1998)
Single numbers represent mean vascular and cardiac blood pressures (mmHg). Dual numbers 
represent systolic/diastolic pressures (mmHg). Oxygen (O2 ), carbon dioxide (CO2 ).
1.1.1 structural overview of the pulmonary circulation
The pulmonary circulation encompasses those vessels that conduct blood from the right 
side of the heart through the lungs, which are the site of gaseous exchange and then return 
it to the left side of the heart in readiness for delivery to the systemic tissues. It begins 
with the main pulmonary artery, which bifurcates before entering the left and right lungs. 
Upon entry into the lungs the pulmonary arteries align themselves adjacent to the airways 
forming bronchio-vascular bundles, which begin to branch repeatedly creating some 15 
orders of pulmonary arteries before ultimately forming vast sheet like, interdigitating 
networks of capillary beds which are the site of gaseous exchange. The capillaries then 
unite to form the venules and then the veins, which eventually leave the lungs via four 
pulmonary veins, which empty into the left atrium (Berne and Levy, 1998;Mandegar et 
al, 2004).
1.1.1.1 Vessel structure
The structural components of the arteries, capillaries and veins, which make up the 
pulmonary circulation, are no different to those of the systemic circulation. However in 
keeping with a low-pressure system the pulmonary arteries have much thinner walls. 
Adjacent to the vessel lumen, the pulmonaiy arteries are lined by a single layer of 
endothelial cells which, are backed by a thin basement membrane. The endothelium is 
known as the tunica intima and structurally is the same as in systemic arteries. The next 
layer, is the smooth muscle layer or tunica media, which is bounded by the internal and 
external elastic laminae. In nonnal pulmonary arteries the media is substantially thinner 
than in corresponding systemic arteries, in keeping with a low pressure system. The outer 
coat, the tunica externa (adventitia), is composed principally of fibroblasts and elastic and 
collagen fibres and is also less thickly developed than in the systemic arteries (Tortora, 
1995) (Fig 1.2).
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Figure 1.2 The structural components a pulmonary artery
(Reproduœd from Tortora, 1995)
The large conducting arteries o f  the pulmonary system are elastic in nature with well- 
developed internal and external elastic laminae, which define the borders o f the medial 
smooth muscle layer. Structurally they are similar to systemic conducting arteries but 
have a less distinct medial smooth muscle layer. Distal to the respiratory bronchioles 
however, the smooth muscle layer becomes markedly reduced and unlike the noticeably 
muscular pre-capillary arteries o f the systemic circulation, the pulmonary pre-capillary 
arteries are only partially muscularised or may lack smooth muscle altogether (Meyrick 
& Reid, 1983).
1.1.2 Physiology of the pulmonary circulation
The primary role of the pulmonary circulation is one of gaseous exchange and because of 
this, the lungs constitute the only organ in the body that receives the entire cardiac output 
at all times, following birth. As gaseous exchange is the result of diffusion, the tissues 
that make up the blood gas interface are required to be very thin and in close opposition. 
In accordance, the pulmonary circulation is therefore nonnally a high-flow, low-pressure 
system. Pulmonary arterial pressure (PAP) is the product of cardiac output (CO) and 
pulmonary vascular resistance (PVR) (Eq 1). As cardiac output can vary up to five-fold 
depending on the metabolic requirements of the body, the key to maintaining high flow 
without a concomitant increase in pressure is maintaining a low PVR (West, 1995).
Eq 1 PAP = CO X PVR
Equation 1) The determinants of pulmonary arterial pressure
PAP = pulmonary arterial pressure, CO = cardiac output, PVR = total pulmonary vascular 
resistance.
As shown in equation 2, resistance is inversely proportional to radius to the power of 4. 
The internal radius of a vessel is therefore the prime determinant of resistance.
E q2 PVR=8Lri
Equation 2) The determinants of pulmonary vascular resistance
PVR = pulmonary vascular resistance, L = vessel length, r\ = viscosity of the blood, r = internal 
radius of the vessel. NB) This equation assumes blood to be a Newtonian fluid. Whilst this is a 
simplification of the true fluid mechanics of blood, the equation remains an adequate descriptor of 
the relative importance of the components which determine resistance to flow.
The conducting arteries of the pulmonary circulation are highly compliant and have a 
large internal diameter confemng them with low resistance. However, as the vessels 
repeatedly branch in order to supply the various regions of the lung with blood, the 
diameter of the arteries decreases exponentially with each succeeding order of branching. 
Given this, one may expect resistance to increase dramatically. However the reduction in 
internal diameter is more than offset by the overall increase in cross-sectional area as the 
number of arteries (resistors) in parallel increases exponentially. This is further aided by 
the low basal tone of the vessels, which maximises the internal diameter. As a 
consequence, in the normal pulmonary circulation PVR is -1/10^^ that of the systemic 
circulation (Mandegar et a l, 2004).
1.1.3 Regulation of pulmonary blood flow
1.1.3.1 Passive regulation of puimonary blood fiow
Regulation of the pulmonary vasculature involves both passive and active control (Daly 
and Hebb, 1966). The main passive factors are those, which change resistance and/or 
flow independently of changes in vascular tone and include cardiac output, gravity, 
distension and recruitment. As cardiac output is primarily determined by systemic 
demand the following discussion will focus on the effects of gravity, distension and 
recruitment, however, it should be recognised that passive regulation is the integration of 
all of the aforementioned factors.
Because the lungs are located both above and below the point at which blood leaves the 
heart, the effects of gravity create a differential hydrostatic pressure which in turn causes 
an uneven distribution of blood flow. The hmg can thus be divided into 3 zones.
Zone 1 : At the very apex of the lung, alveolar pressure may exceed PAP causing the 
capillaries to collapse thus occluding the vessel lumen and increasing resistance; no flow
occurs. This generally only occurs during haemorrhage, as PAP is usually just sufficient 
to maintain some flow to the top of the lung.
Zone 2: Alveolar pressure has not changed, but PAP now exceeds it, as the blood has less 
vertical distance to overcome. However alveolar pressure may still exceed venous 
pressure (e.g. upon exhalation) so flow is deteimined by the difference between arterial 
and alveolar pressures. The vessels act as starling resistors and in times of increased 
flow, previously closed vessels are recruited. The greater the number of resistors in 
parallel, the smaller the resistance to flow. Hence recruitment of these vessels allows the 
pulmonary circulation to increase flow with little or no increase in PVR. Similarly, 
distension of already patent vessels increases their internal radii thus further lowering 
resistance to flow. This zone comprises the middle and upper regions of the lungs.
Zone 5: At or near the basilar area of the lungs, PAP exceeds pulmonary venous pressure, 
which constantly exceeds alveolar pressure. Flow is now continuously driven by the 
arterial venous pressure gradient (West, 1995).
Distension and recruitment are so effective at decreasing PVR that even a five-fold 
increase in CO causes only a trivial change in PAP so long as a low basal tone is 
maintained.
1.1.3.2 Active regulation of pulmonary blood flow
Active factors are those which change resistance and/or flow by altering vascular tone 
through contraction or relaxation of the vascular smooth muscle which makes up the 
medial layer of the vessel wall. Active regulation of flow can to some extent be achieved 
by changing compliance of the large conduit vessels. However, by far the more 
important mechanism is the active regulation of the small pre-capillary arteries. Active 
regulation is therefore the sum of the influences of 1) the autonomic nervous system, 2) 
humoral agents, 3) respiratory gas concentrations and 4) the endothelium (which may
- V : .
influence tone directly or indirectly by modifying the input of the other active factors)
(Barnes & Liu, 1995).
Autonomic control
The influence of the autonomic nervous system on pulmonary vascular physiology is not
:îwell understood. Although the pulmonary vascular bed is innervated by both sympathetic %
(adrenergic) and parasympathetic (cholinergic) neiwes (Fishman and Hecht, 1969), the 
distribution of innervation between species and between vessels of different orders of 
branching is extremely varied (Barnes and Liu, 1995).
Adrenergic control; Generally speaking the extra pulmonary arteries and veins of 
mammals show a dense network of adrenergic fibres which can elicit both a  
adrenoceptor (primarily a i) mediated vasoconstriction and p adrenoceptor (primarily P2) 
mediated vasodilatation in response to circulating catecholamines and neurally released 
norepinephrine (Ingram et al., 1968;Ingram, Jr. et al., 1970;Kadowitz et al, 
1973;Kadowitz & Hyman, 1973;Boe & Simonsson, 1980;Hyman et a l, 1981;Hyman et 
a l, 1986;Docherty, 1988;Hyman et a l, 1990;Hussain & Marshall, 1997). However 
intrapulmonary sympathetic innervation is highly variable, being almost absent in the rat 
and mouse but fairly intensive in man (Cech, 1969;Kai, 1969;Bradley et a l, 1970;Neild 
et a l, 1986). Overall, sympathetic nerve stimulation seems to cause an increase in PVR 
and a decrease in compliance resulting in an increased PAP. It is thought that 
sympathetic output may create a small degree of basal tone under normal physiological 
conditions, (Pace, 1971;Piene, 1976;Nishiwaki et a l, 1993), although this is far lower 
than in the systemic circulation because vasodilators usually have little or no effect on 
PAP in patients with normal lung function (Barnes & Liu, 1995).
Cholinergic control'. Cholinergic innervation of the pulmonary vasculature is also highly 
species and regionally specific but in general seems to be less dense than adrenergic
innervation. In the rat and mouse, cholinergic innervation is limited to the extra- 
pulmonary vessels and in humans it is thought to be entirely absent (Cech, 1973;Bradley 
et a l, 1970;Partanen et a l, 1982). Cholinergic nerves do not seem to be important in the 
maintenance of low basal tone, because even where present their blockade does not result 
in increased PAP (Murray et a l, 1986). However the pulmonary vasculature of many 
mammals including the mouse, rat and humans is responsive to acetylcholine (Ach). The 
response to Ach in mammals can depend on the level of pre-existing tone; 
vasoconstriction occurring if no tone was previously present and vasodilatation if pre­
existing tone was present (Boe et a l, 1980;Fritts, Jr. et a l, 1958;McLean, 1986;Cherry & 
Gillis, 1987;Hyman & Kadowitz, 1988;Hyman & Kadowitz, 1989). Responses to 
exogenous or vagally released Ach are mediated through muscarinic receptors located 
both on the smooth muscle and on endothelial cells, although the subtypes are still 
unclear. Those mediating dilatation seem to be located on the endothelial cells whilst 
those mediating vasoconstriction are located on the smooth muscle cells (SMCs) 
(Greenberg et a l, 1987;Norel et a l, 1996;McMahon et a l, 1992). This knowledge is 
utilised by investigators to confirm the presence of a functional endothelium in isolated 
vessel preparations (i.e. pre-constricted vessels with a functional endothelium relax to 
Ach).
Nonadrenergic, noncholinergic (NANC) control’, In addition to classical adrenergic and 
cholinergic innervation there also exist neural control mechanisms that are not inliibited 
by adrenergic or cholinergic blockade. These are known as nonadrenergic,
noncholinergic (NANC) nerves (Bames et a l, 1991;Bames & Liu, 1995). Both 
vasoconstrictor (excitatory-eNANC) and vasodilator (inhibitory-iNANC) responses have 
been attributed to NANC nerves in mammalian pulmonary arteries although their 
physiological significance remains speculative (Inoue & Kannan, 1988;Maggi et al, 
1990;Liu et a l, 1992a). In the rat pulmonary artery eNANC vasoconstriction has been
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reported to be mediated by ATP whilst in the guinea pig pulmonary artery both nitric 
oxide (NO) and ATP have been reported to mediate iNANC vasodilatation (Inoue & 
Kannan, 1988;Liu e ta l,  1992a;Liu e/a/., 1992b).
Humoral control
The pulmonary vasculature is continuously exposed to a vast array of humoral and 
autacoid factors and it has been proposed that the maintenance of low basal tone is the 
result of the balance of vasoconstrictors and vasodilators being tipped in favour of the 
dilators (Robin, 1982). In pulmonary arterial hypertension it is thought that this balance 
is upset in favour of the vasoconstrictors, resulting in sustained vasoconstriction and 
vascular remodelling.
Substances known to induce only vasoconstriction include angiotensin II (Boe & 
Simonsson, 1981), and a number of protanoids such as thromboxane A2 (TXA2) (Buzzard 
et a l, 1993), Whilst substances known to cause only vasodilatation include the 
prostanoid, prostacyclin (PGI2) (Hyman & Kadowitz, 1979), atrial natiuretic peptide 
(ANP) (Lindberg & Andersson, 1988) and vasoactive intestinal polypeptide (VIP) 
(Nandiwada et a l, 1985). However many substances can cause both vasodilatation and 
vasoconstriction the net response being dependent on the pre-existing level of tone. These 
substances include; endothelin 1 (ET-1) (McKay et al, 1991) serotonin (5-HT) (Neely et 
al, 1993), ATP (Liu et a l, 1989) bradykimiin (Pang et a l, 1982;Lippton et a l, 1984) and 
histamine (Okpaka, 1972;Abacioglu et a l, 1987). In some cases substances may even act 
synergistically to cause substantial elevation in tone (e.g. TXA2 and 5-HT (MacLean, 
1999). However the relative importance of each of these factors seems to vary between 
species and anatomical location within the pulmonary vasculature and therefore the 
relative contributions of these agents to normal pulmonary vascular tone are still being 
elucidated.
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Control by the respiratory gases
Given that the primary function of the pulmonary circulation is gaseous exchange, it is 
not surprising that the respiratory gases actively influence pulmonary vascular tone. Both 
hypoxia and hypercapnia induce vasoconstriction of the pulmonary circulation (Fishman, 
1961). However, whilst increased mixed venous CO2 is the predominant stimulus for the 
hypercapnie response, it is alveolar hypoxia that is the main stimulus for the hypoxic 
response, with mixed venous partial pressure of O2 (P0 2 ) being only a contributory factor 
(Duke, 1954;Marshall & Marshall, 1983).
Hypoxic pulmonary vasoconstriction; Hypoxic pulmonary vasoconstriction (HPV) is 
perhaps the most powerful regulatory mechanism of the pulmonary circulation. Unique 
to pulmonary vessels, HPV is a physiological response that causes vasoconstriction of 
poorly ventilated regions of the lung thus redirecting blood flow to the better ventilated 
regions resulting in an optimisation of ventilation/perfusion matching (Leach & Treacher, 
1995). HPV primarily occurs in the small pre-capillary arterioles of the hypoxic region 
particularly when alveolai' P0 2  drops below VOmmHg (Von Euler & Liljestrand, 
1947;Kato & Staub, 1966;Nagasaka et a l, 1984). The HPV response incorporates the 
acute hypoxic vasoconstrictor response and a chronic vascular remodelling phase 
associated with prolonged alveolar hypoxia (Leach & Treacher, 1995). However, despite 
intensive investigation, the identity of the oxygen sensor remains elusive. It has been 
shown that the acute response is not dependent on the central nervous system, as the 
response is still present in the isolated lung and even in excised segments of pulmonary 
artery (Hauge, 1968a;Dawson et a l, 1979;Madden et a l, 1985). Two main hypotheses 
for the acute intrinsic mechanisms have been proposed. 1) The mediator hypothesis 
suggests that endogenous vasoactive factors are released or suppressed in response to 
hypoxia. However, despite extensive investigations no such factors have been identified 
as being essential to HPV (Hauge, 1968a;Hauge & Melmon, 1968;Hauge,
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1968b;Fishman, 1976;Roos et a l, 1976;Tucker et a l, 1976;Weir et a l, 1976a;Weir et al, 
1976b). Furthermore it has been reported that the acute response is endothelium 
independent making it more likely to be an intrinsic property of pulmonary arterial 
smooth muscle cells (PASMCs) (Yuan et a l, 1990) 2) The second hypothesis is that 
hypoxia has a direct effect on the pulmonary vascular smooth muscle cells. Whilst 
cultured PAMSCs have been shown to contract to hypoxia (Murray et a l, 1990), the 
molecular mechanism, which remains to be identified would have to account for the 
diametrically opposed responses of pulmonary and systemic vessels (which dilate to 
hypoxia). Furthermore, whilst the initiation of the acute HPV response may be 
endothelium independent some investigators have reported a need for an intact 
endothelium for the response to be maintained for more than 20minutes (see- The 
endothelium and HPV, for explanation and refs). Hence it is not inconceivable that both 
hypotheses have merit, that is an endothelium independent acute response, which triggers 
a sub-acute endothelium dependant/facilitated response (Aaronson et a l, 2002).
If the hypoxic challenge is sustained (i.e. cln*onic hypoxia) HPV results in vascular 
remodelling (See 1.2 Pulmonary arterial hypertension) which leads to a sustained 
elevation of PAP and the development of secondary pulmonary hypertension. However, 
the relationship between chronic hypoxia (CH) and HPV are less than clear cut as some 
investigators report attenuated HPV and agonist induced vasoconstrictor responses 
following chronic hypoxia (McMurtry et a l, 1980;Hill & Ou, 1984) whilst others report 
increased HPV and agonist induced vasoconstrictor responses (Emery et a l, 1981;Park et 
al, 1977). Chronic hypoxia also alters the balance between endogenous vasoconstrictors 
and vasodilators and may also increase vascular reactivity (Shimoda et a l, 2000). 
Although the signalling pathways that mediate the response to chionic hypoxia may be 
somewhat more varied than the those that mediate the acute HPV response,
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fundamentally they are both mediated by an elevation of cytosolic fi*ee Ca^ "^  (See 1.1.4 
Smooth muscle contraction).
Endothelial control
Furchgott and Zawadski (1980) brought to light the importance of the endothelium in the 
regulation of vascular tone, when they demonstrated that Ach induced relaxation was an 
endothelium dependant phenomenon. The nonprostanoid substance responsible, 
subsequently termed endothelium derived relaxing factor (EDRJF) (Cherry et al., 1982), 
was found to mediate smooth muscle relaxation in a wide range of arterial and venous 
preparations in response to a diverse range of physiological and pharmacological stimuli 
(Furchgott & Zawadzki, 1980;Furchgott et a l, 1984;Furchgott & Vanhoutte, 1989). 
EDRF is now accepted to be nitric oxide (NO) (Moncada et a l, 1991;Nathan, 1992) 
although a second EDRF known as endothelium derived hyperpolarising factor (EDHF) 
has also been proposed (Komori & Vanhoutte, 1990). In addition to NO, the prostanoid, 
prostacyclin (PGI2) is also synthesised and released by the endothelium and plays an 
important role in the endothelium mediated vasodilator response to increased shear stress 
(Frangos et a l, 1985).
The endothelium and pulmonary tone; A  large number of humoral factors and autacoids 
have been shown to induce pulmonaiy vasodilatation tlirough endothelium mediated NO 
release. Some of these substances have already been introduced in the nervous and 
humoral control sections and include; norepineplnine (Liu et a l, 1991), Ach (McMahon 
et a l, 1992;McMahon et a l, 1991), ATP (Liu et a l, 1992a), bradykinin (Ignarro et a l, 
1987), histamine (Szarek et a l, 1992), ET-1 (Namiki et a l, 1992) and 5-HT (Glusa & 
Richter, 1993). In addition, the endothelial cells also generate, metabolise and degrade 
many of these vasoactive substances, some of which can also mediate vasoconstriction. 
Hence, the endothelium may play a pivotal role in the maintenance of low basal tone
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tlirough its modulation and mediation of the many nervous, humoral and mechanical 
influences.
The relative importance of NO and PGI2 with regards to maintaining pulmonary basal 
tone shows variation from species to species but in the rat, rabbit, cat, guinea pig, and 
sheep, NO appears to be more important than PGI2, as inhibition of NO under normal or 
hypertensive conditions results in an increase in PAP and PVR, which does not occur 
with the block of PGI2 (Oka et a l, 1993;Davidson & Eldemerdash, 1991;Persson et al, 
1990;Fineman et a l, 1991). However this situation is completely reversed in the dog 
with PGI2 inhibition causing increased PVR but NO inhibition having no effect (Barnard 
et a l, 1993). In humans the degree to which NO regulates pulmonary vascular tone 
under basal conditions is still being debated (Celermajer et a l, 1994;Stamler et a l, 
1994;Hampl, 2000), but NO production has been shown to be augmented in times of 
elevated PAP or PVR and is thought to provide a tonic antagonism until the point at 
which endothelial damage or pathological changes limit its effectiveness (Seghaye et a l, 
1997;Takaya et a l, 1998;Hampl, 2000).
The endothelium and HPV; The role of the endothelium in hypoxic pulmonary 
vasoconstriction (HPV) is controversial. HPV has been demonstrated in both pulmonary 
arteries where the endothelium has been removed and isolated PASMCs, suggesting it is 
an endothelium independent mechanism (Harder et a l, 1985;Yuan et a l, 1990;Marshall 
& Marshall, 1992;Wang et a l, 1995;Gelband & Gelband, 1997). However a number of 
investigators have also shown either partial (Rodman et a l, 1989;Zhang & Morice, 
1994;Dipp et a l, 2001) or complete dependence on an intact endothelium for sustained 
HPV of more than 20minutes duration (Holden & McCall, 1984;Demiryurek et al, 
1991;Kovitz et a l, 1993;Leach et a l, 1994;Leach et a l, 2001). It has been suggested 
that the discrepancy for these findings may be that acute HPV consists of 2 phases; an
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initial transient, endothelium independent vasoconstriction (phase 1) superimposed on a 
more slowly developing but sustained (sub acute) endothelium dependent/facilitated 
vasoconstriction (phase 2) (Kovitz et a l, 1993;Leach et a l, 1994;Zhang & Morice, 
1994;Dipp et a l, 2001).
Active regulation favours low pulmonary tone in the normal lung
Whilst much still remains to be imderstood about the relative roles and interplay of the 
active mechanisms which influence pulmonary vascular tone, it is widely recognised that 
in the normal pulmonary circulation the balance of these influences is such that the 
arterial basal tone and hence PVR is very low. In disease states such as pulmonary 
hypertension however it is thought that the balance of the active regulatory mechanisms 
is disturbed leading to an elevation of basal tone (vasoconstriction) and vascular 
remodelling. The combination of these two factors causes an increase in PVR, which in 
turn requires an elevation in PAP to maintain the required blood flow tlirough the lung. 
A key regulator in both vasoconstriction and the cellular proliferation of vascular 
remodelling, is cytosolic [Ca^ ]^ ([Ca^’^ jcyt) (Mandegar et a l, 2004).
1.1.4 Smooth muscle contraction and pulmonary arterial smooth muscle 
cells
1.1.4.1 Cytoplasmic ( [Ca^^cyt) regulation
The low basal tone of PASMCs is primarily a function of low ([Ca '^^ jcyt). The appropriate 
[Ca^’‘’]cyt is maintained by the relative activities of those events which cause an increase in 
[Ca^ '^ jcyt (i.e. trans-sarcolemmal influx of Ca^ "^  and/or the mobilisation of Ca^ *^  from the 
sarcoplasmic reticulum (SR)) and those which reduce [Ca^’^ jcyt (i.e. extrusion of Ca^  ^
thiough the plasma membrane Ca^’^ -Mg^’^ ATPase pump, and sequestration of Ca^  ^ into 
the SR by its Ca '^ -^Mg '^^  ATPase pumps (SERCA)) (Berridge, 1993;Blaustein, 
1993;Blaustein & Lederer, 1999).
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1.1.4.2 Elevation of [Ca^ c^yt; the signal for contraction
influx through the membrane can involve up to 3 types of channel depending on the
stimulus. 1) Voltage dependant channels (VDCC) which are regulated by membrane 
potential (Em), 2) receptor operated channels (ROC) which are activated by the 
interaction of agonists and membrane receptors, and 3) store operated chamiels (SOC) 
which are activated by depletion of Ca^ "^  from the intra-cellular stores (SR) (Nelson et a l, 
1990;Parekli & Penner, 1997).
The SR is the predominant intra-cellular Ca^  ^ store, and can be functionally divided into 
two pools based on the Ca^  ^release caused by inositol trisphosphate (IP3) or caffeine (or 
sensitivity to lyanodine). Both mechanisms have been identified in vascular smooth 
muscle cells (SMCs) (Berridge, 1993;Gurney & Allam, 1995). Caffeine activated 
(ryanodine sensitive) stores are involved in Ca^^-induced Ca^ "^  release, whilst IP3 SR store 
release is triggered by the interaction of agonists and membrane receptors although this 
response can be modulated by a change in Em (Ganitkevich & Isenberg, 1993).
1.1.4.3 Smooth muscle contraction; the mechanism
Smooth muscle contraction is directly triggered by a rise in cytosolic free Ca^ "^  
concentration ([Ca^”^]cyt) which occurs in response to stimuli such as membrane 
depolarisation or the binding of an agonist to cell surface receptors (Somlyo & Himpens, 
1989). Calmodulin (CaM), an intra-cellular Ca^’^ -binding protein, binds free Ca^  ^ as 
[Ca^’*’]cyt rises. The Ca^VCaM complex then activates myosin light chain kinase (MLCK), 
which, in turn, phosphoiylates the myosin light chain (MLC). The phosphorylated MLC 
stimulates the activity of myosin ATPase, hydrolysing ATP to release energy for the 
subsequent cycling of the myosin cross-bridges with the actin filament. The formation of 
these cross-bridges underlies smooth muscle cell contraction, prompting vasoconstriction 
(Somlyo & Somlyo, 1994) (Fig 1.3). Conversely, relaxation is achieved by those
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mechanisms that remove Ca^ "^  from the cytosol; extrusion of Ca^ "^  through the plasma 
membrane Ca '^^-Mg '^^ATPase pump, and sequestration of Ca^  ^ into the SR by its Ca^ "^ - 
Mg^ "^  ATPase pumps (SERCA) (Berridge, 1993; Blaustein, 1993).
1.1.4.4 Smooth muscle contraction and Ca^  ^sensitisation
Although elevation of [Ca^ j^cyt triggers contraction and hence vasoconstriction, the actual 
force produced is dependent on 2 factors. 1) The [Ca^ '^ Jcyt and 2) the Ca^ '^  sensitivity 
(CaS) of the contractile apparatus. These two factors determine the level of 
phosphorylation of the MLC, which is the key event regulating the resulting level of 
contraction (Kamm & Stull, 1985). Under some circumstances thin filament regulation, 
which is independent of MLC phosphorylation may also modify the final response, but 
less is known about the physiological relevance of this mechanism (Arner & Pfitzer, 
1999). Phosphorylation of the MLC is mediated by myosin light chain kinase (MLCK) 
whilst dephosphorylation is mediated by myosin light chain phosphatase (MLCP) and 
both are targets for intra-cellular signalling cascades. It is the influence of these 
signalling cascades on the relative activities of MLCK and MLCP that modulate force 
independent of [Ca^ "^ ]cyt (Pfitzer, 2001;Somlyo & Somlyo, 2003).
Signalling cascades that increase Ca^  ^sensitivity (CaS)
Of the several agonists which have now been found to increase CaS in a variety of 
smooth muscle preparations, most seem to do so by G-protein mediated inhibition of 
MLCP. It was originally thought that inhibition of MLCP occurred via phosphorylation 
of its regulatory myosin-binding subunit (Kimura et a l, 1996;Feng et a l, 1999). 
However recent reports are conflicting, with both an increase and no change in 
phosphorylation of the regulatory myosin-binding subunit at the Thi695 residue being 
reported following agonist stimulation which resulted in MLCP inhibition (Shin et a l, 
2002;Niiro et a l, 2003).
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Figure 1.3 Smooth muscle contraction
2 +The mechanisms underlying vasoconstriction. The relative contribution of each route of Ca 
entry varies depending on the stimulus involved. Voltage dependant channels (VDCC) are 
regulated by membrane potential (Em), whilst receptor operated channels (ROC) and 
phosphoiipase C (PLC) are activated by the interaction of agonists and membrane receptors. 
Inositol trisphosphate (IP3) and diacyigiyceroi (DAG) are produced from phosphatidyl inositol 
bisphosphate during PLC activation. iPg is the intra-cellular signal for sarcoplasmic reticulum 
(SR) Ca^ "^  store release. Store operated channels (SOC) are activated by depletion of Ca^* from 
the SR. Elevated cytoplasmic Ca^ "" concentration ([Ca^%yt) increases the activity of myosin light 
chain kinase (MLCP) via the Ca^Vcalmoduiin complex, resulting in the phosphorylation of the 
myosin light chain and contraction.
A second, indirect mechanism has also been identified, with inactivation of MLCP 
occuring following phosphorylation of protein kinase C-potentiated inhibitory protein
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(CPI-17). CPI-17 is a smooth muscle-specific protein inhibitor of MLCP (Eto et a l, 
2001). However, the exact details of how CPI-17 phosphorylation inhibits MCLP remain 
to be elucidated. Presently, there are two well described G-protein mediated, MLCP 
inhibitory pathways and recent evidence suggests they may both he influenced by 
complex signalling cascades and may invole convergence.
The Rho kinase pathway; The monomeric Rho GTPase has been found to activate Rho 
kinase (ROK)(Matsui et a l, 1996) which causes phosphorylation of the regulatory sub 
unit of MLCP resulting in its inactivation (Kimura et a l, 1996;Feng et a l, 1999). ROK 
activation may also indirectly inactivate MLCP via CPI-17 phoshorylation (Eto et a l, 
2001). It has since been shown using the specific ROK inhibitor Y27632 that the tonic 
component of the contraction caused by agonists, which utilise the ROK pathway could 
be inhibited, but that the initial phasic response remained (Uehata et al., 1997;Fu et al., 
1998;Yoshii et al., 1999;Sward et al., 2000). Thus, some agonists may increase SMC 
tone by both triggering Ca^ "^  influx and by increasing CaS through ROK. However, it has 
also been reported that the concentration (lOpM) of Y27632 used by most investigators 
for inibition of ROK, may also partially inhibit atypical protein kinase C (Eto et a l, 
2001) and therefore its action may not be entirely specific for ROK.
The ROK pathway has also recently been implicated in both phase 2 of HPV (Wang et 
al, 2001;Wang et a l, 2003;Ward et a l, 2004) and the development of pulmonary 
hypertension occuring secondary to chronic hypoxia, although its role in the latter is less 
clear (Sauzeau et a l, 2003a;Nagaoka et al, 2004b).
The protein kinase Cpathway; The second major pathway that has been proposed is the 
phosphorylation of CPI-17, a smooth muscle-specific protein inhibitor of MLCP by 
protein kinase C (PKC). It has been shown that the PKCs involved are atypical with 
conventional PKCs playing only a transient, small role in CaS (Gailly et a l, 1997;Iizuka
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et a l, 1999;Eto et a l, 2001). It has been suggested that either a convergence of, or 
cross-talk between the PKC pathway and the ROK pathway exists, because CPI-17 
phosphorylation can be inliibited by both PKC inliibitors and the specific ROK inliibitor 
Y 27632 (Kitazawa et al., 2000). However the specificity of Y27632 has been questioned 
at the concentration (lOpM) used by Kitazawa (Eto et a l, 2001). Interestingly, several 
Gaq-coupled receptors (such as ET-1 and purinergic receptors) are known to activate 
both ROK and PKC (Somlyo & Somlyo, 2003).
Signalling cascades that decrease Ca^  ^sensitivity (CaS)
Both cAMP and cGMP have been shown to decrease CaS in permeabilised and intact 
preparations (Kerrick & Hoar, 1981;Morgan & Morgan, 1984;Karaki et a l, 1988;Van 
Riper et a l, 1995;Seguchi et a l, 1996;Gailly et a l, 1997).
cAMP desensitisation; Protein kinase A (PKA) has been shown to phosphorylate 2 sites 
on MLCK, although only one of these phosphorylated sites (site A) was associated with 
decreased CaS (Conti & Adelstein, 1981). However, agents that elevate cAMP in vivo 
do not seem to have significant effect at this site so it is possible that cAMP causes 
decreased CaS through some, as yet undefined mechanism, although antagonism of ROK 
has been proposed (Miller et a l, 1983;Stull et a l, 1990;Somlyo & Somlyo, 2003). As 
several effects of cAMP are mediated by cross activation of protein kinase G (PKG) it is 
also possible that PKG may be involved in the cAMP associated Ca^ "^  desensitisation.
cGMP desensitisation; PKG which is activated by cGMP, has no effect on MLCK 
activity but has been shown to activate MLCP. The mechanism of cGMP/PKG action is 
still speculative but there is evidence that it can both increase activity of MLCP and 
independently antagonise ROK (Surks et a l, 1999;Sauzeau et a l, 2000a). ROK 
antagonism has been reported to occui* following increased endothelial nitric oxide 
synthase (NOS III) expression and resulted in reduced contraction to 5-HT and PE in the
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mouse aorta (Budzyn et a l, 2004). It has also been reported that the NO stimulated 
cGMP/PKG desensitisation pathway, rather than reduced [Ca^ j^cyt, is responsible for 
vasodilatation in resistance arteries and that this pathway is antagonised by ROK (Bolz et 
al, 2003). Hence the findings suggest that both the NO/cGMP and ROK pathways are 
key players in the regulation of vascular tone and that the CaS of the contractile apparatus 
may primarily be the net result of these two opposing pathways.
/calmodulin-dependant protein kinase II; It has been reported that some agents 
which induce a substantial increase of [Ca^ "^ ]cyt also cause a significant phosphorylation 
of site A on MLCK thus causing a decrease in CaS (Stull et a l, 1990). Inhibition of Ca^ "^  
/calmodulin-dependant protein kinase II (CaMK II) has been reported to abolish this 
phosphorylation of site A leading to the suggestion that CaMK II might mediate a 
negative feedback mechanism which protects from high levels of MLC phosphorylation 
(Tansey et a l, 1994;Stull et a l, 1990) (Fig 1.4).
1.1.4.5 HPV involves both elevated [Ca^ *]cyt and, Ca^  ^sensitisation
The acute HPV response to hypoxia is characterised by a bi-phasic contraction consisting
of a rapid initial phasic response (lasting ~ up to 20minutes) followed by a lesser but 
sustained sub acute tonic response, which is maintained until the hypoxic challenge is 
ceased (Bennie et a l, 1991;Jin et a l, 1992;Leach et a l, 1994). It is now known that the 
phasic response coincides with an elevation in [Ca^'^yt but that the tonic response shows 
a dissociation between force and [Ca^’*']cyt (Robertson et a l, 1995). This dissociation is 
believed to be due to a change in the CaS of the contractile apparatus. Several signalling 
pathways have been proposed to mediate the CaS response of phase 2 of HPV, including 
PKC and ROK (Robertson et a l, 1995;Robertson et al, 2001;Wang et a l, 2001;Wang et 
al, 2003;Fagan et a l, 2004;Ward et a l, 2004), however it has been shown the response 
can occur in the presence of PKC block (Robertson et al, 2001). It now thought that the
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ROK pathway is primarily responsible for mediating the sub-aciite response (phase 2) of 
HPV (Wang et a l, 2001;Wang et a l, 2003) and that ROK is activated by some 
endothelial derived factor (Aaronson et a l, 2002;Dipp et a l, 2001). If the hypoxic 
challenge is sustained (i.e. chronic hypoxia), HPV persists, and in conjunction with a 
series of other influences results in the development of secondary pulmonary 
hypertension (SPH). PH secondary to chronic hypoxia is a widely used model for the 
study of pulmonary arterial hypertension (PAH) (see chapter 5).
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Figure 1.4 The proposed pathways of smooth muscle Ca^* sensltlsatlon/desensltisatlon
The Rho kinase (ROK) pathway is activated by the smail RhoA GTPase whose activity is 
mediated by both Gaq and G0612/13 G-protein coupled receptors (GPCR). ROK increases Ca^  ^
sensitivity (CaS) by inhibition of myosin light chain phosphatase (MLCP), resulting in increased 
phosphorylation of the myosin light chain (MLC20). ROK may also promote CPI-17  
phosphorylation, which can also result in the inhibition of MLCP. CPI-17  has been shown to be 
activated by the protein kinase C (PKC) pathway, although the PKCs involved are thought to be 
atypical and may be the product of arachidonic acid (A.A) metabolism. Nitric oxide (NO) causes 
a decrease in CaS via gaunyiyi cyclase (G/C) production of cyclic GMP (cGMP). cGMP augments 
protein kinase G activity which activates MLCP thus causing déphosphorylation of MLC20. Cyclic 
AMP (cAMP) and Ca^Vcalmoduiin dependent kinase (CaMK ii) have both been implicated in 
decreased CaS through their inhibition of MLCK. + Stimulation, - inhibition, ? Possible pathway 
convergence. ?/? Relative contribution to pathway stimulation requires further clarification.
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1.2 Pulmonary hypertension
Pulmonary hypertension (PH) is defined as a sustained elevation in pulmonary arterial 
pressure (PAP) above 25mmHg at rest and 30mmHg during exercise (Rich et a l, 1987). 
However, this is a general term, which can be applied to over 30 conditions, many of 
which have different aetiologies. Until the 1998 WHO sponsored World symposium on 
primary pulmonary hypertension, one of the fundamental problems in tackling what is in 
effect a range of complex and multi-factorial diseases, was the classification of its various 
forms.
1.2.1 Classification of pulmonary arterial hypertension (PAH)
Prior to the 1998 WHO classification, PH was described either as Primary
(idiopathic/essential) pulmonary hypertension (PPH) or Secondary pulmonary 
hypertension. PPH was diagnosed when the disease occurred spontaneously without any 
known insult, whilst secondary PH was used as a blanket term to describe PH occurring 
secondary to or in association with, some other known condition. Unfortunately these 
generalisations grouped together patients who may have had little similarity in the 
development of their PH whilst also separating others who may have been found to have 
a shared aetiology. The revisions of 1998 and then 2003 have since produced a 
classification system, which reflects advances in the understanding of pulmonary 
hypertensive diseases and recognises those varieties of the condition, which demonstrate 
similarities in their aetiologies. The diseases are thus defined into 5 main categories 
based upon their common clinical features;
1) Pulmonary arterial hypertension (PAH)
2) Pulmonary hypertension with left heart disease
3) Pulmonary hypertension associated with lung diseases and/or hypoxaemia
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4) Pulmonaiy hypertension due to chronic thrombotic and/or embolic disease
5) Miscellaneous
In essence however, PH is physiologically divided into two broad categories: 1) 
Pulmonary arterial hypertension (PAH) encompasses those intrinsic diseases of the 
pulmonaiy vascular smooth muscle and endothelial cells which, due to abnormalities at 
cellular and molecular levels result in an obliteration of the vessels lumen (Mandegar et 
al, 2004), 2) Secondaiy pulmonary hypertension (SPH) now covers all those conditions 
in which pulmonary hypertension occurs due to a physiological abnormality that arose 
independently and in the absence of any intrinsic pulmonary vascular disease (Mandegar 
et a l, 2004).
In our laboratory we are primarily concerned with PAH. This group of clinically and 
pathologically associated conditions includes those not related to any known previous 
insult, idiopathic PAH (IPAH), cases with a known genetic /familial history (FPAH) and 
those in which PAH occurs in association with, or secondaiy to, some additional known 
risk factor (APAH). Severe PAH has been associated with collagen vascular disease, 
congenital systemic to pulmonary shunts, portal hypertension, HIV, drug (anorexigen & 
amphetamines) and toxin exposure and a number of other conditions (Rich et a l, 1987).
The new classification system should help identify common aspects of the disease, which 
may provide clues to its aetiology. For example, up to 40% of patients with the CREST 
variant of systemic sclerosis (grouped in the collagen vascular disease bracket) will die of 
PAH (Lee et a l, 1992). Interestingly ~ 10% of IP AH and FPAH patients also report 
symptoms of Raynauds phenomenon (collagen vascular disease). This highlights the 
benefits of the new classification system and simplifies identifying possible avenues of 
investigation, as it is becoming apparent that IP AH and FPAH lie at the far end of a 
spectrum of diseases which cause PAH (Peacock, 1999).
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1.2.2 The epidemiology of pulmonary arterial hypertension (PAH)
IP AH and FPAH are rare (combined incidence of 1-2/million), progressive and usually
fatal conditions. Although they can occur at any age, the mean age at diagnosis is 36 
years old and the gender ratio shows a greater prevalence for females (-2:1) (Rich et a l, 
1987). Death is typically the result of right heart failure, which despite significant 
hypertrophy can no longer prevail over the inexorable rise in pulmonary vascular 
resistance (PVR). Due to the relatively non-specific early symptoms such as dyspnea, 
fatigue, angina and sometimes exercise syncope, mean time form onset of symptoms to 
diagnosis is about 2 years (Rich et a l, 1987) and the median survival time after diagnosis 
is reported as 2.5 years in the American National institutes of health registry (D'Alonzo et 
a l, 1991). Clinically, PAH is characterised by a marked derangement of pulmonary 
haemodynamics such as a tliree-fold or greater rise in pulmonary arterial pressure (PAP) 
and increased right atrial pressure but is not usually associated with changes in pressures 
on the left side of the heart. Hence, a definitive diagnosis could only formerly made by 
right heart catheterisation, an invasive procedure, not without risk. However, the recent 
advent of trans-thoracic echocardiography has provided an important step forward in non- 
invasive patient screening making earlier diagnosis likely.
1.2.2.1 The genetic link
Approximately 6% of all formerly classed PPH cases are classified as familial (FPAH), 
but the true figure may be higher as the disease is an autosomal dominant trait with 
incomplete penetrance and shows a pattern of genetic anticipation, a worsening of the 
disease in subsequent generations manifested by greater severity or eaiiier onset (Loyd et 
a l, 1995). Fortunately, children of an affected parent only have a 5-10% lifetime risk of 
developing the disease.
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It is suspected that at least 2 genes are involved in FPAH. The first gene to be ascribed 
to FPAH was designated PPH 1 and has a locus at 2q31~32. More recently the bone 
morphogenetic protein receptor 2 (BMP-R2), a member of the transforming growth factor 
(TGF-p) superfamily has been found to show mutations in most cases of FPAH 
(Machado et a l, 2001).
IP AH displays a virtually identical clinical progression and histopathology to the familial 
form and whilst a family history cannot be demonstrated it is now considered by many 
that the development of severe PAH requires a genetic predisposition (Voelkel & Tuder, 
1995;Voelkel, 1997). However, the BMP-R2 mutation has been found to be present in 
only 15- 25% of IP AH patients and as only ~ 10-20% of people with a BMP-R2 mutation 
develop PPH it is likely that other genetic influences and/or specific environmental 
triggers are necessary to initiate the pathological sequence that leads to the onset of the 
disease (Newman et a l, 2001). Another mutation associated with IP AH is the 
polymorphism of the 5-HT transporter (5-HTT). The L-allelic variant has been found to 
be -two-fold more common in IP AH patients than in controls (Eddahibi et a l, 2001b) 
and is reported to enhance 5-HTT transcription in animal models (Eddahibi et a l, 1999) 
and cause vascular proliferation in human PASMCs (Eddahibi et a l, 2001b). However 
the nature of its role in PH is controversial and it is more thoroughly discussed later in 
this chapter.
1.2.3 The pathology of pulmonary arterial hypertension; vascular 
remodelling
Autopsies have identified that PAH patients all show a histological remodelling of the 
small pulmonary arteries (SPA’s). The most obvious change is the distal “migration” or 
progression of smooth muscle into small peripheral normally non-muscular arteries (Rich 
et al, 2003). This migration may also be observed in SPH such as that occuring secondary
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to chronic hypoxia (Hislop & Reid, 1976;Smith & Heath, 1977;Meyrick & Reid, 1978) 
(Fig 1.5).
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Figure 1.5 The distal progression of smooth muscle Into the small pulmonary arteries
The diagram on the left shows the normal distribution of smooth muscle along the pulmonary 
arterial tree. The diagram on the right shows the progression of smooth muscle into the normally 
non-muscular arteries and arterioles.
Within these remodelled arteries some or all o f the following pathological changes are 
observed; 1) Intimai thickening and formation o f plexiform lesions. 2) Muscularisation 
and thickening o f the media; 3) Thickening o f the adventitia (Rich et al, 2003). Some o f 
these changes can to a degree, be replicated in the chronically hypoxic animal model o f 
PH, making this a useful tool for the study o f PH (Smith & Heath, 1977;Meyrick & Reid, 
1980a;Meyrick & Reid, 1980b). However the phenotypical changes that occur in SPH 
may not be typical o f those that occur in PAH (Lee et ai,  1998).
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1.2.3.1 Intimai thickening and formation of the plexiform lesion
In the normal pulmonary circulation the intima consists of a single layer of endothelial
cells and is separated from the media by a thin elastic basal lamina (Tortora, 1995)(Fig 
1.2). The endothelium shows a marked heterogeneity although the relationship between 
the phenotype and functions of these multiple cell types is not yet fully understood. In 
PAH endothelial proliferation causes a thickening of the intima, resulting in occlusion of 
the vessel lumen. The thickening is further exaggerated by the formation of the 
neointima, which consists of a layer of fibroblasts and extra-cellular matrix proteins (Rich 
et al, 2003) . In the chronically hypoxic (lOdays) rat model of PH, the intima has been 
reported to be thickened upto tliree-fold by endothelial cell hyperplasia and hypertrophy 
of the cytoplasmic organelles (Meyrick & Reid, 1980a). However not all studies have 
found evidence of intimai proliferation following exposure to chronic hypoxia (Smith & 
Heath, 1977)
In some cases of PAH and SPH, endothelial proliferation may also result in the fomiation 
of the plexiform lesion. The lesion is an unusual and pathological glomerular-like mass 
of disorganised capillary formations, which occurs within an anuerysmal dilatation of an 
arterial branch, distal to an obstructed larger artery. The vessels that comprise the lesion 
are primarily composed of endothelial chamiels supported by a stroma containing matrix 
proteins and myofibroblasts. However, plexiform lesions in IP AH are monoclonal whilst 
those from SPH patients are polyclonal (Lee et a l, 1998) leading to speculation of a 
fundamental abnormality of the endothelium in IP AH. Recently mutations in the TGF- 
pR2 gene as well as dysregulation by vasculotropic viruses have been implicated (Yeager 
et a l, 2001;Cool et a l, 2003).
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1.2.3.2 Muscularisation and thickening of the media
The media supplies the mechanical strength and contractile power of the vascular wall. It 
is composed of heterogeneous subpopulations of SMCs with marked differences in the 
phenotype, growth, and matrix-producing capabilities (Dempsey et a l, 1997;Frid et a l,
1997). It is thought that these differences are intrinsic to the cell type and can determine 
the pattern of abnormal cell proliferation and matrix protein synthesis observed in the 
pathogenesis of vascular disease. For example, sub-populations from the outer media 
have an augmented proliferative response to hypoxia relative to those of the middle and 
inner media (Dempsey et a l, 1997;Frid et a l, 1997). Although not completely 
understood, it is thought that in PAH, the media of the normally non-muscular distal 
arteries undergoes hypeiplasia of favoured cell types causing them to become 
muscularised. This not only thickens the medial wall, but as the different phenotypes 
respond differentially to vaso-active factors it can also change the vessels contractile 
profile (Rich et al, 2003). In rat vessels, remodelled as a result of exposure to lOdays 
chronic hypoxia, the media is typically thickened by more than two-fold as a result of 
SMC hypertrophy and an increase in extra-cellular connective tissue and oedema like 
fluid (Meyrick & Reid, 1980b). The thickening of medial layer also causes the internal 
and external elastic laminae, which are themselves thickened two-fold by hypoxic 
exposure, to be further separated and this can be used as a means of identifying 
remodelled vessels (Meyrick & Reid, 1980b) (Fig 1.6).
1.2.3.3 Adventitial thickening
The adventitia is a sheath of comiective tissue with no distinct outer border, which is 
composed mainly of fibroblasts and elastic and collagen fibres. Fibroblasts being less 
differentiated than endothelial or SMCs, demonstrate a tremendous capacity for rapid 
migration, proliferation and trans-differentiation into other cell types (Sartore et al, 
2001). In animal models of PH secondaiy to hypoxia, adventitial fibroblasts appear to be
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the first cells to proliferate and increase synthesis and in conjunction with increased 
collagen synthesis, result in a two-fold thickening o f the adventitia (Meyrick & Reid, 
1980b).
Adventitial fibroblasts can also migrate to the media (and ultimately the intima) and 
contribute to remodelling in these regions o f  the vascular wall. Additionally, as the 
vessel wall thickens, the vasa vasorum, which is responsible for the blood supply to the 
vessels themselves, undergoes neovascularisation (Rich et al, 2003).
The comined effects o f remodelling lead to an occlusion o f the vessel lumen and 
increased vascular tone. This manifests as an increase in resistance to flow, and a 
decrease in compliance, forcing the right side o f the heart to increase its workload in an 
attempt to maintain flow. The result is pulmonary arterial hypertension.
1%
Figure 1.6 Medial thickening of the small pulmonary artery In the chronically hypoxic 
rodent model of pulmonary arterial hypertension.
A) A normal rat small pulmonary artery (SPA). The internal and external elastic laminae have 
been stained black (Van-Geeson staining) and appear as a single band due to the very thin layer 
of smooth muscle separating them. B) A remodelled rat SPA following 2weeks exposure to 
chronic hypoxia. The medial (tunica media) thickening is evident from the now clearly separated 
internal and external elastic laminae, which are also thickened (Keegan e t al, 2001).
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1.2.4 The pathophysiology of pulmonary arterial hypertension; The 
mechanisms behind PAH
The pathological changes just described have been associated with the presence of one or 
more of four predominating mechanisms; 1) vasoconstriction; 2) vascular wall 
remodelling; 3) inflammation and 4) thrombosis.
1.2.4.1 Vasoconstriction
Vasoconstriction has been favoured as a candidate for the initiating mechanism since 
(Wood, 1958) demonstrated vasodilatation in response to an infusion of acetylcholine. 
Vasoconstriction causes decreased vascular compliance and increased PVR, which if 
sustained lead to PAH. The most convincing evidence supporting the role of 
vasoconstriction as an important player in the development of PAH is that ~ of all 
IP AH patients show a 15-20% decrease in PVR and PAP in response to application of 
acute vasodilators such as nitric oxide (NO) (Pepke-Zaba et a l, 1991) or prostacyclin 
(PGI2) (Rubin et a l, 1982). These observations actually form the basis of one aspect of 
the current clinical treatment of PAH. For example, those patients who respond to the 
acute vasodilator challenge are typically prescribed Ca^  ^ channel blockers such as 
nifedipine or diltiazem. In this group of patients there is a 95% survival rate at 5years 
following diagnosis (Rubin, 1997). However no evidence as yet can unequivocally 
confirm vasoconstriction as the initiating stimulus and the fact that -  % of patients do not 
respond to the acute vasodilator challenge suggests an alternative mechanism may be 
responsible for initiating the early lesion. Current consensus is that vasoconstriction is 
more likely to be a contributing factor rather than the initial cause and much effort has 
recently been directed towards greater understanding of vascular remodelling.
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1.2.4.2 Remodelling
In the healthy pulmonary circulation, small pulmonary arteries are usually thin walled, 
highly compliant vessels. The optimum wall thickness and overall tissue mass of these 
vessels is maintained by a delicate balance between proliferation and apoptosis of its 
cellular components such as fibroblasts, SMCs and endothelial cells. Upsetting this 
balance in favour of proliferation leads to SMC hypertrophy and/or luminal occlusion 
which results in decreased vascular compliance and increased PVR, which in turn lead to 
the onset and progression of PAH (Rubin, 1997). However, considering vasoconstriction 
and cellular proliferation as completely separate entities may be counterproductive. For 
example, it has been shown that both elastic stretch of PASMCs, (which has been shown 
to occur during cross-sectional vasoconstriction) and elevation of PAP, promoted 
pulmonaiy arterial cellular growth (Hishikawa et a l, 1994). Most experts now agree that 
PASMC proliferation and to some extent, vasoconstriction lead to the vascular 
remodelling processes that underlie severe PAH (Mandegar et a l, 2004).
Elevation in [Ca^*]cyt mediates vasoconstriction and proliferation of pulmonary arterial 
smooth muscle cells
It seems increasingly likely that vasoconstriction and cellular proliferation may both 
involve common signalling processes that may result in parallel cytosolic events. 
Findings have shown that elevations in [Ca^ j^cyt not only initiates SMC contraction but 
also result in a rapid increase in nuclear [Ca^^] which is an essential component of 
proliferation in SMCs (Allbritton et a l, 1994). In neuronal cells this [Ca^ "^ ]cyt elevation 
has been shown to stimulate the quiescent cells into a state of mitosis, resulting in 
proliferation (Hardingham et a l, 1997). It now seems that at least four steps in the cell 
cycle are sensitive to the activation of the Ca^'^/calmodulin complex; 1) GO to G1 (resting 
state to the beginning of DNA synthesis) 2) transition from G1 to S phase (DNA 
synthesis) 3) transition of G2 to M phase (mitosis) and 4) Mitosis itself (Steps 1-4 quoted
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direct form Mandegar et a l, (2004)). This is entirely consistent with the report that 
resting [Ca^ '^ Jcyt is significantly elevated in proliferating human PASMCs when compared 
to growth arrested cells (Golovina et al, 2001). In addition the signal transduction 
protein, MAP kinase II, which is involved in the initiation of DNA synthesis has also 
been shown to be activated by a rise in [Ca^’^ jcyt. It would thus appear that elevation of 
[Ca^ '^ Jcyt is a fundamental part of the proliferation, signalling cascade.
Elevation in [Ca^ ]^cyt mediates proliferation of pulmonary arterial endothelial cells
Elevated [Ca^ "^ ]cyt has also been shown to increase activating protein-1 (AP-1) activity
and growth factor synthesis in pulmonary arterial endothelial cells (PAECs). AP-Ts are 
transcription factors that regulate expression of genes such as those regulating ET-1, 
vascular endothelial cell growth factor (VEGF) and platelet derived growth factor 
(PDGF) production. These findings are therefore consistent with the report that over­
expression of AP-1 accelerates tumour cell growth, as ET-1, VEGF and PDGF are known 
to be involved in aspects of cell proliferation, migration and apoptosis (Mathas et a l, 
2002).
Apoptosis and vascular remodelling
The changes caused by increased proliferation are often mirrored and further exaggerated 
by a decrease in apoptosis, which has been shown to be markedly inhibited in PASMCs 
from IP AH patients (Zhang et a l, 2003). However, this aspect of remodelling appears to 
be independent of changes in [Ca^ '^ jcyt- Instead reduced apoptosis has been suggested to 
be linked to mutations in the BMP-R2 gene which exerts its influence tlu’ough its indirect 
effects on channels in the sarcolemmal membrane. (Mandegar et a l, 2004). 
Apoptosis is associated with apoptotic volume decrease (AVD) and an increase in 
caspases and nucleases (Remillard & Yuan, 2004), (Bortner & Cidlowski, 1999) 
Maintenance of a high [K"^ ]cyt maintains cell volume and suppresses caspases and
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nucleases, hence inhibition or decreased activity of chamiels causes an accumulation 
of [K'^ lcyt and a reduction in apoptosis. It has been hypothesised that the mutations in the 
BMP-R2 gene prevent the usual down regulation of Bcl-2 by the BMP protein (Mandegar 
et a l, 2004). Bcl-2 is an antiapoptotic membrane protein which, reduces apoptosis by a 
number of mechanisms one of which is inhibition of chaimels (Ekhterae et a l, 2001).
1.2.4.3 Inflammation
Mediators of inflammation such as TGF-f3, interleukin 6, 5-LO and FLAP have been 
shown to cause vasoconstriction and may induce proliferation in animal models of PH 
(Voelkel et a l, 1996;Bhargava et a l, 1999). Elevated levels of these mediators have also 
been reported in patients formerly classed as PPH. However, inflammation of the 
vascular wall is neither a consistent nor prominent feature of the histologic findings at 
autopsy and when present is thought to be a complication of the disease rather than an 
initiating mechanism (Fishman, 1998).
1.2.4.4 Thrombosis
Currently, whilst in situ thrombosis is recognised to contribute to the progression of PAH 
it is not generally thought to be responsible for initiating the early lesion and is thought to 
occur secondary to an interplay between the abnormal endothelium and blood borne 
constituents (Fishman, 1998). However, the fact that a number of studies of PAH patients 
treated with the anti-coagulant Warfarin have demonstrated a significant increase in the 3 
and 5 year survival rates suggests that thrombosis does play an important role in the 
progression of the disease (Frank et a l, 1997;Ogata et a l, 1993).
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1.2.5 The cellular and molecular mechanisms associated with 
vasoconstriction and vascuiar remodeliing in pulmonary arterial 
hypertension
The review so far has shown that the development of PAH is characterised by 3 structural 
and/or functional abnormalities, which result in remodelling of the small pulmonary 
arteies, these are; vasoconstriction, proliferation and apoptosis. Thrombosis and 
inflammation, which increase the risk of additional complications, may also accompany 
these abnormalities (Fislunan, 1998). Wliilst it is considered that a genetic predisposition 
is probably necessary for these changes to occur in such a way as to result in the 
development of severe PAH, there is substantial evidence to suggest some additional 
trigger is usually required (Mandegar et a l, 2004). Whilst this trigger, known as the 
initiating lesion remains a mystery, a number of pathological cellular and molecular 
changes have been repeatedly observed in PAH which are believed to be linked to the 
processes of remodelling.
1.2.5.1 Endothelial cell dysfunction
The normal pulmonary vasculature is highly distensible with little or no basal tone and 
the endothelial cells play an integral role in maintaining this state by producing a wide 
array of vasoactive mediators and growth factors, which mediate PASMC growth and 
contractility (Mandegar et a l, 2004). In the normally functioning endothelium the 
balance of vasoactive mediators and growth factors is maintained so that PAP can be kept 
relatively constant tlirough distension and recruitment, even during a five-fold increase in 
cardiac output as may occur with intense exercise. However when this balance is 
disturbed, vasomotor tone, PAEC and PASMC proliferation, and thrombosis have all 
been shown to be increased. Given the marked heterogeneity in the endothelium of the 
vascular bed and the lack of understanding in the relationship between phenotype and 
function, it is difficult for pathologists to determine the extent of the role which
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endothelial dysfunction has played in a given case of PAH (Rich et al, 2003). However, 
immunohistochemical studies have shown endothelial production of vasoconstrictors and 
co-mitogens such as ET-1 and 5-HT to be increased and vasodilators and 
antiproliferatives such as nitric oxide (NO) and prostacyclin (PGI2) to be decreased in 
PAH patients (Christman et a l, 1992;Giaid et a l, 1993;Giaid & Saleh, 1995;Giaid,
1998). This is consistent with reports that both ET-1 and 5-HT plasma levels are elevated 
in PAH (Herve (%/., 1990;Herve <3 /., 1995;Stewart z^/., 1991),
Increased Endothelln 1 (ET-1)
In IP AH patients, the high arterial levels of ET-1 relative to venous levels, initially 
suggested to researchers that increased pulmonary production of ET-1 contributed to the 
development of the disease (Stewart et a l, 1991). ET-1 is now considered to play a 
crucial role in vascular remodelling and the development of PAH (Kirchengast & Munter,
1999). In short term human clinical trials, bosentan, a competitive antagonist of ETA and 
ETB receptors, has been shown to cause reversal of IP AH and regression of its associated 
histological changes (Rubin & Roux, 2002;Rubin et al, 2002) although the long term 
outcome remains to be seen. Bosentan has now been adopted as the front line approach 
in the treatment of grade 3 PAH patients (moderate symptoms) and is marketed as 
Tracleer. Interestingly the company that produces Tacleer claim it acts as an anti­
mitogen rather than a vasodilator. However the disease is not solely attributable to ET-1 
abnormalities and some patients fail to respond. Furthermore, Tracleer is associated with 
a relatively high risk of liver toxicity and therefore it is not suitable for all patients (Rich 
& McLaughlin, 2003).
Decreased Nitric oxide (NO)
NO, which has been widely shown to inhibit SMC proliferation and vasoconstriction also 
inhibits platelet aggregation (Singh & Evans, 1997). PAH patients with severe
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morphological changes to their pulmonary arteries have been found to have a reduced 
expression of endothelial nitric oxide synthase (NOS III) (Giaid & Saleh, 1995). This is 
corroborated by experiments using NOS III mutant mice which found an elevated PAP 
and an impaired vasodilator response to Ach (Steudel et a l, 1997). NO is also known to 
regulate apoptosis via its effects on Kv chamiels (Krick et a l, 2002)) (see 1.2.5.2 Down 
regulation of Kv chamiels), hence decreased synthesis of NO would be expected to result 
in decreased apoptosis and increased remodelling. NO is used clinically as one means of 
identifying those patients who are likely to respond to Ca^ "^  channel blockers.
Change in the prostanoid baiance; The thromboxane: prostacyclin ratio
Originally linked to endothelial dysfunction, is the reported increase in thromboxane A%
(TXA2) production. In IP AH and SPH patients TXA2 metabolites where found to increase 
where the metabolites of prostacyclin (PGI2) were decreased, (Christman et a l, 1992). 
TXA2 is a vasoconstrictor and SMC mitogen and is thought to play a role in the vascular 
remodelling associated with IP AH. However, the site of increased synthesis in IP AH has 
not been detennined although activated alveolar macrophages and platelets have been 
suggested (Robbins et a l, 2001).
PGI2 is a powerful vasodilator and inhibits platelet adhesion and cell growth. In IP AH 
and PAH patients expression of the PGI2 synthase has been shown to be significantly 
reduced (Tuder et a l, 1999). PGI2 promotes the production of vascular endothelial cell 
growth factor (VEGF) which is an angiogenic factor (Machado et a l, 2001). Growth 
factors such as VEGF and TGF-p are crucial to lung development and play a protective 
role by modulating adaptation to abnonnal conditions such as chronic hypoxia. Defects 
in the function of these factors have implicated them in the development of PAH. 
Experimental research appears to corroborate this. In the rat, studies where VEGF 
receptor blockade was perfoimed, resulted in vascular remodelling (characterised by
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endothelial proliferation) and mild PH in nonnoxic rats and severe irreversible PH in 
clrronically hypoxic rats (Taraseviciene-Stewart et a l, 2001).
PGI2 as a therapeutic tool: PGI2 is an important therapeutic tool, which was originally tried 
because it was observed to produce acute heamodynamic effects in a number of PAH 
patients (Rubin et a l, 1982). However PGI2 was also subsequently found to considerably 
improve the survival time of patients who do not show an acute vasodilator response and 
in these patients it is thought that it may inliibit or perhaps even reverse remodelling 
(Peacock, 1999;Rubin, 1997). In fact, some patients have shown sustained 
heamodynamic and clinical effects even after lOyears of continuous inhision, although 
most do develop a tolerance to its effects. Unfortunately PGI2 requires continuous 
intravenous infusion due to its short half-life. The inconvenience, high risk of infection 
and also the cost, ~£50,000/year/patient, mean this is far from an ideal treatment 
(Peacock, 1999).
PGI2 and gene therapy: An exciting recent development in PGI2 treatment came in 2002 
when gene therapy was successfhlly used to increase PGI2 synthase expression in the 
liver of rats suffering from PH induced by monacrotaline. The rats treated with gene 
therapy showed decreased right atrial pressure, decreased lung ET-1 levels and a 
significant increase in survival rate when compared to monacrotaline induced PH rats 
which had not received gene therapy (Suhara et al., 2002).
The loss of the endothelium as a physical barrier
The endothelium also acts as a physical barrier between the fibroblasts and PASMCs of 
the vascular wall and numerous circulating blood-bome factors. Damage to the 
endothelium allows contact of circulating factors, which can stimulate PASMC and 
fibroblast proliferation resulting in medial and adventitial hypertrophy, both of which are 
features of IP AH. Additionally, endothelial damage can also result in the development
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of thrombosis due to the contact between platelets and the sub-endothelial components of 
the vascular wall (Ruf & Morgenstern, 1995). Tlirombosis causes further occlusion of the 
vessel and exacerbate PAH.
1.2.5.2 D ow nregulation o f v o lta g e  gated potassium  (Kv) channels  
Kv influences vasoconstriction and proliferation
The transmembrane K"*" current (Ik) tlirough voltage-gated (Ky) channels plays an 
important role in regulating the resting membrane potential (£'m) in PASMCs (Yuan, 
1995). As such, the down regulation of would cause a reduction in Ik and result in 
depolarisation of the cell. This in turn could cause increased vasoconstriction and 
proliferation via its direct action on VDCCs and indirectly by its effect on the SR, via 
modulation of IP3 production. As already explained, elevated [Ca^’^ Jcyt is a critical signal 
in both vasoconstriction and proliferation. Evidence for the involvement of Ky 
downregulation comes from IP AH patients who show a decreased amplitude in Ik(v) and 
mRNA/protein expression of Ky channel subunits (Kyi.2 and K yi.5) relative to non- 
pulmonary hypertensive (NPH) and SPH patients (Yuan et a l, 1998a;Yuan et a l, 
1998b). It has also been reported that the genes for the inward rectifier potassium 
chaimels are upregulated in PAH (Geraci et a l, 2001) These findings are consistent with 
reports that resting [Ca^’^ Jcyt is substantially higher in PASMCs obtained from IP AH 
patients than PASMCs obtained from NPH or SPH patients (Yuan et a l, 1998a)). At 
present it is not known whether Ky channel abnonnalities are the result of genetic 
mutations or are acquired, but APAH following anorexigen use could be associated with 
a reduction in Ik as aminorex fumarate, fenfluramine and dexfenfluramine are known K^ 
channel blockers (Weir et a l, 1996).
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Kv influences apoptosis
Downregulation or inliibition of Ky channels may also be associated with the reduction 
in apoptosis in IP AH. Cell sMnkage, known as apoptotic volume decrease (AVD), is a 
hallmark of apoptosis. However, a reduction in Ik has been found to preserve cell 
volume and thus slow AVD (Remillard & Yuan, 2004). Furthermore, a high cytoplasmic 
[K^] also suppresses cytoplasmic caspases and nucleases which are thought to be the 
final mediators of apoptosis (Bortner & Cidlowski, 1999;Kiick et a l, 2001). Reduced 
apoptosis via downregulation of Ky channels has been shown to occur as a result of up- 
regulation of the Bcl-2 antiapoptotic membrane protein (Ekhterae et a l, 2001). Although 
Bcl-2 is down-regulated by the BMP protein in nomial PASMCs, it is hypothesised that 
in IP AH mutations in the BMP-R2 gene lead to a dysfunction in BMP mediated 
signalling as BMP-mediated apoptosis is significantly inhibited in IP AH but not in SPH 
(Zhang et a l, 2003).
Kv as a therapeutic target
As downregulation of K^ chaimels appears to be involved in vasoconstriction, 
proliferation and apoptosis, augmentation of K’’ channel function is a logical therapeutic 
target. Oral dichloroacetate has been found to increase Ky 2.1 chamrel expression, 
decrease remodelling and lower PVR in rats with SPH following exposure to chronic 
hypoxia (Michelakis et a l, 2002). As this drug has already been tested and found to be 
safe in heart failure studies it may be a useful therapeutic tool for the treatment of PAH.
1.2.5.3 Up-regulation of canonical transient receptor potential (TRPC) channels
In addition to store release and Ca^  ^influx tlirough VDCCs, [Ca^ "^ ]cyt can also be elevated
by influx tluough receptor operated (ROC) and store operated chaimels (SOC) (Fig 1.3). 
As already mentioned, elevation of [Ca^’^ jcyt is an important signal for enlianced 
proliferation, which in PAECs can result in intimai thickening and plexifonn lesions and 
in PASMCs results in medial hypertrophy. Depletion of store Ca^ "^ , triggers capacitive
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entry (CCE) through SOCs in order to maintain Ca^ '*' influx and refill intra-cellular 
stores. Canonical transient receptor potential (TRPC) genes have been shown to encode 
for SOCs and are believed to be responsible for CCE (Bimbaumer et al,  1996;Boulay et 
al,  1999;Zhu et al, 1996). Evidence for this in human PAECs comes from experiments 
in which PEACs were exposed to chronic hypoxia. Increases in SOC current and CCE 
induced by hypoxia were found to be paralleled by TRPC mRNA and protein expression 
and the use of TPRC interfering RNA was found to attenuate CCE (Fantozzi et al, 2003). 
In PASMCs increased CCE and proliferation is also associated with TRPC channel 
expression (Golovina et al, 2001) and inhibition of TRPC expression decreases the 
amplitude of CCE and inliibits proliferation. The elevated [Ca^‘*‘]cyt observed in IP AH 
would appear to be at least partially linked to up-regulated TPRC chaimel expression as 
CCE has been shown to be significantly elevated in PASMCs from these patients 
(Mandegar et al,  2004). The evidence suggests that up-regulation of TRPC (SOC) 
chaimels may contribute to the pathogenesis of PAH and could therefore be a suitable 
target for therapeutic intervention.
1.2.5.4 The 5-HT hypothesis
The possible role of serotonin (5-HT) in the development of PAH was first hinted at in 
the late 1960’s when an epidemic of PAH followed the over the counter sale of the 
anorexigen (diet drug), aminorex fumurate (Kay et al, 1971). Aminorex increases 5-HT 
availability by inducing platelet release of 5-HT, inhibiting its re-uptake and by inhibiting 
its breakdown by monamine oxidase (MAO) (MacLean et al, 2000b). In European 
countries where the drug had been sold, cases of PAH increased ten-fold and the 
epidemic continued until shortly after the drug was withdrawn in 1972 (Fishman, 1999). 
In the 1990’s a new epidemic of “dietary” PAH occurred following the combined 
prescription of fenfiur amine/dex fenfluramine and phentemiine.
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Fenfluramine/dexfenfluramine selectively act on the 5-HT transporter (5-HTT) to induce 
5-HT release whilst simultaneously inliibiting 5-HT uptake (McTavish & Heel, 
1992;Garattini et al, 1989), The inhibition of the 5-HTT has been shown to occur in 
serotinergic neurones of the brain, circulating platelets, PAECs and PASMCs (Lesch et 
ah, 1994), but interestingly the use of anorexigens have not been associated with 
remodelling in any other organ system but the lungs, Phentermine on the other hand, can 
inliibit MOA and has been shown to increase the vasoconstrictor effects of 5-HT in the 
rat lung (Seiler et al, 1976). In combination these drugs had a similar effect as the 
baimed aminorex fumurate. It has since been determined that use of anorexigen drugs 
causes a thirty-fold increase in the risk of developing IP AH (Fishman, 1999). These 
observations and findings lead to the 5-HT hypothesis of PAH.
5-HT acts as a vasoconstrictor and mitogen
In comparison to control subjects, some PAH patients have been shown to have reduced 
platelet 5-HT storage, increased platelet 5-HT release during aggregation and an 
increased 5-HT plasma concentration. These include those formerly classed as PPH as 
well as those with PAH associated with anorexigen use and portal hypertension (Herve et 
al, 1995;Herve et al, 1990;Laffi et al, 1992;Liu & Lee, 1999). Hence elevation of 
plasma 5-HT and possible localised 5-HT elevations due to abnormal fimctioning of the 
5-HTT could cause the pulmonary circulation to increase its tone. This would not only 
increase PVR but could also increase the reactivity of the vessels to other agonists 
tluough synergistic interactions between Gi and Gq proteins (MacLean, 1999)
Unlike a number of other mammals such as the rat, dog and cow where 5-HT induced 
vasoconstriction is mediated primarily through the 5-HT%A receptor, in the human 
pulmonaiy circulation, vasoconstriction seems to be mediated primarily tluough the 5- 
HTib receptor (MacIntyre et al,  1992;Morecroft et al, 1999;MacLean et al, 1996a).
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However rat models of chronic hypoxia induced SPH, show increased 5-HTm mRNA 
and an increased contribution of the 5-HTib receptor to the contractile response 
(MacLean et al, 1996b). Furthermore, treatment with the 5-HTib/d antagonist GR 
127935 substantially reduces the development of right ventricular hypertrophy in these 
animals (Keegan et al, 2001). These findings suggest the 5-HTib receptor may play a 
role in the development PAH. Therapeutically this would be an attractive target as unlike 
the 5 -HT2A receptor, which also mediates vasoconstriction in systemic vessels, the 5- 
HTib receptor is confined to the pulmonary circulation. This would avoid the problems 
of systemic hypo-tension associated with drugs like the 5-HT:A receptor antagonist 
ketanserin, which has proven to be relatively ineffective in the treatment of PAH.
However, perhaps the more important role of 5-HT in the development of PAH is related 
to its mitogenic activity. The mitogenic effects of 5-HT have been demonstrated in rat, 
bovine and human PASMCs (Lee et al,  1991;Pitt et al,  1994;Eddahibi et a l,  2001b) 
although 5-HT induced proliferation does not seem to occur in PAECs (Lee et al, 
1989;Lee et al,  1994b;Lee a/., 1997).
Mitogenesis and the 5-HT transporter (5-HTT)
There is an increasing body of evidence, which suggests that the mitogenic effects of 5- 
HT primarily occur through the internalisation of 5-HT by the 5-HT transporter (5-HTT) 
although mitogenesis may also be mediated thiough cell surface receptors. (Lee et al, 
1989;Lee et al, 1991 ;Lee et al,  1994a;Lee et al, 1994b;Pitt et al, 1994;Lee et al, 
1997;Eddahibi et al, 1999;Eddahibi et al, 2001b). For example, the proliferative effect 
of 5-HT on bovine and rat PASMCs has been shown to be dose dependently inhibited by 
the 5-HTT selective inhibitors paroxetine and fluoxetine (Lee et al,  1991;Eddahibi et al, 
1999). Furthermore, paroxetine and fluoxetine inhibit [^H]5-HT uptake and 5-HT
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induced cell proliferation at concentrations which suggest the phenomena are linked 
(Eddahibi et al, 1999).
The relationship between 5-HTT, chronic hypoxia and vascular medial remodelling
Whilst increased proliferation may be associated with the 5-HTT, there is however, a
significant contradiction in the literature as to how up-regulation of the 5-HTT is 
involved in PH. One research group has consistently reported the 5-HTT to be essential to 
the medial proliferation associated with cluonic hypoxia induced SPH. Clironic hypoxia, 
an intervention which can be used experimentally to cause vascular medial remodelling 
of PASMCs was found to cause a transient two and a half-fold increase in 5-HTT mRNA 
and a sustained three-fold increase in 5-HT uptake in vitro (Eddahibi et al, 1999). In 
vivo, 5-HTT mRNA expression was also been found to be enhanced in the lungs of rats 
exposed to chronic hypoxia (Eddahibi et al,  1999) and reduced in transgenic mice which, 
under-express 5-HTT (Eddahibi et al,  2000). At first these findings may seem to 
contradict the anorexigens having a role in the development of PAH, as the anorexigens 
are generally associated with inhibition of 5-HTT uptake and it might be expected that 
their use would therefore attenuate 5-HTT associated mitogenesis. However, it has been 
shown that discontinuation of dexfenfluramine treatment can also trigger an increase in 5- 
HTT expression. The increased expression resulted in significantly enlianced 
remodelling and right ventricular hypertrophy in rats, which were subsequently exposed 
to chronic hypoxia relative to those that had not been treated with dexfenfluramine 
(Eddahibi et a l,  2001a). Furthermore the anorexigens may themselves act as a substrate 
for the 5-HTT and it is possible they could be accumulated inside the cell, having effects 
similar to or greater than the 5-HT whose uptake they are preventing (Rothman et al,
1999). It has also been proposed that the anorexigens can cause inliibition of channels 
leading to elevated [Ca^ '^ Jcyt the effects of which have already been discussed.
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Although the exact mechanism by which the anorexigens trigger increased remodelling is 
not known, the findings that 5-HTT over-expression or increased activity play a critical 
role in the development of PH secondary to chi’onic hypoxia, naturally suggests the 
possibility of a role in PAH. Recent studies have demonstrated an increased expression 
of 5-HTT in lung tissues and pulmonary arteries isolated from patients with IP AH. 
PASMCs from these patients demonstrated a marked enhancement of proliferative 
growth to 5-HT, which did not occur in response to other growth factors. Furthennore 
the enhancement was abolished by the presence of 5-HTT inhibitors (Eddahibi et ai, 
2001a). Thus it is possible that anorexigens may contribute to the development of 
“dietary” PAH by 1) elevating [5-HT]piasma 2) acting as a substrate for 5-HTT (which 
then mimics the effect of internalised 5-HT) 3) affecting 5-HTT expression.
However, a number of other investigators strongly disagree that increased 5-HTT 
expression is involved in chronic hypoxia induced SPH. A number of studies have in fact 
reported a marked decrease in the expression, protein and activity of the 5-HTT following 
chronic hypoxia (Jeffery et al, 2000;Hoshikawa et al, 2003;MacLean et a l,  2004). In 
one in-vivo study, genetically induced over-expression of the 5-HTT was found to elevate 
PAP but did not cause remodelling or right ventricular hypertrophy, implying that over­
expression of the 5-HTT caused vasoconstriction prior to the onset of morphological 
change. The study also found that following chronic hypoxia, expression and activity of 
the 5-HTT were significantly attenuated despite the symptoms of PH being exacerbated 
(MacLean et al, 2004). Hence whilst the 5-HTT may well be involved in the 
development of PAH its role is presently far from clear.
5-HTT gene polymorphism and IPAH
It is thought that a 5-HTT gene polymorphism, could be responsible for the susceptibility 
of some IPAH patients. For example, a patient diagnosed with PAH associated with
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anorexigen use may have had an underlying 5-HTT polymorphism which on its own was 
not sufficient to trigger the onset of PAH but was subsequently exacerbated by the effect 
of anorexigen use.
A polymorphism in the promoter region of 5-HTT has been shown to alter transcriptional 
activity and has been associated with increased proliferation in human PASMC (Eddahibi 
et al, 2001b). The L-allelic variant of the 5HTT gene promoter was present in 
homozygous form in 65% of IPAH patients but in only 27% of controls and has a two to 
three-fold greater 5-HTT transcription relative to the S-allelic variant. As normal 
signalling from the BMP-R2 is associated with suppression of PAMSG proliferation and 
promotion of apoptosis, it has been hypothesised that it may antagonise the proliferative 
effects of 5-HT (Morrell et al, 2001;Zhang et al, 2003). If a BMP-R2 mutation is 
present, the antagonism to the proliferative effects of 5-HT (or substrates which can 
mimic its action) may be lost resulting in proliferation and increased expression of the 5- 
HTT. If this were to occur in patients who also posses the homologous L-allelic variant 
of the 5HTT gene promoter then the proliferative response and expression of the 5-HTT 
would be particularly enlianced (Mandegar et al, 2004). However it must be pointed out 
that at present there is no direct evidence for this but no doubt this avenue will be fully 
explored in the very near future.
1.2.5.5 Human urotensin II (hU-ll), a role In pulmonary arterial hypertension?
A recent development in the field of research into PAH, was the report by MacLean et
al, (2000a) that contractile responses to the endogenous peptide human urotensin II (hU- 
II), were enhanced in the rat main pulmonary artery by conditions which mimic aspects 
of PAH, such as nitric oxide synthase (NOS) inhibition and exposure to chronic hypoxia. 
The same group also reported that NOS inliibition umnasked a highly variable response 
to hU-II in 30% of human small pulmonary arteries tested. hU-II is the most potent
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peptide identified to date (Douglas & Ohlstein, 2000) and has been likened to ET-1, as 
initial studies suggested a number of similarities between these G-protein stimulating 
agonists (Maguire & Davenport, 2002). Hence it has been suggested that hU-II may be 
involved in the aetiology of PAH (MacLean et a l,  2000a). However, although hU-II has 
been linked to some aspects of systemic cardiovascular disease (Lapp et al, 
2004;Thanassoulis et al,  2004), there is currently no evidence from studies involving 
PAH patients. Furthermore, other studies using modelled conditions of PAH in rats and 
isolated human lungs and vessels, have failed to substantiate this hypothesis (Zhang et 
al, 2002;Bennett et al,  2004). Consequently, the role of hU-II in the regulation of 
pulmonary arterial tone and the pathogenesis of PAH requires further investigation and 
constitutes one of the aims of tliis thesis. A thorough review of hU-II is presented in the 
introduction to chapter 3.
1,2.5.6 Additional mechanisms
A number of studies using tissue obtained from PAH patients have demonstrated 
persistent matrix protein synthesis. This observation has led to a number of animal 
studies, which have shown promising results, but require further investigation.
Endogenous vascular elastase and vascular remodelling
In rats with chronic hypoxia or monacrotaline induced PH, a characteristic of remodelling 
is the thickening of the elastic laminae, which define the boundaries of the medial smooth 
muscle layer (Finlay et al, 1986;Todorovich-Hunter et al,  1992). The formation of the 
laminae are characterised by an early increase in serine elastase activity and the 
proteinase-dependent deposition of the extra-cellular matrix smooth muscle cell survival 
factor tenascin-C (Jones et al, 1997) . Tenascin-C amplifies the response of SMCs to 
growth factors, which are liberated through matrix proteolysis. In vitro studies using 
hypertrophied rat pulmonary arteries have shown that elastase inhibitors suppress
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tenascin-C and induce SMC apoptosis resulting in the complete regression of the 
hypertrophied vessel wall (Cowan et al, 1999). It has since been shown in vivo using the 
monacrotaline rat model, that inhibition of serine elastase resulted in 8 6 % survival and a 
regression of structural changes associated with PH, compared with a 100% mortality in 
the group that did not receive the elastase inhibitor (Cowan et al,  2000). This is 
corroborated by experiments in transgenic mice which show that over-expression of the 
serine elastase inhibitor elafm protected the mice from developing PH secondary to 
chronic hypoxia (Zaidi et a l , 2002). These findings suggest that elastase inhibitors may 
be useful in halting or reversing aspects of the vascular remodelling associated with PAH.
Statins
When activated, Rho GTPases, which are fundamental components of G protein coupled 
receptor transduction mechanisms, couple membrane growth factor receptors to the intra­
cellular MAP/ERK kinase signalling pathways that influence proliferation. In addition 
Rlio GTPase activation also inhibits endothelial NO production. Statins which are HMG- 
CoA reductase inhibitors better known for there cholesterol reducing effects, prevent the 
isoprenylation of Rho GTPases, thus reducing proliferation and augmenting 
vasodilatation through increased endothelial NO synthesis (Laufs et al, 2000;Eto et al, 
2002). Simvastatin has subsequently been shown to reverse PH and increase survival in 
both monacrotaline and chronically hypoxic rat models of PAH (Nishimura et al, 
2003;Girgis et al, 2003). Hence these findings suggest that statins may provide yet 
another possible avenue for treating PAH.
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1.3 Aims
Recently the peptide, human urotensin II (hU-II), has been reported to be capable of 
causing both vasoconstriction (in the presence of L-NAME) and vasodilatation in human 
small pulmonary arteries (MacLean et al, 2000a;Stirrat et al, 2001). The study by 
MacLean et al, (2000) also found that contractile responses to hU-II were enhanced in 
the main pulmonaiy artery of rats suffering from PH secondary to chronic hypoxia. 
However, other studies have found no response to hU-II in human vessels with 
endothelial dysfunction (Bennett et al, 2004) and that hU-II does not increase PAP in the 
clrronically hypoxic rat in-vivo (Deuchar et al, 2005)) (submitted for publication). 
Hence, the first aim of this thesis was to deteimine the role of hU-II in the regulation of 
pulmonary arterial tone and whether hU-II could be involved in the aetiology of PAH.
Another recent development in the pulmonary vascular field has been the report that ET- 
1, which is widely implicated in the development of PAH, can modulate Ca^ "^  sensitivity 
(CaS) in the rat small pulmonary artery (Evans et al, 1999). Furthermore, the Rho kinase 
(ROK) pathway, which is known to mediate increases in CaS, has also been implicated in 
the elevated basal tone of PH occurring secondary to chronic hypoxia, although the 
limited number of reports are conflicting (Sauzeau et al, 2003a;Nagaoka et al, 2004b). 
The second aim of this thesis was therefore to detennine the role of CaS in the regulation 
of pulmonary vascular tone and to determine whether modulations in CaS could be 
involved in the aetiology of PAH. The two areas chosen for study where PH secondary 
to chronic hypoxia and the 5-HT system. However only one previous pemieabilisation 
study has been performed in the rat small pulmonary arterty (Evans et al, 1999) and the 
technique used was not found to produce a sustainable preparation using the tools 
available to the author of this thesis. Hence it was first necessary to develop a suitable 
protocol.
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Chapter 2
General Methods
The common methodology underlying
the studies
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2.1 Tissue preparation
2.1.2 The 5-HHT over-expression model (mouse)
Female C57BL/6xCBA wild type (WT) mice were used to generate transgenic (TG) mice 
over-expressing the human 5-HT transporter (5-HTT). The transgene was a 500-kb yeast 
artificial chromosome (YAC35D8) containing the human 5-HTT gene and its presence 
was confirmed after weaning (-1 month) by tail tipping and RT-PCR. Transgenic mice 
yielded a 240bp product (2% agarose, ethidiimi bromide gel) which was absent in wild 
type mice. The forward and reverse primers were 5’-TTC TTT CCCT TAC TAA GTT 
GAG AAC G- and 3’5’-TGG CAT GCA ATT GTA GTC TC-3’ respectively. 
Environmental conditions and dietaiy composition were identical for both wild type and 
transgenic groups. This model has been previously used to study 5-HTT over-expression 
(MacLean et al,  2004).
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2.1.1 The chronically hypoxic model (rat)
Male Wistar rats aged 28 days were divided into 2groups, age matched control (AM) and
]i
i ■those to be exposed to 14-15days chronic hypoxia. The chronically hypoxic (CH) rats
■?
were placed in a hypobaric chamber (Royal Hallamshire Hospital Sheffield, U.K.) which
was depressurised to 550mbar over two days and then maintained at this pressure for a «I
further 12 day s. The chamber was ventilated with room air at ~ 45 1 miiT . Environmental 
conditions (e.g. temperature and light exposure) and dietary composition were identical
ffor both groups. The chronically hypoxic rat is an accepted model for the study of 
pulmonary hypertension (PH) (Rabinovitch et al, 1988;Suggett & Barer, 1988;Eddahibi 
et al, 1997;McCulloch et a l,  1998;MacLean et al, 2004).
2.2 Sacrifice and tissue procurement
2.2.1 Animal tissue
Rats were killed at 42-45 days old (180-250g), and mice at Smonths (20-25g) by cervical 
dislocation followed by exsanguinatinon. The heart and lungs were removed en bloc and 
immediately placed in ice-cold Kiebs buffer solution. The arteries (see vessel 
identification) were then dissected free from the surrounding lung parenchyma and 
sectioned into 2 mm lengths ready for mounting.
2.2.2 Human tissue
2mm long segments of intra-lobar pulmonary arteries (see 2.2.3 vessel identification) 
were dissected free (see appendix) from macroscopically normal pieces of lung tissue 
obtained following bronchial carcinoma removal. The tissue was obtained from tlxree 
female and two male patients aged between 54 and 78 years. The study was approved by 
the Research and Ethics Committee for North Glasgow Hospitals University Trust and all 
patients had given written informed consent (see appendix).
2.2.3 Vessel identification
Both extra-lobar and intra-lobar, rat and mouse pulmonary arteries were used in the hU-II 
study, whilst permeabilisation studies were limited to the rat and mouse intra-lobar, small 
pulmonary artery (SPA). The vessels were defined as follows:
Rat: Extra-lobar; main pulmonary artery (2-3mm i.d.) (Referred to as A-class vessels) 
and the first branch, pulmonary arteiy (l-2mm i.d.) (B-class). Intra-lobar; the 1®^ 
generation intra-lobar, pulmonaiy artery (0.75 -1.25mm i.d.) (C-class) and the 2"^  
generation intra-lobar, pulmonary artery (150-350pm i.d.) (D-class, also known as small 
pulmonary arteries (SPA’s)) (Fig 2.1).
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Extra-lobar
First branch 
(B-class)
D. 1- 2 mm
Main PA 
(A-class)
I.D. 2- 3 mm
Intra-lobar
1st gen 
intralobar 
(C-class)
I.D. 0.76
-1.25 mm
2nd gen
Intralobar
(D-class)
I.D. 150- 350pm
Figure 2.1 Vessel guide
The in situ location of the various classes of pulmonary arteries (sizes quoted are typical for rat 
vessels).
Mouse: Extra-lobar; main pulmonary artery (0.75-1.25mm i.d.) (Referred to as A-class 
vessels) and the first branch, pulmonary artery (0.5-1.0mm i.d.) (B-class). Intra-lobar; 
the 1®* generation intra-lobar, pulmonary artery (250 -550pm  i.d.) (C-class also known as 
SPA’s) (Anatomical locations as in Fig 2.1).
Human: Intra-lobar; 750-1500pm (size equivalent to C-class rat vessels) and 150-300pm 
(size equivalent to D-class rat vessels).
2.2.4 Assessment of pulmonary hypertension
The development o f pulmonary hypertension (PH) was assessed by measuring the ratio o f  
the right ventricular (RV) to total ventricular weight (TV). The heart was dissected free 
from the lung lobes, and the atria and all great vessels removed. The right ventricle was 
then dissected free o f the septum and left ventricle, blotted lightly and weighed. The left
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ventricle was incised to remove any remaining blood clots and the left ventricle/septum 
then blotted lightly and weighed along with the right ventricle. The RV/TV ratio is a 
reliable and accepted index for the development of PH in rats (Herget et al,  1978;Sheedy 
et al,  1996;Keegan et al, 2001).
2.3 Vessel set up
The isolated 2mm long vessel sections were mounted on a Mulvaney-Halpem isometric 
wire myograph (model 610M, JP Trading, Aarhus, Denmark) (Fig 2.2) and bathed in a 
Krebs-Hanseleit buffer solution of the following composition (mM); NaCl 118, NaHCOs 
25, D-glucose 1 1 , KCl 4.7, CaCh 2.5, KH2PO4 1 .2 , MgS0 4  1 . 2  (pH 7.4) at 24°C 
(permeabilisation studies) or 37 '^C (hU-II studies). The preparation was constantly 
gassed (16% O2 , 5% CO2, balance N2) to mimic normotensive, in vivo pulmonary arterial 
gas tensions.
Following 45minutes equilibration the vessels were tensioned in a stepwise manner until 
a stable tension, equivalent to a transmural pressure of 12-16mmHg was obtained. This 
procedure was intended to mimic the physiological in vivo pulmonary arterial transmural 
pressure and is known as normalisation. Normalisation is based on the law of Laplace 
(see Eq 2.1 and 2.2) for a thin walled tube. The procedure is adapted from the technique 
described by Mulvany and Halpem (1977), which is a reliable and accepted normalisation 
procedure in systemic vessels.
Eq 2 . 1  T  =  TjP
Equation 2.1 The law of Laplace for a thin walled tube
T = wall tension, n = internal radius, P = transmural pressure.
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Eq 2.2 P = T
Ti
Equation 2.2 Normalisation of pressure In a thin walled vessel
Where wall tension is calculated as (Force recorded /2)xvessel length and n is calculated from the 
micrometer readings (Mulvany & Halpern, 1977).
Transducer arm icrometer arm 
(Adjustable)
2mm
Figure 2.2 Isolated small pulmonary artery (rat D-class 150-350pm i.d.) mounted between 
the adjustable jaws of an isometric wire myograph unit
2.4 Determining the tension standard
Following the normalisation o f the replicated transmural pressure, each vessels response
to either a nominally iso-osmotic 120mM KCl solution exchange (permeabilisation
studies) or a hyper-osmotic 50mM KCl addition (hU-II and 5-HT general pharmacology
studies in unpermeabilised vessels) was determined. Any vessel which did not produce a
maximum force o f > ImN was discarded. The composition o f the nominally iso-osmotic
KCl solution was as follows (mM): KCl 120, NaHCO] 25, D-glucose 11, CaCh 2.5,
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KH2PO4 1.2, MgS0 4  1.2 (pH 7.4). Following the ascertainment of a stable maximal 
response to the chosen depolarising solution, vessels were thoroughly washed ( > 6  times) 
in Krebs buffer and allowed to return to baseline in readiness for use in their specific 
protocol.
2.5 Assessment of endothelial function (hU-ll studies only)
Following determination of the vessels tension standard response, the integrity of the 
vessels vascular endothelium was established by the ability of acetylcholine (Ach) 
(1 pM) to cause a relaxation of >20% in vessels pre-constricted with either phenylephrine 
(PE) or 5-HT (AM; IpM, CH; 0,1 pM). All vessels were then thoroughly washed again 
and allowed to return to baseline prior to commencing the individual protocols.
2.6 Specific protocols
Specific protocols are presented in the methods section of each results chapter.
2.7 Data analysis
Data were captured on Myodaq 2.01 multi and analysed using Myodata 2.02 (JP Trading, 
Aarhus, Denmark). All force data were recorded in mN and time data in seconds. The 
manner in which data are expressed (i.e. normalised, when this occurred) is described in 
the methods section of each results chapter. Wliere efficacy (Emax) is reported, it is 
expressed as a percentage of the tension standard. Logarithmic concentration-response 
plots were fitted by non-linear regression using the Hill equation (Eq 2.3) and potency 
(pECso values) obtained from the lines of best fit using Graphpad Prism 3.00. All data
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are presented as the mean ± s.e.m. and n represents the number of animals/patients 
sampled unless otherwise stated. Statistical analyses were performed using Graphpad 
Prism 3.00 and original traces transferred for presentation using Origin pro 6.1. Data 
were compared using the, students t-test or one way analysis of variance (ANOVA) 
followed by a multiple comparisons test (Tukey’s), but where appropriate, normalised 
data were compared using a non-parametric. Maim Whitney test, a Wilcoxon matched 
pairs test, or a Kruskal Wallis test. P<0.05 was considered to be statistically significant.
Eq 2.3 E[
E =  -------
[1+(D /Kd)]"
Equation 2.3 The Hill equation
E = response, E^ax = maximal response, D = drug concentration, Kq = dissociation constant, 
n = Hill coefficient
2.8 Solutions and Drugs
2.8.1 Mock intra-cellular solutions (permeabilisation studies)
The free Ca^’*’ concentration of the mock intra-cellular (MI) solutions was regulated by
the ratio of K.2EGTA/Ca^^EGTA present in the solution. Stock MI solutions of the 
following composition (mM) were produced fresh each day; KCH3COO 100, HEPES 25, 
MgCl2 5.5, CrP 10, ATP 5, DTT 0.1, W C a EGTA 10. All MI solutions were adjusted to 
pH 7.1 using KOH, in order to mimic actual intra-cellular pH. Temperature was 
maintained at 24°C in order to maximise the stability of endogenous high-energy 
compounds such as ATP and creatine phosphate. To preseiwe pH in the absence of bi-
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A .,: /  V /
carbonate (HCO3 ) all gassing was ceased immediately upon exposure to the MI 
solutions. 0ATP MI solutions were of the same composition as the normal MI solutions 
but contained no ATP and therefore had their Mg^^ content reduced to ImM.
2.8.2 Preparation of drugs used in permeabilisation studies
P-escin was dissolved in a pCa 5.7 MI solution, whilst all 5-HT agonist stock solutions
were dissolved in a pCa 6.64 MI solution. All agonist solutions were adjusted to pH 7.1 
at 24°C where required (except for general pharmacology experiments).
2.8.3 Drug procurement
ATP, A 23187, p-escin. Caffeine, L-NAME, 5-HT, 5-CT, and ame 5-HT were obtained 
from SIGMA (Poole, Dorset, U.K.). Citalopram, Fluoxetine, CP 94253, Thapsigargin and 
Y-27632 were obtained from Tocris (Avonmouth, Bristol U.K.). ET-I was obtained from 
Scientific Marketing Associates (Barnet, Hertfordshire, U.K.). LY 393588 was obtained 
from Eli Lilley (Windlesham, Surrey, U.K.). Human urotensin II was a gift from E.H. 
Ohlstein, GlaxoSmithKline.
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Chapter 3
Results Part I
The Role of Human Urotensin II (hU-ll) in the 
Regulation of Pulmonary Arterial Tone
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3.1 Introduction
Urotensin II (U-II) was first discovered in extracts from the urophysis of teleost fish just 
over 35 years ago (Bern & Lederis, 1969). Teleosts are the dominant super-order of bony 
fish and their urophysis is functionally analogous to the mammalian posterior pituitary. 
U-II was subsequently isolated and sequenced from the Goby, Gillichthys mirabilis, and 
found to be a “somatostatin like” dodecapeptide ( 1 2  amino acid peptide) with a 6  amino 
acid cyclic region near the C-terminal (Pearson et al, 1980). The extract was found to be 
vasoactive generally causing smooth muscle contraction including vasoconstriction in the 
Goby (Bern et al, 1985). In mammalian preparations, U-II has been found to cause both 
endothelium dependant vasodilatation (Gibson et al, 1986;Gibson, 1987) and 
endothelium independent contraction (Itoh et al, 1987;Ames et al,  1999;Douglas et al,
2000). It has been reported to be the most potent vasoconstrictor identified to date, being 
ten-fold more potent than ET-I in the rat aorta and more than one hundred-fold more 
potent in the primate femoral artery, however its efficacy is often much lower than that of 
ET-1 (Ames et al, 1999;Douglas et al, 2000). The vasoactive properties of U-II have 
been found to be highly variable, demonstrating both species and anatomical variation 
and have generated a number of conflicting reports (Gibson et al, 1986;Itoh et al, 
1987;Itoh et al,  1988;Ames et al, 1999;Douglas et al, 2000). To date there have been 
fewer than 10 studies that have reported on the effects of U-II pulmonary circulation. Of 
these, 6  have involved the use of the human isoform
3.1.1 Homologues of urotensin II (U-II)
The strong vasoactive properties of U-II led to the search for homologues in other species 
and in 1992 a similar but unique form of U-II was isolated and sequenced from frog brain 
(Conlon et al, 1992). Subsequently, mouse, rat, (Coulouam et al, 1999) porcine (Mori 
et al, 1999) and human (Coulouam et al, 1998) isoforms of U-II have all been cloned.
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All forms of U-II demonstrate absolute conservation of the C-teiminal cyclic hexapeptide 
sequence, with the homologues predominantly differing from one another in the first four 
to seven amino acids of the N-tenninal (Douglas & Ohlstein, 2000). The conserved 
cyclic sequence is thought to be responsible for ligand binding and hence for U-ITs 
biological activity as the different iso forms exhibit similar potencies both in vitro (Ames 
et al,  1999;Liu et al,  1999;Mori et al, 1999;Russell et al, 2001) and in vivo (Gardiner et 
al, 2001). Furthermore, substitution of residues outside of the ring has little effect on the 
biological activity of the various isoforms, whereas substitution of residues within the 
conserved ring or disruption of the disulphide-bridge markedly attenuates their biological 
activity (Brkovic et a l,  2003;Labarrere et al, 2003).
3.1.2 Human urotensin II (hU-ll)
Human urotensin II (hU-II) is the shortest of the U-II homologues and is an eleven amino 
acid peptide (Coulouam et al, 1998). As with all of the homologues of U-II so far 
identified it retains the conserved cyclic hexapeptide region (-Cys-Phe-Trp-Lys-Tyr-Cys- 
) of the C-terminal (Fig. 3.1). Reports from several species and various tissues suggest 
the potency and general effects of hU-II are very similar to that of the other homologues 
and most animal studies now use hU-II rather than the animals own endogenous 
homologue (Ames et al,  I999;Liu et al, 1999;Mori et al,  I999;Gardiner et al, 
2001;Russell et al,  2001).
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C-term inus
Val f  Cys
Tyr
Lys
Trp
Phe
Glu
Figure 3.1 The structure of human urotensin II (hU-ll) showing the conserved cyclic 
hexapeptide sequence near the C-terminus
3.1.3 Human urotensin II (hU-ll) synthesis
Cloning studies in human tissues have shown high concentrations o f precursor hU-II 
mRNA (Pre-pro hU-II mRNA) in the medulla oblongata and motoneurones o f the spinal 
cord (Coulouam et ai,  1998;Ames et al,  1999;Nothacker et al,  1999;Coulouam et al,  
2001). Additionally, lower concentrations o f prepro hU-II mRNA were also found in 
peripheral tissues such as the kidneys (Coulouam et al, 1998;Nothacker et al,  1999) 
adrenals and spleen (Coulouam et al,  1998), although initially none was reported in 
cardiovascular tissues (Ames et al,  1999;Nothacker et al,  1999). However more 
recently, quantitative RT PCR has shown hU-II mRNA to be abundantly expressed in the 
adrenals and kidney, as well as in the pituitary, placenta, and colonic mucosa (Totsune et 
al,  2001). Furthermore, lower levels o f expression were also reported in the heart, aorta, 
thoracic arteries and saphenous vein (Matsushita et al, 2001;Totsune et al,  2001) and in 
coronary artery and umbilical vein endothelial cells (Totsune et al,  2003). It is interesting 
to note that three o f the sites implicated in hU-II synthesis, the medulla, the kidneys and 
the adrenals, play important roles in the regulation o f blood pressure.
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In humans, two pre-pro hU-II peptides have been identified and are 124 and 139 residue 
alternate spliced variants (Coulouam et al., 1998;Ames et al., 1999). Both of these 
variants encode identical mature hU-II, which is thought to be liberated following the 
processing of a putative polybasic KKR site (Ames et al, 1999;Chai*trel et al, 2004). 
Recent evidence suggests that pre-pro hU-II undergoes post-translational cleavage within 
the cells that produce it by a putative, U-II converting enzyme (UCE). One of the 
proteolytic enzymes proposed to be UCE is Furin, a type I endoprotease which is also 
involved in the cleavage of Pre ET-1 (Russell et al, 2004).
3.1.4 Human urotensin II (hU-ll) localisation
Immunohistochemical studies using human and monkey tissues, have shown U-II like 
immunoreactivity not only in the spinal cord motoneurones but also in vascular and 
cardiac tissue, including human cardioinyocytes and coronary atheroma (Ames et al, 
1999). This has been conoborated by Maguire et al, (2000) who found the highest levels 
of immunoreactivity in skeletal muscle, and low levels in the left ventricle, aorta and 
coronary arteries. The presence of hU-II in the vasculature has been reported both in 
endothelial cells (Maguire & Davenport, 2002;Maguire et al, 2004) and in SMCs (Ames 
et al, 1999). Circulating plasma levels of hU-II are relatively low (5 ~70pM) (Totsune et 
al,  2001;Dschietzig et al, 2002;Totsune et al,  2003;Totsune et al,  2004), well below 
reported pEC^o values, which are typically in the low nM range. Hence it is thought that, 
like ET-1, hU-II may principally act as a paracrine/autocrine agent rather than as a 
circulating hormone (Totsune et al, 2001). Furthermore, like ET-1, elevated plasma 
levels of hU-II have been reported in conditions such as diabetes mellitus and 
cardiovascular disease (Totsune et al, 2003;Lapp et al, 2004;Thanassoulis et al, 
2004;Totsune et al,  2004).
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3.1.5 Human urotensin II receptor(s) (UT-II)
The first receptor for U-II was recently discovered by Ames et al., (1999), using what has 
been teimed as reverse pharmacology. Whilst attempting to identify novel G-protein 
coupled receptors (GPCR) a human seven transmembrane orphan GPCR with 75% 
homology to the rat GPR14 (SENR), was isolated and labelled human GPR14 (now 
known as UT-II). Within two months of these findings, tliree other independent groups 
(Liu et a l,  1999;Mori et al, 1999;Nothacker et al, 1999) had reported the action of 
various U-II homologues (fish, frog, porcine and human) on the rat GPR14 confirming U- 
II as the ligand for GPR14. UT-II is thought to be selective for U-II homologues as out 
of the 700 or so ligands tested, not even somatostatin, which shares the closest structural 
similarity to U-II, competed for binding, although it should be noted that ET-1 was not 
tried (Ames et al,  1999).
UT-II mRNA has been found to be widely expressed both within the central nervous 
system and peripheral tissues of mammals (Ames et al, 1999;Liu et a l,  1999;Nothacker 
et al,  1999;Gartlon et al, 2001;Maguire & Davenport, 2002). In human peripheral 
tissues, UT-II mRNA has been reported in the heart (atria and ventricles), aorta, thoracic 
arteries as well as in the lung, kidneys, pancreas, adrenals and tumour cell lines (Douglas 
& Ohlstein, 2000;Matsushita et al, 2001;Totsune et al, 2001;Maguire & Davenport, 
2002;Takahashi et al,  2003). On a cellular level, UT-II mRNA was found to be present 
both in arterial smooth muscle and endothelial cells consistent with hU-II’s action as an 
endothelium independent vasoconstrictor and an endothelium dependant vasodilator 
(Ames et al, 1999;Maguire, 2003). These findings are consistent with UT-II receptor 
protein expression which was also detected in human vascular smooth muscle and 
endothelial cells and cardiac myocytes (Maguire et al, 2000;Douglas et al, 2002)
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3.1.6 hll-ll signal transduction
The UT-II receptor is believed to be a G-protein coupled receptor (Gq/n family) as its 
activation is linked to PLC stimulated phosphoinositide turnover and IP3 production 
(Saetrum et al, 2000). Binding of hU-II to UT-II has been shown to cause both Ca^  ^
mobilisation (Ames et al, 1999;Liu et al, 1999;Nothacker et al, 1999;Sauzeau et al,
2001) and Ca^  ^sensitisation in rat systemic arterial SMCs through activation of the small 
GTPase RlioA and its down-stream effector, Rlio kinase (ROK) resulting in 
vasoconstriction and proliferation (Sauzeau et al, 2001). Additionally activation of the 
UT-II receptor has also been associated with activation of PLA2 and arachidonic acid 
metabolism (Mori et al, 1999). Vasodilatation is presmned to occur in as a result of Ca^  ^
mobilisation in endothelial cells triggering the release of endothelial derived relaxing 
factors, however the specific nature of the agents released seems to vary between 
vascular beds. NO, PGI2 and endothelial derived hyperpolarising factor (EDHF) have all 
been implicated (Bottrill et al, 2000;Gardiner et al, 2004).
3.1.7 The pharmacological profile of hU-ll as a vasoactive agent
Most of the in vitro responses to hU-II observed to date have been limited to the arterial
side of the vasculature and are consistent with the initial findings of UT-II/GPR 14 
expression by RT PCR (Ames et al, 1999) (Table 1). This has led to hU-II being 
labelled as an arterial selective spasmogen (Newby & Jalan, 2000). Although a human 
(Maguire et al, 2000), and a primate (Hay et al, 2000) study have reported venous 
responses to hU-II, the constriction was of veiy low efficacy (<20% of the tension 
standard). Furtheimore, in the case of the human saphenous vein there have also been 
two contradictory reports that found no response to hU-II in this vessel (Hillier et al, 
2001;Paysant et al, 2001).
66
hU“II also demonstrates species selectivity. For example, in the Cynomolgus monkey 
(old world primate)(Douglas et al,  2000) and the cat (Behm et al, 2004), every arterial 
vessel tested to date has demonstrated a potent and very efficacious vasoconstrictor 
response, whereas in the marmoset (new world primate), mouse (Douglas et al, 2000) 
and human vessels (Maguire et al, 2000;Hillier et al, 2001;Paysant et al,  2001), 
contractile responses have either been entirely absent or where present, of very low 
efficacy (Table 1). This species selectivity is not simply the result of vasoconstriction 
being offset by an opposing vasodilator action as in many of these vessels the responses 
were unaffected by removal of the endothelium (Douglas et al, 2000).
Consistent with the earliest in vivo report of the vasodilator action of U-II in the 
anaesthetised rat (Gibson et al, 1986), in vitro hU-II has been reported to cause 
endothelial dependant vasodilatation in rat and human isolated arteries (Bottrill et al, 
2000;Stirrat et al,  2001). However, in keeping with the complicated pattern of 
mammalian hU-II pharmacology, the mechanism by which this occurs seems to vary 
between vascular beds, with NO reported to be the mediator in rat coronary arteries, 
EDHF thought to be responsible in rat small mesenteric arteries (Bottrill et al, 2000), and 
prostaniods being reported to be involved in hindquarter vasodilatation in the rat in vivo 
(Gardiner et al, 2004).
In vivo studies of hU~II have been performed in the rat, Cyiiomolgous monkey and 
humans. The findings of these studies highlight the species-specific response to hU-II 
and seem to be broadly consistent with what has been established from in vitro studies so 
far. In the rat, hU-II infusion caused an initial reduction (at high concentrations -3nM) in 
mean arterial pressure (MAP), which was characterised by mesenteric and hindquarter 
vasodilatation and non-reflex tachycardia. However this was subsequently followed by a
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Table 1
Vessels Mouse Rat Cat Dog Pig Marmoset Cynomolgus
monkey
Human
Systemic arteries
Thoracic aorta 0/ +++/0 +++/ 0/ ++?/ +/ +++/
Common carotid ++/ +++/ 0/ ++?/ +71 +++/
Abdominal aorta 0/ +/ 0/ +?/ +71 +++/
Femoral 0/—? +++/ 0/ +?/ 0/ +++/
LCX coronary +++/ 0/ +++/ +?/
LAD coronary ++?/— +++/ +++/ 0/
Basilar +/. 0/ +++/
Internal mammary 0/ 01 +++/ +?/
Renal 0/ +++/ 01 0/ +++/
Mesenteric 0/— +++/ 01 ++?/ +71 +++/
Radial +71
Subcutaneous 0/
Abdominal +++/ / -
arterioles
Pulmonary arteries
Extra-iobar ++/ 01 ++?/ +++/
intra-lobar 0/ 0 / -
Systemic Veins
Saphenous 0/ 0/ 01 +71
Jugular 0/ 0/ 0/
Portal 0/
Subcutaneous 0/
Umbilical 01 0/ 01 +/
Pulmonary veins
Adjacent to atria +l
Table 1. Summary of the in vitro responses to the peptide human urotensin II (hU-ll) 
performed in isolated vessels with an intact endothelium, taken from various species and 
vascular beds
+ vasoconstriction, - vasodilatation, 0 no response, blank response not tested.
+ < 25% of the tension standard, low efficacy, ++ 25%-75% moderate efficacy, +++ >75% high 
efficacy, same scale for dilatation.
? variable response, where vessels have regularly failed to respond within a study and/or reports 
suggesting no response from other authors.
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slow onset increase in MAP after -30 -120mins (Gardiner et al, 2001;Gardiner et al, 
2004).
In contrast, hU-II infusion in the Cynomolgous monkey caused a massive increase in 
peripheral resistance and cardiac dysfunction resulting in circulatory collapse, which is 
entirely consistent with the constrictor profile form in vitro studies (Ames et al, 1999). 
In vivo responses in humans are conflicting with localised vasoconstriction (Bohm & 
Pernow, 2002) and vasodilatation (Lim et al, 2004) reported with administration of hU-II 
to specific vascular beds. However, general i.v. infusion of hU-II has been reported to 
have no effect on haemodynamics or arterial compliance even at high concentrations 
(Affolter et al, 2002;Wilkinson et al, 2002) and seems to be consistent with the 
generally low efficacy or unresponsive reports from in vitro studies.
3,1.8 hU-ll, pulmonary vascular regulation and pulmonary arterial 
hypertension
hU-II has recently been reported to cause vasodilatation (Stirrat et al, 2001) but not 
vasoconstriction of normal hmnan small pulmonary arteries (MacLean et al, 
2000a;Bermett et al, 2004). Additionally, vasoconstriction of the main pulmonary artery 
has been reported in the Cynomolgous monkey, pig (Douglas et al, 2000) and rat 
(MacLean et al, 2000a). These findings suggest a role for hU-II in the regulation of 
pulmonary arterial tone and raise the question of whether hU-II could be involved in the 
pathological changes of PAH. Models, which mimic the pathological changes of PAH 
such as medial remodelling due to chronic hypoxia, replicated endothelial dysfunction 
due to inhibition of NOS by L-NAME and elevated tone using ET-1, have all been 
reported to enhance responses to endogenous vasoconstrictors in the pulmonary 
circulation (MacLean, 1999). It is therefore interesting to note that in human small 
pulmonary arteries pre-treated with the NOS inhibitor L-NAME, a highly variable
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contractile response has been reported in 30% of vessels tested, suggesting a possible role 
for hU-II in the pathogenesis of PAH, although the vessels did not respond in the 
presence of ET-1 (MacLean et al,  2000a). However, the dysfunctional endothelial 
hypothesis of hU-II’s action has recently been questioned, with evidence that neither hU- 
II nor gU-II caused increased constriction of human pulmonaiy vessels obtained from 20 
patients who might be expected to exhibit some degree of endothelial dysfunction, 
including those with hypertension, coronary artery disease, peripheral vascular disease, or 
diabetes (Bemiett et al, 2004). Although the vessels obtained were not from PAH 
patients, no contractile effects to hU-II were observed despite some vessels having a 
dysfunctional endothelium as indicated by the absence of vasodilatation to Ach in pre­
constricted vessels. The same group also reported that hU-II failed to induce either 
vasoconstriction or vasodilatation in the isolated perfused lung (Bemiett et al, 2004).
In addition its action on arterial preparations, hU-II has also been reported to be a potent 
vasoconstrictor of primate aiiways and pulmonary veins. However only those veins 
which were directly adjacent to the atria responded and hU-II had no effect on the more 
distal veins (Hay et al, 2000).
Plasma levels of hU-II have not been measured in PAH patients to date, but in chronic 
heart failure patients (left heart failure), reports are conflicting with both an elevation 
(Douglas et al, 2002;Russell et al, 2003) and no change of hU-II plasma levels being 
reported (Dschietzig et al, 2002). Most PAH patients eventually die of right heart 
failure.
In the rat, it has been reported that the efficacy but not the potency of the main pulmonary 
artery’s contractile response to hU-II was increased ~ 60% by incubation with the NOS 
inhibitor L-NAME. However it was also reported that removal of the endothelium by 
mechanical denudation or raising the vessel tone with ET-1 prior to hU-II exposure did
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not increase the efficacy of the hU-II response, although it did increase its potency some 
two and a half-fold (MacLean et al, 2000a).
The chronically hypoxic rat model of PAH, which exhibits medial hypertrophy, increased 
PAP and right-sided heart failure, has also been reported to show an enhanced contractile 
response to hU-II with an -80% increase in efficacy but no change in potency (MacLean 
et al,  2000a). However, although hU-II content has been reported to be increased two­
fold in the right ventricle of chronically hypoxic rats consistent with the development of 
right ventricular hypertrophy, it was also reported that there was no increase in either 
plasma hU-II levels or lung tissue concentration of hU-II following exposure to chronic 
hypoxia (Zhang et al, 2002). These findings would suggest that any pathogenic changes 
in the hU-II response of the chronically hypoxic rat, may occur at a receptor or intra­
cellular signalling level, for example through increased receptor expression or increased 
efficiency of G-protein coupling.
3.1.9 Aims
The aims of this chapter were three-fold. 1) To pharmacologically profile the 
vasoconstrictor and vasodilator responses to hU-II in the mouse, rat and human, 
pulmonary arterial systems. 2) To determine if responses to hU-II are augmented in 
“single aspect” models of PAH. 3) To determine if responses to hU-II are further 
enhanced in combined models of PAH (e.g. combinations of clironic hypoxia, NOS 
inhibition and ET-1 raised tone).
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3.2 Methods
Mouse, rat and human pulmonary arteries were dissected out and set up as described in 
the general methods section. PH was confirmed in animals exposed to 2weeks chronic 
hypoxia by assessment of the RV/TV ratio (see chapter 2). Vessels were normalised 
using tensions, which created the equivalent of a transmural pressure of either 1 2 - 
16mmHg (to mimic normotensive in vivo pressures) or 30-35mmHg (to mimic 
hypertensive in vivo pressures). Following normalisation, the response of each vessel to 
50mM KCl was established and used as the tension standard. Endothelial function was 
then established as described in chapter 2. The following studies where then perfomied:
3.2.1 Responses to hU-II in control, isolated rodent and human pulmonary 
arteries
3.2.1.1 Vasoconstriction
To determine the vasoconstrictor profile of hU-II, cumulative concentration response 
curves (CCRCs) (IpM - IpM) were constructed using the following vessels; Mouse; 
extra-lobar A and B-class, intra-lobar C-class. Rat; extra-lobar A and B-class, intra- 
lobar C and D-class. Human; intra-lobar 750-1500pm (size equivalent to C-class rat 
vessels) and 150-300pm (size equivalent to D-class rat vessels).
3.2.1.2 Vasodilatation
To determine the dilator profile of hU-II, tone was raised using 0.1 pM PE (mouse) or 1- 
lOnM ET-1 (rat) in paired vessels from the same animal, taken from the following 
sources. Mouse; extra-lobar A and B-class, intra-lobar C-class. Rat; extra-lobar A and 
B-class, intra-lobar C and D-class. Following establishment of a stable raised tone, 
CCRCs to hU-II (IpM - IpM) were constructed using one of each of the paired vessels, 
whilst the remaining vessel of the pair acted as a time control to determine the natural
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rate of deterioration of the raised tone. The hU-II dilator response in the human small 
pulmonary artery has previously been reported (Stirrat et al., 2001).
3.2.2 Contractile responses to hU-ll in single aspect models of pulmonary 
arterial hypertension
3.2.2.1 Wistar rat pulmonary arteries
To determine if the contractile effects of hU-II could be enhanced in PAH, CCRCs to hU- 
II (IpM - IpM) were constructed under 3 separate conditions (each modelling a single 
aspect of PAH) in the following rat pulmonary arteries; extra-lobar A and B-class, intra- 
lobar C and D-class. The conditions were. 1) Inhibition of nitric oxide synthase (NOS) 
with lOOpM L-NAME (20rnins incubation), to mimic endothelial dysfunction. 2) ET-1 
(l-3nM) induced tone to mimic elevated basal tone. 3) Vascular remodelling by using 
vessels from animals that had been exposed to 2 weeks chronic hypoxia.
3.2.2.2 Human pulmonary arteries
To confirm reports that contractile responses are uncovered by NOS inhibition in human 
intra-lobar pulmonary arteries and determine their suitability for receptor 
characterisation, hU-II, CCRCs (IpM - IpM) were constructed using the following 
vessels which had been incubated (20mins) with lOOpM L-NAME; human intra-lobar; 
750-1500prn (size equivalent to C-class in rat vessels) and 150-300pm (size equivalent to 
D-class rat vessels).
3.2.3 Contractile responses to hU-ll in Wistar rat puimonary arteries in the 
presence of increased resting tension
Observations from the models of PAH suggested that increased tension might unmask an 
augmented contractile response to hU-II. To investigate this hypothesis further hU-II,
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CCRCs (IpM - IpM) were constmcted using the following rat pulmonary arteries; extra- 
lobar A and B-class, intra-lobar C and D-class, both in the presence and absence of L- 
NAME at tensions which mimicked a transmural pressure equivalent to 30-35mmHg.
3.2.4 Contractile responses to hll-ll in combination models of pulmonary 
arterial hypertension in the Wistar rat
As some individual A-class rat pulmonary arteries had shown a modified response to hU- 
II under the single aspect models of PAH and all had demonstrated a marked increase in 
efficacy under conditions of elevated tension, it was hypothesised that these responses 
may be further enhanced in a combination model of PAH, which simultaneously 
mimicked several aspects of PAH. Similarly the uncovering of a small contractile 
response in the chronically hypoxic rat, D-class (SPA) vessels suggested a possible role 
in the increased vasoconstriction of PAH, which predominantly occurs at this site. To 
determine if the contractile effects of hU-II could be enhanced in combination models of 
PAH, CCRCs to hU-II (IpM - IpM) were constructed in the combined presence of NOS 
inhibition and ET-1 raised tone using A and D-class vessels from chronically hypoxic
74
rats.
3.3 Results
3.3.1 Responses to hU-ll in control, isolated rodent and human puimonary 
arteries
The aim of the first series of experiments was to systematically determine the vasoactive 
profile of hU-II in the mouse and rat pulmonary arterial circulations. This approach was 
intended to identify which animal(s) and vessel class(es) would be suitable for further 
study under modelled conditions of PAH.
3.3.1.1 Mouse
hU-II failed to induce either vasoconstriction or vasodilatation in any of the vessels 
studied (Vasoconstriction; A, B, C-class (all groups) n=8 , vasodilatation; all groups n=4). 
However, hU-II did cause a potent (pECgo 7.53 ± 0.20) and sustained contraction in the 
aorta that was 21± 6 % (n=8 ) of the 50mM KCl tension standard response, confirming the 
hU-II peptide was active.
The mean internal diameter and replicated transmural pressure of each vessel class was as 
follows: A-class; 1037 ± 41pm / 15.1 ± 0.4mmHg, B-class; 759 + 44pm / 14.7 + 
0.4mmHg, C-class; 383 ± 18pm / 13.5 ± 0.3mmHg (all groups n=12). Endothelial 
function of A-class vessels used in the vasodilatation study was confirmed by Ach 
induced relaxation (30 ± 5%, n=4) of 0.1 pM PE induced tone. However, endothelial 
function could not be routinely confirmed in the B and C-class vessels. The internal 
diameter, replicated transmural pressure and PE raised tone used during the hU-II 
vasodilatation CCRC, was not different between the time control and response vessels in 
any group (P>0.05).
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3.3.1.2 Rat
hU-II had a potent, but low efficacy, constrictor action on A-class (Emax: 19 ± 4% (of 
the response to 50mM KCl); pECso 8.64 ±0.17, n=9 rats), B-class (Emax: 9 ± 2 %; pECso 
8.57 ± 0.16, 11=13) and C-class vessels (Emax: 13 ± 3%; pECso 8.54 ± 0.19, n=14), but 
had essentially no action on the D-class vessels (n=14) (Fig 3.2 & 3.3).
hU-II failed to elicit a dilator response in any of the ET-1 pre-constricted rat vessels (n>6 , 
(all groups (A,B,C,D-class)). Endothelial function of all A, B, C-class and 3/6 D-class 
response vessels in the vasodilatation study was confirmed by Ach induced relaxation of 
PE raised tone prior to the hU-II CCRC (A-class relaxation to Ach; 58 ± 12% of the 
phenylephrine induced tone, B-class; 53 ± 13%, C-class; 63 ± 9%, D-class; 16 ± 5%, 
n=6-7 all groups). Furthermore the ET-1 raised tone was found to be attenuated by Ach in 
a dose dependant manner in randomly selected vessels following the hU-II CCRC. There 
was no difference in internal diameter, replicated transmural pressure or the magnitude of 
the ET-1 raised tone between the time control and response vessels in any group 
(P>0.05).
The mean internal diameter and replicated transmural pressure of each vessel class was as 
follows: A-class; 2433 ± 25pm / 15.9 ± 0.2mmHg, n=15, B-class; 1426 ± 41pm / 13.8 ± 
0.2mmHg, n=19, C-class; 959 ± 31pm / 13.5 ± 0.2mmHg, n=22, D-class; 217 ± 12pm /
14.7 ± 0.3mmHg, n=21.
3.3.1.3 Human
hU-II failed to cause a constrictor response in any of the vessels tested (750-1500pm C- 
class size equivalent n=3, 150-300pm D-class size equivalent n=4). The mean internal 
diameter and replicated transmural pressure of the vessels was as follows: C-class size
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equivalent; 874 ± 76pm / 14.0 ± 0.7mmHg, n=3, D-class size equivalent; 270 ± 9pm /
14.8 ± 0.4mmHg, n=4.
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Figure 3.2 The contractile profile of hU-ll in the pulmonary circulation of the Wistar rat
Experimental traces showing the protocol used to construct hU-ll CCRCs in A) Extra-iobar A- 
class vessels B) Extra-lobar B-class vessels C) Intra-lobar C-class vessels and D) Intra-lobar D- 
class vessels. hU-ll was added in 13 incremental steps over the range 10"^^- 10'®M.
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Figure 3.3 hU-ll CCRCs in Wistar rat pulmonary arteries
A) Experimental trace showing a typical hU-ll CCRC in an A-class vessel. B) Graph showing the 
potent, but low efficacy constrictor profile of hU-ll in extra-iobar and intra-lobar vessels. Extra- 
iobar; A-ciass n=9, B-class n=13, Intra-iobar; C-class n=14, D-class n=14.
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3.3.2 Contractile responses to hU-ll in single aspect models of pulmonary 
arterial hypertension
3.3.2.1 Wistar rat pulmonary arteries 
inhibition of nitric oxide synthase (NOS) using L-NAME
Incubation with the nitric oxide synthase inliibitor L-NAME (100|j,M) caused an increase 
in tone in A, B and C-class vessels, but only elvated tone in 3/11 D-class vessels (L- 
NAME tone: A-class; 3 + 1% of the 50mM KCl response, B-class; 5 ± 1%, C-class; 15 ±
3%, D-class; <1 ± 1%, n > 10 all groups). The presence of L-NAME induced tone failed 
to significantly enhance either the efficacy or potency of the contractile response to hU-II 
in any vessel class (n > 10 all groups, E>0.05, all unpaired t-test), although a small but |
rapid spiking phenomenon was uncovered in 3/10 A-class vessels. This phenomenon, 
was not observed in any other vessel group (Fig 3.4).
Elevated vascular tone induced by endothelin 1 (ET-1)
Elevating vascular tone by 10-20% (of the 50mM KCl tension standard) with ET-1 (1- 
3nM) failed to significantly increase either the efficacy or potency of the contractile 
response to hU-II in any vessel class tested (n > 6  vessel groups A, B, D, P>0.05, all 
unpaired t-test). However the presence of ET-1 induced tone did uncover a rapid spiking 
phenomenon in 4/6 A-class and 1/8 B-class vessels challenged with hU-II. This occurred 
over the hU-II concentration range of 3nM - 0,1 pM. In 2 A-class vessels the ET-1 
associated spiking phenomenon was substantial (-80-90% of the 50Mm KCl tension 
standard), however it should also be noted a similar unusually large response also 
occurred in 1 control vessel. The frequency of the phenomenon did not appear to be 
modulated by hU-II (Fig 3.5).
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Vascular remodelling associated with chronic hypoxia
2 weeks chronic hypoxia failed to enhance either the efficacy or potency of the contractile 
response to hU-II in A, B and C-class vessels (A and B-class; n>7, P>0.05, unpaired t- 
test). In fact, hypoxia caused a significant attenuation in the C-class vessel response to 
hU-II (AM C-class Emax; 11+ 3% of the 50mM KCl response, n=7 vs CH; 3 + 2%, n=8 , 
P<0.05, unpaired t-test). 2weeks chronic hypoxia did however, cause a very small but 
significant increase in the D-class contractile response to hU-II (AM; <1 + 0.4% vs CH; 6  
+ 2%, n=8 , P<0.05 unpaired t-test) (Fig 3.6).
Vessel’s from clironically hypoxic rats, which did not stabilise to a true basal tone by the 
3^  ^ KCl exposure where discarded from the study. Unstable, A-class vessels from 
chronically hypoxic animals demonstrated a rapid spiking behaviour, which 
spontaneously and progressively increased basal tone until the vessels were often near 
maximal contraction. When these vessels were incubated with 2 APB, which 
competitively blocks IP3 receptors, the spiking phenomenon immediately ceased and the 
vessels returned to a stable basal tone. Studies perfonned in A-class vessels in the 
presence of 2 APB, found that unstable vessels from hypoxic rats did not show an 
enhanced response to hU-II relative to control vessels under identical conditions (AM; 7 
± 2% of the 50mM KCl tension standard response, n=5 vs CH; 5 + 2%, n=6 , jP>0.05 
unpaired t-test). The RV/TV ratio was significantly larger in the clu'onically hypoxic 
groups and was consistent with the development of PH secondaiy to chronic hypoxia 
(AM; 0.217 ± 0.002 n=12 vs CH; 0.318 + 0.008, n=12, P<0.0001, unpaired t-test).
The internal diameters and replicated transmural pressures of the age matched control 
vessels and those vessels incubated with L-NAME or ET-1, were not different and were 
comparable with those of the vessels reported in results section 3.3.1.2 (n > 6  all groups, 
P>0.05, unpaired t-test). Although the internal diameters of the age matched control and
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chronically hypoxic vessels were not different (n > 7 all groups, P>0.05, unpaired t-test), 
the initial replicated transmural pressure was at least two-fold greater in all chronically 
hypoxic vessel goups relative to the control vessel groups (A-class; 33.3 ± 0.9 mmHg vs
15.8 ± 0.4mmHg, 13-class; 33.9 ± O.dmmHg vs 13.4 ± 0.3mmHg, C-class; 32.4 ± 
O.SmmHg vs 13.2 ± 0.2mmHg, D-class; 32.9 ± O.SmmHg vs 15.1 ± 0.5mmHg, n > 7 all 
groups, P<0.0001, unpaired t-tests).
3.3.2.2 Human pulmonary arteries
Inhibition of nitric oxide synthase (NOS) with L-NAME
Inhibition of NOS using L-NAME failed to unmask a contractile response to hU-II in any 
of the human pulmonary arteries tested (750-1500pm C-class size equivalent n=3, 150- 
300pm D-class size equivalent n=4). The internal diameters and replicated transmural 
pressures of those vessels incubated with L-NAME, were comparable with those of the 
control vessels (n =3-4, P>0.05, unpaired t-test).
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Figure 3.4 The effect of nitric oxide synthase (NOS) inhibition on the hU-ii response in 
Wistar rat, A-ciass (extra-lobar) pulmonary arteries
A) Experimental trace showing the small spiking phenomenon observed in 3/10 vessels during 
the performance of the hU-ll CCRC. B) Graph comparing hU-ll CCRCs performed in A-class 
extra-lobar vessels in the presence and absence of the NOS inhibitor L-NAME (n=10/10, P>0.05). 
The tone associated with L-NAME incubation, which is shown in the figure was subtracted prior to 
statistical comparison.
83
A
1e-7
- 9 0 %
3e-0
3e-7
2 0 0 0 s
ET-1 raised tone
h U -!l C C R C
B
2  75-|IL-fl
25-
4- ET-1 raised tone
Control
13 -12 -11 6 51 0  - 9 -8 -7
hU-n (Log M)
Figure 3.5 The effect of ET-1 raised tone on the hU-II response in Wistar rat, A-class (extra- 
lobar) pulmonary arteries
A) Experimental trace showing the unusually large spiking phenomenon observed in 2/6 vessels 
during the performance of the hU-ll CCRC in the presence of ET-1 raised tone. A similar 
response was also observed in 1 control vessel. B) Graph comparing hU-ll CCRCs performed in 
A-class extra-lobar vessels in the presence and absence of ET-1 raised tone (n=6/8, P>0.05). 
The tone associated with ET-1 which, is shown in both the trace and the graph was subtracted 
prior to statistical comparison.
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Figure 3.6 The effect of 2weeks chronic hypoxia on the hU-ll response in Wistar rat, extra- 
lobar and intra-iobar pulmonary arteries.
A) Extra-lobar vessels; A-class (n=8/8, P>0.05), B-class (n=8/7, P>0.05). B) Intra-iobar vessels 
C-class (n=7/8, P<0.05), D-ciass (n=8/8, P<0.05). AM = age matched control vessels - Black 
symbols, CH = vessels from rats exposed to chronic hypoxia -  White symbols.
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3.3.3 Contractile responses to hU-H in Wistar rat pulmonary arteries in the 
presence of Increased resting tension
Increasing resting tension by additional stretch of the vessel wall, mimicked a two-fold 
increase in transmural pressure (30-35mmHg) but failed to significantly enhance either 
the efficacy or potency of the contractile response to hU-II in any vessel class (n > 6  all 
groups (A,B,C,D class), P>0.05 unpaired t-test). However the increased tension did 
uncover a small but rapid spiking phenomenon at hU-II concentrations above 3-lOnM in 
4/7 A-class vessels. This phenomenon was also observed in 1/12 B-class group vessels 
(not shown).
In contrast, the combination of increased resting tension and NOS inhibition by L-NAME 
caused a substantial three-fold increase in the efficacy, but not the potency of the A-class 
hU-II contractile response. The response was characterised by the onset of a large rapid 
spiking phenomenon in 7/7vessels at hU-II concentrations of >3nM (AM control hU-II 
response Emax; 18 ± 3% of the 50mM KCl response, n=7 vs AM 35mmHg + L-NAME 
hU-II response Emax; 65 ± 5%, n=7, P<0.0001, unpaired t-test) (Fig 3.7). Incubation 
with 2 APB completely inliibited both the L-NAME induced elevation in basal tone and 
the hU-II CCRC associated spiking phenomenon in these vessels. In the presence of 2 
APB, efficacy was no longer significantly different fi'om that of control vessels treated 
with 2 APB (AM 16mmHg control response Emax; 7 ± 2% of the 50mM KCl response, 
n=5 vs AM 35mmHg + L-NAME response Emax; 9 ± 1%, n=8 , P>0.05, unpaired t-test).
The combination of increased resting tension and NOS inhibition did not significantly 
increase the efficacy or potency of the hU-II contractile response in B, C or D-class 
vessels (n>7, all groups, P>0.05) although the spiking phenomenon was observed more 
frequently in B and C-class vessels.
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The internal diameters and replicated transmural pressures were significantly larger in 
the A, B and C-class elevated tension vessels relative the the controls (A-class; 3703 ± 
60pm/ 32.7 ± 0.5 mmHg vs 2597 ± 28pm/ 14,7 ± 0.2mmHg, B-class; 2142 ± 115pm/
33.5 ± 0.5mmHg vs 1383 ± 15pm/ 13.8 ± 0.2mmHg, C-class; 1183 + 57pm/ 33.2 ± 
O.SmmHg vs 948 ± 39pm 13.3 ± 0.3mmHg, n > 12, all groups, P<0.005, unpaired t- 
tests). In D-class vessels however, whilst the replicated elevated transmural pressure was 
more than two-fold greater in the elevated tension vessels relative to control vessels, the 
internal diameter was not significantly different between the two conditions (D-class;
32.6 ± 0.5mmHg vs 15.2 ± 0.3mmHg, n = 12, P<0.0001, unpaired t-test).
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Figure 3.7 The effect of increased resting tension on the hU-ll response in the presence 
and absence of nitric oxide synthase inhibition in Wistar rat, A-class (extra-lobar) 
pulmonary arteries.
A) Experimental trace showing the large spiking phenomenon observed in ali 7 A-class vessels 
during the performance of the hU-ll CCRC in the presence of both increased resting tension 
(replicating a transmural pressure of 30-35mmHg) and NOS inhibition by L-NAME. B) Graph 
comparing hU-ll CCRCs performed in A-class extra-lobar vessels in the absence (n=7) and 
presence of increased tension (n=7 P>0.05), NOS inhibition using L-NAME (n-7, P>0.05) and a 
combination of both (n=7, P<0.0001).
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3.3.4 Contractile responses to hU-ll in combination models of PAH in 
Wistar rat puimonary arteries
The previous series of experiments suggested that in models of dysfunction, individual 
extra-lobar (A-class vessels) could show a modified contractile response to hU-IL 
Furthermore, the combination of, increased resting tension (due to stretch of the vessel 
wall) and NOS inhibition immasked a strong contractile response in all A-class vessels 
tested. However the A-class response seemed to be attenuated, though not significantly 
in vessels remodelled by 2 weeks exposure to chronic hypoxia. Conversely whilst the 
control D-class vessels showed no contractile activity under any of the models or 
conditions of increased resting tension, the D-class vessels which came fiom rats exposed 
to chronic hypoxia did develop a small contractile response to hU-II. To help determine 
the relevance of these observations to PAH where these conditions occur together, the 
responses to hU-II of A and D-class vessels, obtained from chronically hypoxic rats, 
where studied in a combined model of PAH, in which all of the abnormalities were 
mimicked simultaneously. As the B and C class vessels showed no significant increase in 
contractile activity under any of the previous PAH models or the elevated transmural 
studies, these vessels were not studied further.
3.3.4.1 Extra-lobar main pulmonary artery (A-class vessels)
The combined effects of replicated endothelial dysfunction (NOS inhibition) and ET-1 
raised tone could not be studied in A-class vessels obtained from chronically hypoxic 
rats. Vessels set up under this combination of conditions where inherently unstable often 
spontaneously contracting to near maximal tone before the commencement of the hU-II 
CCRC (Fig 3.9).
89
3.3 4.2 Intra-iobar small pulmonary arteries (D-class vessels)
The combined effects of replicated endothelial dysfunction (NOS inhibition), ET-1 raised 
tone and increased resting tension (replicating a transmural pressure of 30-35nunHg) did 
not elicit any contractile response to hU-II in the age matched control rat D-class vessels. 
As in the previous group of chronically hypoxic rats, exposure to 2weeks hypoxia was 
associated with the development of a small but significant contractile response in these 
vessels (AM hU-II response Emax; 1 ± 0.5% of the 50mM KCl response vs CH; 10 ± 
2%, n==6, P<0.05 unpaired t-test). However, neither the efficacy nor the potency of this 
response was further significantly enhanced by either the individual or combined effects 
of replicated endothelial dysfunction (NOS inhibition) and ET-1 raised tone (CH; 10 ± 
2% of the 50mM KCl response, n=6 vs CH + L-NAME; 8 ± 2%, n=6 vs CH + ET-1; 12 ± 
2%, n=6 vs CH + ET-1 + L-NAME; 18 ± 5%, n=7, P>0.05, unpaired ANOVA) (Fig 3.8).
The RV/TV ratio was significantly larger in the chronically hypoxic group consistent 
with the development of PH (AM; 0.207 ± 0.003 n=16 vs CH; 0.285 ± 0.003, n=12, 
P<0.0001, unpaired t-test). All vessels obtained from chronically hypoxic rats were 
normalised to an initial resting tension which replicated a transmural pressure of 30- 
35mmHg, which was two-fold greater than the replicated trasmural pressure of the 
vessels from the age matched control rats. However the internal diameter was not 
significantly different between any of the chronically hypoxic or age matched control 
vessels (n >6, H>0.05, unpaired ANOVA).
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Figure 3.8 The effect of combined models of PAH on the contractile response to hU-ll in 
Wistar rat, small pulmonary arteries (SPA’s) (D-class).
CH = Vessels from chronically hypoxic rats (n=6), CH + L-NAME (n=6), CH+ ET-1 raised tone 
(r/t) (n=6), CH + ET-lr/t + L-NAME = combined model of PAH (n=7) (P>0.05). For ease of 
comparison the ET-1 and L-NAME tone is not shown.
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3.4 Discussion
3.4.1 hU-ll does not regulate pulmonary arterial tone in the mouse
hU-II was found to have no vasoactive effects in any mouse pulmonary vessel tested,
despite the biological activity of the peptide being confimied in the mouse aorta where it 
caused a reliable and potent (IC50 ~30nM) but low efficacy response (-20% of the tension 
standard). Interestingly the response in the aorta is in contrast to previous reports that 
hU-II had no effect in this vessel (Douglas et a l, 2000). Although endothelial function 
could only be consistently confirmed in the mouse extra-lobar (A-class) main pulmonary 
artery there was no reason to suspect that failure of the smaller vessels to relax to 
acetylcholine or subsequently to hU-II was due to endothelial damage incurred by the 
mounting procedure. Vessels of a similar size were routinely mounted and demonstrated 
to have an intact endothelium in the rat. The findings suggest that hU-II does not 
influence pulmonary vascular tone in the mouse and therefore this species was unsuitable 
for further study.
3.4.2 hU-ll is a potent but low efficacy vasoconstrictor of rat pulmonary 
arteries but does not cause vasodilatation
In the rat, hU-II was found to be a potent but low efficacy vasoconstrictor of the extra- 
lobar (A and B-class) and 1®^ generation intra-iobar (C-class) vessels but not the 2"^  
generation intra-iobar (D-class) vessels. A general pattern of decreasing efficacy along 
the arterial tree was observed (Fig 3.2), which suggested a similarity with the contractile 
profile reported in the systemic circulation of the rat (Bottrill et a l, 2000;Douglas et a l, 
2000;Maguire et a l, 2000) (Table 1). The potency of the response in the main 
pulmonary artery (A-class) was found to be virtually identical (~3nM) to the previous 
report by MacLean et al, (2000), although the efficacy of the response was -50% less.
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The previous study had reported no response in the more distal vessels, however with the 
very low efficacy reported in the present study this discrepancy could be due to biological 
variability. Inconsistency of low and moderate efficacy responses have been reported in 
both pig and human vessels (Douglas et a l, 2000;Maguire et a l, 2000;Hillier et al., 
2001;Paysant et a l, 2001). The very similar pECso values of the responsive A, B and C 
class vessels in the present study suggested mediation by a single receptor type, 
presumably the UT-II, although as there are presently no selective UT-II antagonists 
available, this could not be confirmed. No hU-II induced vasodilator action could be 
demonstrated in any of the vessel classes (A, B, C or D-class) despite these vessels 
showing a consistent relaxation to Ach both prior to and after challenge with hU-II. 
Hence the vessels were functionally capable of relaxing the ET-1 raised tone. Presently 
no suitable animal models of hU-II pulmonary vasodilatation have been identified.
3.4.3 hU-ll does not cause vasoconstriction of human intra-iobar 
pulmonary arteries
Neither of the human intra-iobar vessel groups tested (750-1500pm size equivalent to C- 
class rat vessels, 150 -300pm D-class equivalent), responded to hU-IL These findings 
were consistent with both previous studies in human vessels which also found no 
response in intra-iobar small pulmonary arteries (150-500pm) (MacLean et al, 
2000a;Bennett et a l, 2004). However, inhibition of NOS using L-NAME did not 
uncover a contractile response as has been previously reported (MacLean et a l, 2000a). 
Bennett et a l , (2004) also failed to demonstrate a contractile response to hU-II in human 
vessels which lacked a dilator response to acetylcholine. However, as only 3/10 vessels 
in the study by MacLean et al., (2000) responded in the presence of L-NAME it is 
conceivable that failure to uncover this response could have been a function of sample 
size. One other possible explanation for the discrepancy exists. The samples from both
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the study by MacLean et al, (2000) and the present study came from patients with lung 
carcinoma. Both hU-II localisation and UT-II receptor expression have been found in 
human renal and adrenocortical tumoirrs and their associated vasculature (Takahashi et 
a l, 2001;Shenouda et al, 2002;Takahashi et a l, 2003) so it is not inconceivable that UT- 
II receptor expression could have been affected in some of these samples even though 
they were believed to be from tissues that were macroscopically normal. Unfortunately 
human tissue became unavailable shortly after beginning this study making a larger 
sample impossible to achieve. The dilator response to hU-II in human small pulmonary 
arteries has already been reported (Stirrat et a l, 2001).
3.4.4 hU-ll contractile responses are not enhanced in rat models of 
pulmonary arterial hypertension
The relatively consistent findings in the rat suggested possible a role for hU-II in the 
regulation of pulmonary arterial tone and raised the question of whether hU-II could be 
involved in the aetiology of PH in this species. Models, which mimic individual aspects 
of the pathological changes of PAH such as medial remodelling resulting from exposure 
to chronic hypoxia, replicated endothelial dysfunction due to inhibition of NOS and 
elevated tone using ET-1, have all been reported to enhance responses to endogenous 
vasoconstrictors in the pulmonary circulation of the rat (MacLean, 1999). In a previous 
study, it was reported that NOS inhibition by L-NAME and 2 weeks chronic hypoxia 
both increased the efficacy, but not the potency of the rat main (A-class) pulmonary 
artery contractile response to hU-II and that endothelial removal and ET-1 raised tone 
both increased the potency but not the efficacy of the response (MacLean et a l, 2000a). 
In the present study however, no significant augmentation of the hU-II contractile 
response took place in the extra-lobar (A and B-class) or 1®^ generation intra-iobar (C- 
class) vessels in any of the models of PAH which mimicked individual aspects of the
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disease. In fact, some B and C-class responses appeared attenuated although these were 
generally not significant changes. The only significant increase was obseiwed in the 
formerly unresponsive small pulmonary arteries (D-class) following 2weeks of chronic 
hypoxia. These vessels showed a very small but significant contractile response to hU-II 
(-5-8% of the tension standard). This was consistent with the “migration” of smooth 
muscle distally into the small pulmonary arteries, which is a hallmark of vascular 
remodelling associated with exposure to chronic hypoxia (Meyrick & Reid, 1978). 
Conversely, in the more proximal vessels there was a general pattern of decreased 
responsiveness to hU-II following exposure of the rats to 2weeks hypoxia, although this 
was only significant in the 1®‘ generation intra-iobar (C-class) vessels. This had the 
overall effect of creating a veiy weak (<10% of the tension standard) but uniform 
contractile response along the arterial tree. These findings are consistent with a recent in- 
vivo study in the rat (Deuchar et a l, 2005) (submitted for publication), which found that 
hU-II caused a very small increase in right ventricular pressure (RVP) (which is 
indicative of PAP) in the control rat and that following treatment with L-NAME or 2 
weeks chronic hypoxia, the hU-II response was no longer observed.
3.4.5 hU-fl responses in rat main puimonary arteries are augmented by a 
combination of increased tension and NOS inhibition
The data from the present study appeared to contradict the earlier in vitro study by 
MacLean et al, (2000a). However it was observed that some individual extra-lobar (A- 
class) vessels in the present study had shown a modified response under the modelled 
conditions, but that these responses were generally not large or consistent enough to be of 
significance. This suggested that in the previous study, an additional stimulus/factor 
might have unmasked the enhanced contractile response. The most obvious explanation 
would be that of variability of UT-II receptor expression. Inconsistent responses have
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been widely reported in hU-II studies in several species even when the experiments have 
been performed in the same lab using identical technique (Douglas et al., 2000).
A second variable was also investigated. The initial study had been performed using the 
traditional organ bath set up in which all vessels were tensioned to a fixed, pre- 
detennined level of force (1.5g) as is accepted pharmacological practice in these vessels. 
However at a uniform predetermined level of force, the replicated transmural pressure 
each vessel wall experiences will depend on its internal diameter. Hence given the range 
of internal diameters in normal, main pulmonary arteries, the final replicated transmural 
pressure of a vessel set up in the organ bath can vary by a factor of nearly 2 , with some 
vessels being set to nearly SOmmHg. In contrast, the myograph set up allows the 
operative to set the replicated transmural pressure of each vessel individually thus closely 
mimicking actual in vivo pressure. The actual variation in the replicated pressure of the 
vessels set up on the myograph is usually less than 20% (14-16mmHg in extra-lobar 
vessels, 12-14mmHg in intra-iobar vessels).
When the main pulmonary artery, NOS inliibition study was repeated on the myograph 
under conditions of increased tension (-two-fold increase in replicated transmural 
pressure), the contractile response to hU-II in the presence of L-NAME was enhanced 
some three-fold to levels similar to that reported previously in the earlier organ bath 
studies (MacLean et al., 2000a). The enhanced response was characterised by a large but 
now consistent spiking phenomenon, which could be completely abolished by 2 APB. 
Interestingly following incubation with 2 APB, responses to hU-II in the presence of L- 
NAME and increased tension were indistinguishable from control responses obtained 
following incubation with 2 APB. Control responses were themselves reduced by -  50% 
by the presence of 2 APB (P<0.05). This implied that -  50% of the control response to 
hU-II in the main pulmonaiy artery was associated with IP3 mediated Ca^  ^ store release
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and that the augmented responses could not occur in the absence of IP3 mediated Ca^  ^
store release. Increased tension also appeared to modify the contractile response to sub- 
maximal concentrations of ET-1 (used to raise tone in these vessels), making a stable 
raised tone unachievable. These observations suggested that stretch of the vascular wall 
increased the likelihood of Ca^”^ store release in response to both (hU-II and ET-1) of 
these G-protein linked agonists. The mechanism underlying the stretch induced response 
was not determined (see next section).
3.4.6 increased tension may account for previous reports of enhanced hU- 
II contractile responses following chronic hypoxia in the rat
The findings of the increased tension study may also have relevance to the discrepancy
between the present study and the previously reported, augmented hU-II response of the 
main pulmonary artery following exposme of the rats to 2weeks of clrronic hypoxia 
(MacLean et a l, 2000a) as a somewhat similar phenomena was observed in these vessels.
Vessels from chronically hypoxic rats were initially normalised to a tension equivalent to 
30-35mmHg to replicate in vivo hypertensive pressures. However unless these vessels 
fully dilated to their own time basal tone (~12-20mmHg) following repeated exposures to 
KCl, spontaneous, rhythmic, contractions caused the vessel tone to become progressively 
elevated (Fig 3.9). This often resulted in a near maximal contraction, despite the absence 
of any challenge. This spontaneous contractile behaviour was unpredictable and made it 
impossible to differentiate spontaneous activity from agonist induced tone. The 
spontaneous activity of these unstable vessels was immediately and completely abolished 
by 2 APB suggesting it to be at least partly mediated via IP3 triggered Ca^  ^store release. 
Interestingly phospholamban the protein, which regulates SERCA 2 mediated Ca^ "^  
uptake into the SR has been found to demonstrate, increased phosphorylation in rats 
exposed to clmonic hypoxia (J. Milieu, Glasgow, unpublished observations).
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Phosphorylation of phospholamban increases SERCA 2 activity and would therefore be 
expected to increase Ca^ "^  uptake by the SR, perhaps resulting in overloading and 
instability. Spontaneous rhythmic contractions have been previously reported in the 
chronically hypoxic rat main pulmonary artery (Wanstall et a l, 1997;Bonnet et al, 
2001b). Occurring with a 90% incidence following 2weeks chronic hypoxia, these 
spontaneous rhythmic contractions are superimposed on any existing tone and are 
associated with a reduction in resting Em, due to down regulation of Kv chaimels. The 
contractions involve both L-type Ca^  ^channels and SR Ca^  ^ store release (Bonnet et a l, 
2001b) and may be the result of an amplification loop. Interestingly by the third week of 
exposure to clironic hypoxia their prevalence has reduced to 20% and by 4weeks are 
absent, suggesting they may be part of an adaptive process (Bomiet et a l, 2001b)
As the results of the chronically hypoxic rat study were in direct opposition to the 
previous report, it was considered that the few persistently unstable vessels, which had 
been discarded from the study, could have included vessels, which may have been more 
reactive to hU-II. However, unstable hypoxic and stable age matched control vessels 
treated with 2 APB showed no difference in either the efficacy or potency of their 
response to hU-II. This suggested that ROC mediated Ca^  ^ sarcolemmal flux was not 
increased and therefore there was no suggestion of increased UT-II expression/signalling, 
although this assumption needs to be confirmed using molecular techniques. Given these 
findings and the difficulty of interpreting any hU-II response data fiom these vessels it 
was considered justified to eliminate these vessels from the study.
No attempt was made to reset the tension in stabilised vessels obtained from hypoxic rats 
as to do so invariably caused the instability to return making further study impossible. 
It was thus assumed that the initial tension (equivalent to a transmural pressure of 30- 
35mmHg) recreated the previously existing in vivo transmural pressure and that
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resistance under these conditions was the result of both passive elastic recoil and some 
element of vasoconstriction. Hence relaxation following KCl responses, should not have 
changed the component of the replicated transmural pressure which was caused by 
passive recoil of the vascular wall and that any attempt to readjust the tension back to the 
equivalent of 30"35mmHg would have increased this component well beyond its normal 
in vivo value. This had already been demonstrated to effect SR discharge in response to 
hU-II (study 3.4.5). The approach was corroborated by the aforementioned in vivo 
chronically hypoxic rat study, which showed no response to hU-II infusion despite basal 
RVP being two and a half-fold higher in these animals (Deuchar et al., 2005).
3.4.7 hU-ll contractile responses are not enhanced in the rat small 
pulmonary artery in the combined model of pulmonary arterial 
hypertension
A-class (main) pulmonary arteries were too unstable to study, under the conditions 
created by the combined model and vessels typically maximally contracted before the 
hU-II challenge could be performed, D-class vessels (SPA’s) were more stable, but failed 
to show any significant augmentation of their contractile response to hU-II under the 
combined model conditions. Furthermore, hU-II contractile responses in these vessels 
were not enhanced even when the tension was readjusted to an equivalent of 30-35mmHg 
following any fall off.
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Figure 3.9 Spontaneous contractile activity in a main pulmonary artery (A-class) from a 
Wistar rat exposed to 2weeks chronic hypoxia
Experimental traces showing A) a stable and B) an unstable A-class vessel form chronically 
hypoxic (CH) Wistar rats. Both vessels were initially normalised to an equivalent transmural 
pressure of SOmmHg. This instability also occurred in previously stable A-class vessels from CH 
rats, when attempting to recreate the conditions necessary for the combined model of PAH.
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3.5 Conclusion
The data suggested that hU-II was not involved in the regulation of pulmonary arterial 
tone in the mouse and this animal was therefore unsuitable for further study. Similarly, 
hU-II had no vasoconstrictor effect in any of the human intra-iobar vessels tested 
regardless of the presence or absence of a functional endothelium. In control rat extra- 
lobar (A and B-class) and generation intra-iobar (C-class) vessels, hU-II caused a 
potent but low efficacy response, which at high concentration has been shown to result in 
a small pressor response in vivo (Deuchar et al, 2005). However, hU-II did not cause 
vasodilatation in any rat pulmonary artery.
The models of PAH suggested that the hU-II contractile response in extra-lobar branch 
and intra-iobar pulmonary arteries (B, C and D-class vessels) was not a contributory 
factor in the elevated PVR that is central to the development of PAH. In PAH it is 
primarily the pathological changes of the small pulmonaiy arteries (D-class vessels) that 
are associated with elevated PVR and hence elevated pressure. The main pulmonary 
artery (A-class) contractile response to hU-II was not significantly augmented in any of 
the single aspect models of PAH, but was enhanced by the specific conditions of 
increased tension (caused by stretch) combined with NOS inhibition. Contraction of large 
conduit vessels is associated with decreased vascular compliance and elevation in systolic 
pressure (Mandegar et al., 2004). However the combined model of PAH, suggested that 
the main pulmonary artery was so unstable under these conditions that it would be 
strongly constricted even in the absence of any other challenge and therefore the 
influence of hU-II on this vessel may not be of consequence. The physiological 
relevance of this finding would however, need to be confirmed by an in vivo study in the 
chronically hypoxic rat, using a selective hU-II antagonist (when one becomes available) 
which would determine if the elevated basal tone associated with chronic hypoxia was 
being contributed to by endogenous hU-II production.
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The findings of the present study suggested that in the normal rat pulmonary circulation, 
hU-II has a low efficacy constrictor effect, which may slightly increase pulmonary 
arterial tone. However the evidence was generally not consistent with hU-II contributing 
to the development of PAH in the mouse, rat or human.
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Chapter 4
Results Part II
The Role of Calcium Sensitivity in the 
Regulation of Pulmonary Arterial Tone 
i) Protocol development
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4.1 Introduction
4.1.1 G-protein mediated smooth muscie contraction; a roie for the 
modulation of Ca^  ^sensitivity (CaS) in the pulmonary circulation?
Smooth muscle contraction is the basis for the active regulation of blood pressure and
flow within organ beds. The key event coupling the extra-cellular signal to contraction in 
smooth muscle is the elevation in cytoplasmic Ca^ "^  concentration ([Ca^’^ jcyt) and the 
relationship between [Ca^ "^ ]cyt and force production is known as the Ca^  ^sensitivity (CaS) 
of the contractile apparatus (Somlyo & Himpens, 1989). It has become evident however 
that this relationship can be modified by some endogenous circulating agonists (Kitazawa 
et al., 1989). A review of this phenomena reported that in swine carotid artery a general 
pattern was apparent: Agonists causing G-protein activation and concomitant release of 
intra-cellular Ca^”^ stores mediated via IP3, were associated with an increase in CaS, 
whilst those agonists that only promoted Ca^ "^  influx via the sarcolemma were associated 
with a decrease in CaS (Rembold, 1992). More recently the G-protein linked receptor 
agonist, endothelin 1 (ET-1), which is known to be an important modulator of pulmonary 
vascular tone and has been implicated in the development of pulmonary arterial 
hypertension (PAH) in humans (Giaid et a l, 1993;Stewart et a l, 1991), has been shown 
to cause an increase in CaS in the rat small pulmonary artery (SPA) (Evans et a l, 1999). 
This raises the question of whether other G-protein activating agonists, which play a role 
in the regulation of pulmonary vascular tone, such as 5-HT, influence the CaS of the 
contractile apparatus? Furthermore, does the modulation of CaS play a role in the 
aetiology of PAH and is this change observed in models of PAH such as the chronically 
hypoxic rat model where the effects of these G-protein activating agonists have been 
reported by some, to be enhanced (McCulloch et a l, 1998).
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4.1.2 Techniques for studying sensitivity (CaS) in isolated vessels
The techniques that have been applied to the study of Ca^  ^sensitisation of the contractile
apparatus can be broadly classified into two categories; 1) Those that selectively 
penneabilise the smooth muscle cell membrane and permit [Ca^ "*']cyt to be clamped by the 
choice of the extra-cellular bathing solution and 2 ) those that use fluorescent imaging 
techniques to measure [Ca^ '^ Jcyt and force simultaneously in unpermeabilised vessels. 
Imaging techniques have the advantage of causing minimal anatomical and physiological 
disruption to the SMCs, however, whilst they can accurately measure [Ca^ "^ ]cyt they 
cannot control it (Sato et a l, 1988). The technique is ideal for temporal Ca^  ^
measurement but cannot buffer local intra-cellular Ca^”^ gradients and is therefore not so 
suited to spatial Ca^  ^measurement (Somlyo & Himpens, 1989). In the present series of 
experiments where whole segments of vessels were to be studied, any fluorescent 
measurement would be a reflection of the mean [Ca^’^ ]cyt at a given time and may 
therefore not necessarily be an accurate reflection of the actual [Ca^^] responsible for a 
given force. In contrast, permeabilisation tecliniques allow the investigator to precisely 
control the [Ca^’^ Jcyt and also prevent localised Ca^ "^  gradients (Himpens et a l, 1990). The 
disadvantages of permeabilisation techniques, are the possibility of disruption to the 2 "^  
messenger systems and the gradual loss of intra-cellular regulatory factors/proteins 
following permeabilisation (lizuka et a l, 1994;Fujita et a l, 1995;Konishi & Watanabe, 
1995;Akopov et a l, 1998), however these problems can be minimised if the protocol is 
optimised for the tissues in which it is to be used.
As the effects of chronic hypoxia and the 5-HT system on the CaS of the contractile 
apparatus of the rat small pulmonary artery had never been previously studied it was 
decided to use a chemical permeabilisation technique to be certain that any response was 
indeed due to a change in CaS and not just the action of some localised Ca^ "^  gradient. Of 
the various chemical permeabilisation tecliniques available, two have been most widely
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used in intact smooth muscle preparations; a-toxin and p-escin. Although both options 
were considered, financial restraints precluded using the somewhat more precise bacterial 
pore forming Staphylococcus aureus a-toxin.
4.1.3 p-escin
P-escin, a triterpeniod saponin derived from the seed of the horse-chestnut tree -Aesculus 
hippocastanum, has been successfully used to permeabilise a wide range of smooth 
muscle preparations in order to study CaS (Itoh et al, 1992;Iizuka et a l, 1994;Savineau 
& Marthan, 1994;Yoshida et a l, 1994;Lee et a l, 1996;Iizuka et al, 1997;Akopov et a l,
1998;Kitazawa et a l, 2004;Soloviev et al, 2004). It was originally believed to aggregate #
yi:
only the cholesterol component of the sarcolemma, resulting in the formation of aqueous
'Vpores, whilst retaining receptor coupling (Kobayashi et a l, 1989). However, more 
recent reports have also suggested a more complex but as yet undefined action. For 
example, it has been shown to inhibit loading of the SR (which has a low cholesterol 
content) in skeletal muscle (Launikonis & Stephenson, 1999). Additionally, its effects on 
the sarcolemma occur in a concentration dependant manner (lizuka et a l, l994;Konishi 
& Watanabe, 1995) rather than at some critical concentration. It is therefore best suited 
to studies in which preservation of sarcolemmal receptor coupled mechanisms is 
paramount but preservation of SR function is not (Launikonis & Stephenson, 1999).
4.1.4 Optimising the p-escin permeabiiisation protocoi for use in the rat 
smaii puimonary artery
To date, only one publication has reported on the phenomenon of Ca^ "^  sensitisation in rat ;
small pulmonary arteries using a chemical permeabilisation technique (Evans et al, .
1999). Evans et al, (1999) reported that both p-escin and a-toxin produced a functioning 
permeabilised preparation but that the p-escin preparation was subject to significant “run
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down” within 30minutes. However the protocol described was originally employed for 
use in strips of rabbit portal vein and guinea pig ileum (lizuka et a l, 1994) and made no 
mention of being optimised for use in the rat small pulmonaiy artery. Although p-escin 
permeabilised preparations have been shown to “leak” proteins of a molecular weight up 
to 150kD, contractile function and receptor-coupled signal transduction can be adequately 
preserved if the P-escin is correctly applied (lizuka et a l, 1994). This may suggest that 
some aspect of the p-escin protocol used by Evans et al., was responsible for the “run 
down”. Furthermore, even when using a-toxin, which reduces the loss of these high 
molecular weight proteins, the published maximum tone achieved by Evans et al, (1999) 
following permeabilisation was only 0.28mN at a maximal [Ca^ j^cyt of pCa 4.5. This 
raised an additional concern; Although the KCl tension standard responses for this study 
were not reported, a typical response for a 2mm length of Wistar or Sprague Dawley rat 
small pulmonary artery (150-350pm i.d.) to a KCl depolarisation obtained by the author 
of this thesis would be around 5-6mN. This would suggest that the a-toxin permeabilised 
vessels had retained only ~ 5% of their unpermeabilised force production potential.
Preliminary experiments based upon p-escin permeabilisation methods applied to 
systemic arterial smooth muscle preparations also yielded very poor responses. For 
example, when a constant exposure time for P-escin was applied to the Wistar rat small 
pulmonary artery, the results suggested the presence of unpermeabilised SMCs in a 
number of vessels and over permeabilisation characterised by a loss of signal 
transduction in others. This method had been successfully applied to ovine cerebral 
arteries (Akopov et al, 1997), but was clearly less than optimal in the rat small 
pulmonary artery, possibly due to the significant variation in the amount of smooth 
muscle present in these vessels as suggested by the huge variation contractile force 
generated in response to KCl depolarisation.
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Of even greater concern was that some component of the mock intra-cellular (MI) 
solutions was acting as an agonist and seemed to be causing a substantial and prolonged 
activation of the 2"  ^ messenger systems in the unpermeabilised Wistar rat small 
pulmonary artery. Naturally this raised concerns as to whether CaS was being modulated 
by the MI solution. Evans et al., (1999) had not reported this response, but it was 
consistently observed in the present study. ATP was considered the most likely culprit as 
several P2 receptors have been reported in the rat small pulmonary artery (Chootip et al, 
2002). Furthermore it has also recently been reported that multiple P2Y receptors, some 
of which are activated by ATP are capable of activating Rho kinase (ROK) in vascular 
myocytes (Sauzeau et a l, 2000b). ROK is an important component of a Ca^”^ sensitising 
pathway, which has recently received much attention. Due to these concerns it was 
decided that the protocol should be redeveloped to specifically adapt the method for use 
in the Wistar rat small pulmonary artery.
4.1.5 Overview of the protocol development
The development of the protocol covered 5 main areas 1) Selection of an optimum 
tension standard for use in assessing contractile force. This would be important in 
assessing how detrimental the penneabilisation procedure was to the preparation, given 
that the action of p-escin is now known to be concentration dependant (lizuka et al, 
1994). 2) Determination of the composition of the MI solution in which the vessels were 
to be bathed during and following permeabilisation. An appropriate solution would 
sustain the permeabilised vessels and maintain normal contractile fiinction but not 
modulate CaS of the contractile apparatus. 3) Selection of an appropriate sensitising 
agonist standard to assess the effect of permeabilisation on the normal functioning of the 
receptor-coupled signal transduction mechanisms. 4) Determination of the most 
appropriate method of p-escin permeabilisation and the optimum concentration for its
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use. 5) Selection of the best way to prevent the SR from compromising the clamped 
[Ca^ '^ Jcyt in response to agonist or other stimulation.
Following protocol development in the Wistar control rat small pulmonary artery, the 
protocol was then tested on chronically hypoxic rat small pulmonary arteries and wild 
type and transgenic mouse small pulmonary arteries and adapted where necessary.
Due to the extensive number of experiments and broad range of inquiries involved in the 
protocol development it was decided that each of the studies would be presented as a 
discrete section. Each study therefore comprises a brief background to the problem, 
specific methods, results and a short explanation of how the findings were applied to the 
evolving protocol. This was intended to help present the protocol development as a series 
of logical and progressive steps.
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4.2 Study 1) Selecting the optimum tension response standard
4.2.1 Background
The aim of this study was to determine the most appropriate standard for assessing 
changes in force during the development and subsequent application of the 
permeabilisation protocol. The initial question this study was intended to address was; is 
an iso-osmotic depolarising solution significantly superior (with regard to magnitude and 
rate of force development) to the more straight forward, hyper-osmotic addition of KCl. 
If not, what is the optimum concentration for a hyper-osmotic KCl addition?
Hyper-osmotic additions are simple to perfoim only requiring the addition of a 
predetermined amount of stock KCl to the bathing solution. However, whilst this results 
in depolarisation and hence contraction, it also increases the osmolarity of the extra­
cellular medium and this has been associated with a decreased maximum force and a 
slowed rate of force production (Kent et a l, 1983;Karaki et a l, 1984). For example, even 
the addition of just 50mM KCl would increase the osmolarity of the bathing solution 
from ~300ni0smoles to ~400m0smoles, a 33% increase. It was important that the chosen 
standard consistently yielded a true maximum response so that any deleterious effects of 
exposure to the MI solutions or the permeabilisation procedure could be accurately 
assessed.
The alternative was to use a nominally iso-osmotic solution exchange, which maintains 
osmotic balance, thus the magnitude and rate of force production should be an accurate 
reflection of the vessels normal physiological response to a depolarisation.
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4.2.2 Methods
Small pulmonaiy arteries from Wistar rats were procured, set up and normalised to 12- 
14mmHg at 24^C, as described in the general methods. The following questions were 
then addressed:
4.2.2.1 Are nominally iso-osmotic tension response standards superior to hyper­
osmotic tension response standards?
Following normalisation, the maximum responses to 2 repeated KCl exposures (separated 
by washout and return to baseline) were ascertained. The following challenges were 
examined; 50, 100 or 120mM hyper-osmotic KCl additions or a nominally iso-osmotic 
120mM KCl solution exchange. A hyper-osmotic addition consisted of adding a 
predetennined amount of KCl to the Krebs-buffer solution in which the vessels were 
bathed. An iso-osmotic solution exchange involved draining the Krebs-buffer solution 
and then replacing it with a K'*’ based buffer solution which was nominally iso-osmotic 
(~300m0sm) to the cytoplasm of the SMCs. After washout of the second selected KCl 
challenge and return to baseline tension, the vessels were challenged with 2  repeated 
exposures (separated by washout and return to baseline) of a nominally iso-osmotic 
120mM potassium acetate (K^CHsCOO ) solution (Fig.4.1).
The series of experiments was then repeated using fresh vessels, but this time performing 
the exposures to the iso-osmotic 120mM K’^ 'CHsCOO' solution prior to the selected KCl 
challenges.
I l l
d) 120mM K"CH COO'
c) KCl hyper/iso-osmotic
5000s
Figure 4.1 Experimental trace showing the protocol to determine if iso-osmotic 
depolarising solution exchanges are superior to hyper osmotic depolarising additions
a) Normalisation; setting the tension to replicate the equivalent in vivo  pressure b) "Wake up" 
depolarisation followed by re-adjustment of tension if required c) Repeated depolarisations using 
hyper-osmotic KCl additions or an iso-osmotic 120mM KCl solution exchange d) Repeated 
depolarisations using an iso-osmotic 120mM K^CHaCOO' solution exchange.
4.2.2.2 Does acetate/chloride substitution affect contractile function?
The results of the previous experiments raised the question of whether the replacement of
the chloride ion with the acetate (CH3COO") anion was deleterious to the un­
permeabilised vascular preparation. Hence, fresh vessels were challenged with either 4 
repeated exposures (separated by washout) to iso-osmotic 120mM K^CHsCOO" or 4 
repeated exposures to iso-osmotic 120mM KCl.
Data analysis
As the MI solutions all use the impermeant acetate (CH3COO') ion as the dominant 
anion, all depolarisation challenges were nonnalised against the iso-osmotic 120mM 
K^CHgCOO" response of each vessel. The magnitude of force developed was expressed 
in mN as 90% of the maximum force (F90) and the time taken to reach F90 in seconds.
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4.2.3 Results
4.2.3.1 Are nominally iso-osmotic tension response standards superior to hyper­
osmotic tension response standards?
During these measurements it became immediately obvious that challenges pre 
K^CHsCOO" exposure showed different kinetics to those performed post K^CHgCOO' 
exposure, therefore pre and post exposures were considered as different experiments so 
that the effect of acetate/chloride substitution could be determined.
Hyper-osmotic vs iso-osmotic KCi standards (pre K^CHgCOO exposure)
The responses to hyper-osmotic (H) KCl additions took 2-4 times longer to reach F90,
than those produced by a nominally iso-osmotic 120mM K^CHaCOO' solution (50mM H; 
1308 ± 144secs vs 729 ± 109secs, n= 4, P<0.005) (lOOmM H; 2608 ± SOsecs vs 682 ± 
lllsecs, 11=4 , P<0.0005) (120mM H; 3259 ± 337secs vs 782 ± 33secs, n=3, P<0.05) (all 
paired t-test). It was also observed that when the hyper-osmotic responses were 
standardised to their paired iso-osmotic 120mM K^CHsCOO" responses, time to F90 was 
significantly increased with the increase in osmolarity from 50mM to lOOmM KCl 
(50mM H; 182 ± 8% of the iso-osmotic 120mM K^CHgCOO' response time vs lOOmM 
H; 400 ± 53%, n=4, P<0.05) (unpaired ANOVA).
Additionally, the hyper-osmotic 100 and 120mM KCl additions both produced an 
attenuated force (F90) relative to the nominally iso-osmotic 120mM K^CHsCOO’ 
responses to which they were paired (lOOmM H; 1.74 ± 0.41mN vs 2.37 ± 0.36mN, n=4, 
f<0.05) (120mM H; 2.77 ± 0.83mN vs 4.06 ± 1.06mN, n=3, P<0.05, all paired t-test).
In contrast, the responses to a nominally iso-osmotic 120mM KCl solution were virtually 
identical to those produced by the iso-osmotic 120mM K'^CHsCOO' solution (Time to 
F90; 732 ± 32secs vs 741 ± 94secs, n-4, P>0.05, paired t-test) (F90; 5.07 ±0.40mN vs 
5.07 ± 0.43mN, n=4, P>0.05, paired t-test) (Fig 4.2 “PRE”).
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Hyper-osmotic vs iso-osmotic KCl standards (post K^CHaCOO' exposure); effect of 
acetate/chioride substitution
Exposure to K^CHgCOO' prior to KCl challenge caused a decrease in force (F90) in all 
subsequent hypertonic and iso-osmotic challenges (% Pre F90; 50mM H: pre; 82 ± 6%, 
n=4 vs post; 6 6  ± 2%, n=4, P<0.05) (lOOmM H; 72 ± 3% vs 62 ± 2%, n-4, P<0.05) 
(120mM H: pre; 67 ± 3%, n=3 vs post; 51 ± 2%, n=4, P<0,005) (120mM I: pre; 100 ± 
1%, n-4  vs post; 93 ± 2%, n=4, P<0.05) (all unpaired t-test) (all vessels standardised to 
their paired iso-osmotic 120mM K’^ CHsCOO' solution responses). Additionally there 
was also an increase the time taken to reach F90 in the hyper-osmotic 50mM and iso- 
osmotic 120mM KCl challenges (50mM H: pre; 182 ± 8 %, n=4 vs post; 401 ± 42%, n-4, 
P<0.005) (120mM KCl I: pre; 104 ± 14%, n=4 vs post; 170 ± 10%, n=4, P<0.05, 
unpaired t-test) (Fig 4.2 “POST”).
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Figure 4.2 The effect of osmolarity and acetate/chloride substitution on tension standard 
contractile responses in the Wistar rat small pulmonary artery
Plots of 90% maximum force (Fgo) against time to Fgo for hyper-osmotic {A; 50mM, B; 1Q0mM, C; 
120mM) and iso-osmotic (D;120mM) KCl depolarisations (O - White circies) reiative to each 
vessels paired response to iso-osmotic (A-D;12GmM) K^CHsCOO" depolarisations (#  - Black 
circles). PRE; left hand column - KOI challenges pre-ceded K'^'CHaCOO'challenge. POST; right 
hand column shows responses where KCl challenges followed K^CHaCOO'challenge.
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4.2.3.2 Does acetate/chloride substitution affect contractile function?
All vessels challenged with repeated iso-osmotic 120mM K^CHsCOO' exposures
demonstrated a progressive increase in their time to F90 with each subsequent exposure 
until the fourth challenge, where a decrease in F90 became the significant trend. (Time to 
F90; exp 1; 820 ± 58secs vs exp 2; 1190 ± 60secs vs exp 3; 1524 ± 8 6 secs, n=7, P<0.01) 
paired ANOVA) (F90; exp 1; 6.54 ± 1.33mN vs exp 4; 5.28 ± 1.14mN, n=7, f<0.05, 
paired ANOVA) (Fig 4.3).
Similarly, there was also a successive increase in the fall off (F/0) period (Time to 
F/O90), which was the time taken to return to 1 0 % above basal tone following washout. 
This, was also accompanied by a progressive elevation in basal tone (B/T), which was 
significant following the third exposure (exp) to 120mM K^CHgCOO' (Time to F/O90; 
post exp 1; 1844 ± 138secs vs post exp 2; 2914 ± 364secs vs post exp 3; 3184 ± 546, n=7, 
P<0.005, paired ANOVA). (B/T; pre exp 1; 0.68 ± 0.15mN vs post exp 3; 1.37 ± 
0.21mN, n=7, P<0.01, paired ANOVA) (Fig 4.3 B).
Repeated exposures to iso-osmotic 120mM KCl demonstrated no significant changes 
over the course of the four repeated challenges (n=4, P>0.05, all paired ANOVA) (Fig
4.3 A).
The vessels from all groups were of a comparable internal diameter and replicated 
transmural pressure (P>0.05, unpaired ANOVA). The mean internal diameter and 
replicated transmural pressure of the vessels used in study 1 was 253 ± 7pm and 13.6 ± 
0.2mmHg respectively (n=42 vessels).
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Figure 4.3 The effect of acetate/chloride substitution on tension standard contractile 
responses in the Wistar rat small pulmonary artery
Experimental traces showing responses to A) 4 repeated iso-osmotic 120mM KCl challenges and 
B) 4 repeated iso-osmotic 120mM K’^ CHsCOO* challenges. 0) Plots of 90% maximum force (Fgo) 
against time to Fgo for 4 repeated iso-osmotic 120mM K^CHaCOO’ challenges. ( • )  Black circles - 
1st Challenge. (#) Dark grey circles - 2nd challenge. ( ) Light grey circles - 3rd challenge. (O) 
White circles - 4th challenge.
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4.2.4 Application to protocol
Hyper-osmotic additions and acetate/chloride substitution were both found to affect the 
magnitude and rate of force development. Hence, vessels in all subsequent studies were 
normalised to 12-14mmHg and then challenged with a nominally iso-osmotic, 120mM 
KCl solution exchange to determine their standard response whilst minimising exposure 
of the unpermeahilised vessel to acetate. However, as there was no evidence in the 
literature to suggest the effects of acetate were detrimental following penneabilisation, it 
was provisionally retained in the mock intra-cellular (MI) solution.
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Figure 4.4 The range of nominally Iso-osmotic 120mlVI KCl tension standard responses 
obtained during protocol development experiments
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4.3 Study 2) Investigation into the agonist action of the pCa9.9 
mock intra-celluiar (Mi) solution in un-permeabilised vessels
4.3.1 Background
Upon exposure of the Wistar rat small pulmonary arteries vessels to the '‘Ca^’*' free”, pCa
9.9 MI solution it was immediately apparent that one or more of its components was 
causing a large, possibly bi-phasic contractile response. The response rapidly peaked 
(phasic response) at ~ 50% of the 120mM KCl tension standard response, then 
deteriorated exponentially (fall off) over ~90minutes until it eventually stabilised (tonic 
response) at -5-10% above the nonnalised basal tone (Fig 4.5).
PR
TR
2000s
Figure 4.5 Experimental trace showing the "bi-phasic" response caused by a mock intra­
cellular (Ml) solution exchange
PR - Phasic response, TR - tonic response, F/0 - fall off.
Although the presence of K"*" in the MI solution would cause immediate depolarisation of 
the vessels, it seemed highly unlikely that the response was solely due to sarcolemmal 
flux of unbuffered interstitial Ca^ ,^ as the tone remained elevated above baseline for 
several horns. A similar response was observed in the Sprague Dawley rat small
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pulmonary artery, although this had not been reported by Evans et al, (1999). It was 
considered that the tonic response may have been an artefact of the acetate/chloride 
substitution as had been observed in study 1. However, the response was ablated by a 
single addition of the Rho kinase (ROK) inhibitor Y 27632 (lOpM), suggesting that the 
ROK pathway was activated in the presence of the MI solution, and raising the possibility 
that some component of the solution was modulating CaS (Fig 4,6).
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Figure 4.6 The effect of Rho kinase inhibition on the tonic response (T/R) caused by the 
solution exchange to a pCa 9.9 mock intra-cellular (Ml) solution
It was therefore necessary to identify the component of the solution that was causing the 
response and determine what impact this may have on the preparation, especially with 
regard to the CaS of the contractile apparatus. Unfortunately, background reading 
suggested the most likely candidate was ATP (Chootip et al, 2002). Purinergic (P2) 
receptors, some of which are strongly activated by ATP, have recently been linked to 
ROK activation and the ability to ipfluence CaS in rat aortic myocytes (Sauzeau et al,
2000). If ATP was modulating CaS this would pose a serious problem, as ATP would be 
necessary to supply the energy needs of the permeabilised SMCs and was therefore a
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fundamental component of the MI solution. Preliminary permeabilisation studies using 
the technique of Akopov et al, (1997) (50-200pM p-escin, for 20mins in a pCa 9.9 MI 
solution) found that reducing the concentration of ATP in the MI solution to a level 
(lOOpM ATP) that did not activate 2"^  messenger systems (as implied by the absence of a 
tonic response upon exposure to the MI solution), was detrimental to both maximal force 
and rate of force development (-50% decrease) when these vessels were subsequently 
placed in a pCa 4.55 MI solution. The findings suggested that endogenous production by 
ATP synthases was not sufficient to maintain normal contractile function following 
penneabilisation and was consistent with a previous report which found that reducing 
exogenous ATP to lOOpM in peimeabilised guinea-pig taenia coli, reduced force and rate 
of contraction by half (Amer & Hellstrand, 1985). Unfortunately, pharmacological 
manipulation of the P2 receptors involved was not feasible due to the high concentration 
of ATP (5mM) used, the lack of non-competitive antagonists and the large number or P2 
receptors reported to be present in rat small pulmonary artery (Chootip et al., 2002). 
Hence the aims of this study were to detemiine: 1) What component of the MI solution is 
responsible for the observed response? 2) Does the tonic response involve mobilisation of 
Ca^ """ stores? 3) Does the component modulate CaS?
4.3.2 Methods
Two main types of protocol were used in the following experiments 1) Cumulative 
Concentration Response Curves (CCRCs) and 2) Single dose additions to create a fixed 
bath concentration. Following set up and detemiination of their 120mM KCl tension 
standard response, all vessels were equilibrated in Krebs-buffer until their tensions had 
returned to baseline levels (-Ihour). The following questions were then addressed.
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4.3.2.1 Is ATP responsible for the contractile response to the mock intra-cellular 
bathing solution?
It was necessary to compare the contractile profile of ATP to that witnessed upon 
exposure to the pCa 9.9 MI solution. This would not only confirm whether ATP was the 
responsible agonist but also help to determine if the response was modified in any way by 
other components of the MI solution. To achieve this, vessels set up as previously 
described were placed in one of 3 solutions. 1) Krebs-buffer 2) Ca^  ^free (0Ca^^) Krebs- 
buffer 3) 0ATP, pCa 9.9 MI solution. The vessels were then challenged with a single 
dose addition of 5mM ATP. A fourth vessel was simultaneously challenged with 
exposure to a 5mM ATP, pCa 9.9 MI solution to act as a control. All vessels were 
observed imtil the responses had fully stabilised.
4.5.2.2 How Does 5mM ATP effect store release?
It was considered useful to further elucidate the role of the SR and the relative 
contribution of IP3 sensitive and ryanodine sensitive Ca^ "^  stores in the ATP associated 
response.
Vessels were set up as previously described and then placed in a 0ATP, pCa 9.9 MI 
solution. Four conditions were studied; 1-3) The addition of a single dose of 5mM ATP 
to vessels incubated with 1) thapsigargin (2pM, lOmins incubation) to inhibit SR Ca^  ^
uptake, 2) 2 APB (lOOpM, 30mins) to block IP3 mediated store release, or 3) nothing, to 
act as a control. 4) Rapid application of lOmM Caffeine to determine the potential 
contribution of the ryanodine sensitive stores.
4.3.2.3 Does 5mM ATP modulate sensitivity of the contractile apparatus?
Due to the effects of ATP and Y27632 on sarcolemmal Ca^  ^penneability and contractile
kinetics respectively, it was impossible to answer this question conclusively using a 
single experimental protocol. Instead evidence was gathered using 2 different approaches
122
centring on the use of the known ROK inhibitor Y27632. The ROK pathway was 
selected for study first in preference to other proposed sensitisation pathways as it had 
already been shown to be active in the presence of the MI solution (see introduction). 
Once the effect of 5mM ATP on the ROK pathway had been established the intention 
was then to study the action of 5mM ATP on the other proposed sensitisation pathways 
such as the PKC pathway.
CCRCs in unpermeabilised vessels in the presence and absence of 5mM ATP and 
ROK inhibition
Thapsigargin (2pM) was added to all vessels lOmins prior to a solution exchange from 
Krebs-buffer to a 5mM ATP, pCa 9.9 MI solution to deplete the SR. Following SR 
depletion, some vessels were bathed in a 0  ATP MI solution and some in a 5mM ATP 
MI solution. Half of the vessels from each group were then incubated with lOpM of the 
selective ROK inhibitor Y27632 for 45mins. The following solution exchanges were 
performed to produce the cumulative exposure to Ca^ "^ ; pCa; 9.9, 5.7, 4.55, 4.0, 3.5, 3.0, 
2.5, 2.0, 1.5. During solution exchange, vessels were washed twice with the following 
solution to minimise the possibility of dilution by the previous solution.
Single addition of the ROK inhibitor Y-27632 in unpermeabilised vessels with a sub- 
maximally raised tone in the absence of ATP
Following equilibration in a 0ATP pCa 9.9 MI solution the depolarised vessels were 
exposed to an increasing extra-cellular by increasing the ratio of
Ca^^EGTA/K2EGTA in the MI solution until a stable tone which was -25% of the 
120mM KCl response was achieved. lOpM Y27632 was then added to one of each of the 
paired vessels, whilst the remaining vessel acted as a time control. The responses were 
observed for 1 hour or until the response had stabilised, whichever was the shorter.
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4.S.2.4 Do the remaining components of the mock intra-celiular solution 
contribute to the observed contractiie response?
Whilst the previous experiments addressed the action of ATP, it still remained important 
to determine if the other components of the MI solution where contributing to the 
contractile response which occurred upon the vessels exposure to the pCa 9.9 MI 
solution. The most likely cause of any remaining response upon exposure to the MI 
solution in the absence of ATP was residual interstitial Ca^  ^originating from the previous 
Krebs-buffer solution. To detennine if this was the case some vessels were first washed 
in 0Ca^^ Krebs-buffer solution prior to the 0  ATP pCa 9.9 MI solution exchange. The 
procedure was then repeated with fresh vessels either using a Na"^  based pCa 9.9 MI 
solution (substitution of K^) and also a K^ based pCa 9.9 MI solution using Cl" as the 
dominant anion (substitution of CH3COO"). Finally, fresh vessels bathed in a 0ATP pCa
9.9 MI solution were challenged with either a single addition of lOmM Creatine 
phosphate or a lOOpM DDT addition to detennine if these components were involved in 
any part of the observed response.
4.3.3 Results
4.3.3.1 Is ATP responsible for the contractile response to the mock intra-cellular 
bathing solution?
Exchanging a 0Ca^^ Krebs solution for a 5mM ATP pCa 9.9 MI solution produced a bi- 
phasic contraction, consisting of a rapid phasic response (P/R; 50 ± 6 % of the 120mM 
KCl response, n=7) and a sustained tonic response (T/R; and 9 ± 4%, n=7), separated by 
a slow exponential fall off (F/0). The responses were not different in either magnitude or 
profile to that produced by a single addition of 5mM ATP to vessels bathed in a 0ATP, 
pCa 9.9 MI solution (n=7, P>0.05, unpaired t-tests). However, although adding a single 
dose addition of 5mM ATP to vessels bathed in a 0Ca^^ Krebs solution did not alter the
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magnitude of the phasic and tonic responses (n=5-7, P>0 .05, unpaired test), the 90% fall 
off period (Time to F/O90), as measured in seconds from the peak of the phasic response 
until the force reached a point at which it was 10% of the difference between P/R and 
T/R, was substantially reduced (922 ± 109secs, n=5 vs 4023 ± 305secs, n= 8  P<0.0001, 
unpaired t-test). The presence of 2,5mM free Ca^  ^in the Krebs buffer solution enhanced 
the magnitudes of the phasic and tonic responses to a single dose of 5niM ATP (P/R; 76 ± 
7% vs 50 ± 6 %, T/R; 41 ± 7% vs 9 ± 4%, n=7, P<0.0001, unpaired t-tests) but did not 
further increase the rate of fall-off beyond that which had been observed in the 0 Ca^  ^
Krebs condition (n=7, P>0.05, unpaired test) (Fig 4.7).
4.3.3 2 How does 5mM ATP affect SR stores?
Incubation with 2pM thapsigargin, a specific inliibitor of the SERCA 2 Ca^  ^ ATPase, 
which regulates Ca^’*' uptake into the SR, did not attenuate the phasic response of a 5mM 
ATP single dose addition. However the phasic response was almost completely 
abolished by incubation with lOOpM 2 APB, a known inliibitor of IP3 mediated Ca^  ^store 
release. Rapid application of lOmM caffeine, which causes SR Ca^ "^  release via activation 
of Ryanodine sensitive channels, caused only a very small phasic response relative to the 
single 5mM ATP addition (P/R: control; 45 ± 5% of the 120mM KCl response, n=7 vs + 
Thaps; 39 ± 9%, n=5 vs +2 APB; 2 ± 1%, n-7 vs Caffeine; 3 ± 1%, n-7, P<0.001, 
unpaired ANOVA).
In contrast, the tonic response was completely ablated by thapsigargin but was enhanced 
by 2 APB. Rapid application of Caffeine failed to produce a tonic response (T/R: 
control; 7 ± 2% vs + Thaps; <1 ± 1%, n=5, +2 APB; 15 ± 2%, n=7 vs Caffeine; -1 ± 1% 
P<0.001, unpaired ANOVA) (Fig 4.8).
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Figure 4.7 Identification of 5mM ATP as the component of the Ml solution responsible for 
2 nd messenger activation
2+The phasic (P/R) and tonic (T/R) responses observed upon: A) Solution exchange from a 0Ca 
Krebs buffer to a pCa 9.9 Ml solution containing 5mM ATP (n=7). B-D) Single addition of 5mM 
ATP to vessels bathed in a B) 0ATP pCa 9.9 Ml solution (n=7). C) 0Ca^"^ Krebs buffer solution 
(n=5). D) 2.5mM free Ca^^ Krebs buffer solution (n=7).
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Figure 4.8 The role of the SR and the relative contribution of IP3  and ryanodine sensitive 
Ca^  ^stores to the phasic and tonic response caused by a single dose of 5mM ATP
The phasic (P/R) and Tonic (T/R) responses observed upon a single addition of 5mM ATP to 
vessels bathed in a 0ATP pCa 9.9 Ml solution in the absence (Control, n=7) and presence of 
either 2pM Thapsigargin (n=5) or 100(.iM 2 APB (n=7). Rapid application of 10mM caffeine (n=7) 
was used in place of 5mM ATP to assess the contribution of ryanodine sensitive stores.
4.3.3.S Does 5mM ATP modulate Ca^ * sensitivity of the contractile apparatus?
Ca^* CCRCs in the presence and absence of 5mM ATP and ROK inhibition
In vessels pre-treated with 2p,M thapsigargin (to eliminate modulation of intra-cellular
Ca^ *^  levels by the SR Ca^ "^  release) the presence of 5mM ATP in the MI solutions caused 
a markedly significant left shift in the Ca^”^ CCRC relative the Ca^  ^CCRC performed in 
the 0ATP MI solution. This shift was partly, but not entirely reversed by incubation with 
lOjuM of the ROK inhibitor Y27632 (pECso values: 0ATP; 3.04 ± 0.07 vs 5mM ATP; 
3.95 ± 0.07 vs, 5mM ATP + Y27632; 3.48 ± 0.08, n=8, P<0.01, unpaired ANOVA). In 
the 5mM ATP condition at pCa 4.55 the presence of Y27632 was associated with a 50% 
reduction in tone (33 ± 5% of own maximum vs 16 ± 4%, n=8, P<0.05, unpaired t-test) 
(Fig 4.9).
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Incubation of vessels bathed in 0  ATP MI solutions with lOjuM Y27632 caused a 
substantial slowing of the rate of force production making the time required to perform 
the CCRC prohibitively long. The magnitude of the shift caused by the presence of 
lOpM Y27632 in the 0  and the 5mM ATP MI solutions could therefore not be 
compared. However, the relative reduction in tone caused hy Y27632 at pCa 4.55 in the 
5mMATP condition was comparable to the reduction in tone caused by Y27632 in the 
0ATP condition in the single addition experiment (see next section).
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Figure 4.9 The effect of Rho kinase inhibition on Ca^* CCRCs in the presence and absence 
of 5mM ATP performed in depolarised intact (unpermeabilised) vessels
Black symbols - vessels bathed in a 5mM ATP based Ml solution, White symbols - vessels 
bathed in a 0  ATP Ml solution. Control vessels -  circles, + Y27632 -  diamonds. All groups n=8 
(except 0ATP Ml +10pM Y 27632 (O) Open diamonds, n=2).
Single addition of the ROK inhibitor Y-27632 in unpermeabilised vessels with a sub- 
maximally raised tone in the absence of ATP
A single addition of lOpM Y27632 to unpermeabilised vessels with a sub-maximally 
(pCa 4.55) raised tone caused a 47 ± 16% (P<0.001, unpaired t-test) reduction in tone 
relative to the time control vessels. Mean pre-tone (P/T) was not significantly different
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between the response and control groups suggesting the comparison was valid (P/T; 30 ± 
7% of the 120mM KCl response, n=5 vs 35 ± 9%, n=3, P>0.05, unpaired t-test) (Fig 
4.10). Unfortunately the experiment could not be satisfactorily repeated in vessels bathed 
in a 5mM ATP MI solution. These vessels were subject to an unpredictable but sustained 
decline in tension, which prevented the attainment of a stable sub-maximal pre-tone. 
However, the reductions in tone at pCa 4.55 caused by Y27632 in the present 0ATP 
experiment and the previous 5mM ATP Ca^  ^CCRC were comparable.
4.3.3,4 Do the remaining components of the mock intra-cellular solution 
contribute to the observed contractile response?
In the absence of ATP, the solution switch from Krebs buffer to a 0ATP pCa 9.9 MI 
solution still produced a phasic response that was 25 ± 4% of the 120mM KCl response 
(n=7). This phasic response was significantly attenuated to 6 ± 2% (n=6, P<0.05, 
unpaired t-test) by first switching to a 0Ca^^ Krebs solution (which had Na^ as the 
dominant cation) for lOmins prior to switching to the 0  ATP MI solution. Substituting 
the K^ cation with Na"^  in the MI solution (thus preventing depolarisation), completely 
abolished the remaining response (n=4). Substitution of the acetate anion with Cl" 
however, had no effect (n=4, P>0.05, unpaired t-test). There was no tonic response 
associated with the Krebs to MI solution switch in the absence of ATP regardless of the 
dominant cation present or whether or not the vessels had first been washed in 0Ca^^ 
Krebs. Neither Phosphocreatine (n=4) nor DTT (n=4) was found to cause any response 
in unpermeabilised vessels.
The vessels hom all groups were of a comparable internal diameter and replicated 
transmural pressure (P>0.05, unpaired ANOVA). The mean internal diameter and 
replicated transmural pressure of the vessels used in study 2 was 239 ± 6pm and 14.0 ± 
0.2mmHg respectively (n=l 13 vessels).
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Figure 4.10 Confirmation of the constitutive activity of Rho kinase in the absence of 
exogenous ATP
Experimental traces showing: A) The effect of a single dose addition of the Rho kinase inhibitor Y 
27632 (lOpM) to an intact depolarised vessel with a sub-maximal raised tone B) The paired time 
control vessel. 0) Bar graph showing the mean reduction in tone caused by a single dose 
addition of 10pM Y27632 (n=5) relative to the time control vessels (n=3) (P<0.001, unpaired t- 
test).
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4.3.4 Application to protocol
Although the study could not conclusively prove whether the presence of 5mM ATP in 
the MI solution modulated the CaS of the contractile apparatus, it did clearly show that 
the ROK pathway was active both in its presence and its absence. Furthennore the 
magnitudes of the effect of ROK inhibition (-50% decrease in tone) at sub-maximal tone 
(pCa 4.55) both in the presence and absence of 5mM ATP were comparable and 
suggested any effects of ATP on the ROK pathway were minimal. 5mM ATP was 
therefore included in all subsequent MI solutions unless stated otherwise.
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4.4 Study 3) Selection of a sensitising agonist as a standard
4.4.1 Background
Before a comparison of permeabilisation techniques and agent concentrations could occur 
it was necessaiy to establish a sensitising agent, which would act as a standard against 
which post permeabilised responses could be compared. The standard would be 
invaluable in assessing how well the receptor-coupled second messenger systems 
tolerated a chosen penneabilisation procedure and would allow the investigator to create 
a valid index for comparison. As ET-1 has previously been shown to increase CaS in the 
Sprague Dawley rat small pulmonary artery (Evans et al, 1999) it was the obvious choice 
for further study. In the a-toxin permeabilised Sprague Dawley rat small pulmonary 
artery, ljuM ET-1 was reported to be capable of causing a contractile response, which 
was ~50% of the maximum permeabilised response to pCa 4.5. This response could not 
be attributed to any mechanism other than the sensitisation of the contractile apparatus.
The aim of this study was therefore to establish whether ET-1 was a suitable sensitising 
agonist in the Wistar rat small pulmonary artery and to determine the most appropriate 
concentration for its use.
4.4.2 Methods
4.4.2.1 What is the concentration range of the ET-1 induced vasoconstrictor 
response in the Wistar rat small pulmonary artery?
To establish the concentration range for the action of ET-1 and the concentration at which 
its maximal effect occurred, CCRCs to ET-1 (lpM-lp,M) were performed in vessels 
bathed in Krebs-buffer.
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4.4.2.2 What is the concentration range and Emax of the assumed ET-1 induced 
Ca^ * sensitisation response in the Wistar rat small pulmonary artery?
It was also necessary to establish whether ET-1 was likely to have a sensitising effect in
the Wistar rat small pulmonary artery as had been reported in the Sprague Dawley (Evans 
et ai, 1999). To determine the approximate magnitude and concentration range of any 
such response, CCRCs to ET-1 (IpM-lfaM) were performed in vessels with a negated SR 
(2pM thapsigargin) under 3 separate conditions: 1) pCa 9.9; the virtual absence of extra­
cellular Ca^  ^ and Ca^%t- 2) pCa 6.64; the [Ca^ *^ ] predicted to cause a raised tone of -  
25% in permeabilised vessels but no induced tone in unpermeabilised vessels. 3) pCa 
4.55; the [Ca^ '*'] predicted to cause a raised tone of ~ 25% in unpermeabilised vessels and 
maximal tone in permeabilised vessels .
Under these conditions the vessels were depolarised, extra-cellular Ca^ "*" levels were 
clamped and the SR’s Ca^  ^ stores negated. It was considered that any subsequent 
response to ET-1 would be indicative of its sensitising capabilities. However, it was 
recognised that ET-1 could modulate the activity of sarcolemmal Ca^  ^ channels leading 
to a change in Ca^  ^ permeability, thus compromising the [Ca^ "^ ]cyt and that this could 
influence the response, particularly in the pCa 4.55 condition.
4.4.2.S Does 5mM ATP affect the ET-1 induced response in the Wistar rat small 
pulmonary artery bathed in a 0Ca^  ^mock intra-ceiluiar solution?
It was suspected that 5mM ATP was causing chronic activation of the SR and that in
conjunction with lOmM EOT A, this action may effectively prevent the SR from 
modulating [Ca^’^ jcyt in permeabilised vessels, thus negating the need for additional 
intervention. To determine whether the presence of 5mM ATP in the MI solution could 
drain the SR as effectively as thapsigargin inhibition of Ca^ "^  uptake, ET-1 CCRCs (IpM- 
l|uM) were repeated in 0  and 5mM ATP pCa 9.9 MI solutions in the absence of 
thapsigargin.
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4.4.3 Results
4.4.3.1 Over what concentration range does the ET-1 induced vasoconstrictor 
response occur in the Wistar rat small pulmonary artery?
Cumulative doses of ET-1 to vessels bathed in Krebs-buffer solution produced a 
sigmiodal dose dependent response curve with a tlireshold at InM and an Emax of 128 ± 
8 % at IpM. The pECso was 7.81 ± 0.07 (n=7) (Fig 4.11).
4.4.5.2 Does ET-1 induced sensitisation occur in the Wistar rat small pulmonary 
artery? What is the concentration range and magnitude of the effect?
Exposure of vessels (pre-treated with thapsigargin to negate the SR) to the 5mM ATP MI 
solutions caused a sustained elevation in tone, which appeared to be dependent on the 
level of free Ca^  ^ in the solutions. The pCa 4.55 MI solution initially produced a sub- 
maximal raised tone (pre-tone) that was 40 ± 3% (n=5) of the 120mM iso-osmotic KCl 
response. However, this was not stable and diminished to 27 ± 8 % (n=5) before any 
response to ET-1 was observed. Relative to the pCa 4.55 MI solution, the pCa 9.9 and 
pCa 6.64 MI solutions produced attenuated (P<0.05, unpaired ANOVA) but entirely 
stable pre-tones, which were not significantly different from one another (2 ± 1%, vs 3 ± 
2% n=5, R>0.05, unpaired t-test).
The concentrations at which the threshold and maximum response to ET-1 occurred were 
lOnM and IpM respectively, regardless of the pCa of the depolarising MI solution and its 
associated level of pre-tone. The efficacy and potency of the ET-1 induced response was 
not different in the pCa 9.9 and pCa 6.64 conditions. However, the efficacy but not the 
potency of ET-1 was significantly enhanced in the pCa 4.55 condition (Emax: in pCa 9.9; 
11 ± 2% of thel20mM KCl response vs pCa 6.64; 11 ± 2% vs pCa 4.55; 21 ± 4%, n=5, 
P<0.05, unpaired ANOVA) (pECso: pCa 9.9; 7.20 ±. 0.16 vs pCa 6.64; 7.24 + 0.18 vs 
pCa 4.55; 7.27 ± 0.27, n=5, P>0.05, unpaired ANOVA). Expressing the IpiM ET-1
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response in pCa 4.55 as a percentage of the (pCa 4.55) pre-tone indicated a 74 ± 20% 
increase (n=5) (Fig 4.11).
4.4.3.3 Does SmIVI ATP affect the ET-1 induced response in the Wistar rat small 
pulmonary artery bathed in a mock intra-cellular solution in the absence of extra- 
ceilular Ca^ ?^
The efficacy of the response to ET-1 in the 5mM ATP MI solution was unchanged by the 
absence of thapsigargin pre-treatment. However in the absence of ATP and thapsigargin, 
the efficacy of the response was significantly augmented (Emax; in 5mM ATP pCa 9.9 + 
Thaps; 11 ± 2% of the 120mM KCl response vs 5mM ATP pCa 9.9; 13 ± 3% vs OATP 
pCa 9.9; 32 ± 7%, n=5, P<0.05, unpaired ANOVA).
In contrast, the absence of thapsigargin increased potency of the ET-1 response, both in 
the presence and absence of ATP (pECso: 5mM ATP pCa 9.9 + Thaps; 7.20 ± 0.16 vs 
5mM ATP pCa 9.9; 8.03 ± 0.14 vs OATP pCa 9.9; 8.07 ± 0.14, n=5, P<0.005, unpaired 
ANOVA) (Fig 4.11).
The vessels from all groups were of a comparable internal diameter and replicated 
transmural pressure (P>0.05, unpaired ANOVA). The mean internal diameter and 
replicated transmural pressure of the vessels used in study 3 was 231 ± 10pm and 13.7 ± 
0.2mmHg respectively (n=32 vessels).
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Figure 4.11 ET-1 is a suitable sensitising agent standard
A) CCRC to ET-1 in Krebs buffer (n=7). B) CCRCs to ET-1 in 5mM ATP based pCa 9.9 mock 
intra-cellular (Ml) solutions in the presence of thapsigargin (aii n=5, P<0.05). C) CCRCs to ET-1 
in 0  and 5mM pCa 9.9 ATP Ml solutions in the absence of thapsigargin (ail n=5, P<0.05). The 
pre-tone was subtracted prior to statistical comparison.
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4.4.4 Application to protocol
The data suggest that in optimally permeabilised vessels, with a sub-maximal raised tone 
25% of max response), a single addition of an optimum concentration of ET-1 should 
increase tone by -10-20% of the vessels own maximum response. The optimum 
concentration of ET-1 was found to occur between 0.1 and IpM depending on the 
presence of thapsigargin/DMSO.
Additionally the response in the pCa 9.9 MI solution was recognised as a useful index of 
permeabilisation, which permitted the identification of intact SMC populations following 
permeabilisation. Furthermore, as the ET-1 responses in pCa 9.9 and pCa 6.64 MI 
solutions in unpermeabilised vessels were virtually identical, it was considered that 
following permeabilisation any response observed to ET-1 in pCa 9.9 would be indicative 
of the potential error (caused by the presence of unpermeabilised SMCs) in the ET-1 
response at pCa 6.64.
The augmented response to ET-1 in the absence of thapsigargin in the 0ATF pCa 9.9 MI 
solution also suggested that 5mM ATP caused a chronic activation of the SR, which 
effectively drained the SR to levels comparable with thapsigargin pre-treatment. It was 
recognised that this may negate the need for the additional treatment of the SR in 
permeabilised vessels and that this approach should be investigated further.
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4.5 Study 4) Selecting the optimum p-escin concentration for 
permeabilisation
4.5.1 Background
To ensure uniformity in the permeabilised preparations, each vessel was exposed to p- 
escin in a pCa 5.7 MI solution. This solution caused no change in tone in the 
unpermeabilised SMCs but near maximal contraction of the permeabilised SMCs. Hence 
the development of tone reported on the progress of the permeabilisation procedure, and 
when tone finally stabilised this suggested the procedure was complete. Using this 
method, each vessel would therefore be exposed to a given concentration of P-escin for 
an optimum period of time (Fig 4.12).
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Figure 4.12 Experimental trace of the permeabilisation protocol
This technique uses Ca^ "" entry into the permeabilised cells to report on the progress of the 
procedure, thus optimally permeabilising each vessel.
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However, the dose dependant nature of P-escin also meant that whilst above a certain 
threshold, all concentrations would produce a fully permeabilised preparation, only a 
certain range of concentrations would also preserve the second messenger systems that 
were necessary to future studies. Hence, the aim of this study was to determine the 
optimum concentration of p-escin for use in the permeabilisation protocol.
This required the development of an index of permeabilisation and also a separate index,
'f
which reported on the preservation of signal transduction systems. The permeabilisation ;■Î
.findex would allow an assessment of the degree of permeabilisation achieved for each
.1
concentration of p-escin tested and hopefully provide a useful quality control test that 
could be applied at the end of future experiments. The previous study had already 
provided one index of permeabilisation, the response to ET-1 in a pCa 9.9 MI solution.
However, whilst this was acceptable for the purpose of the protocol development it could 
not be used routinely, as ET-1 is resistant to washout making any vessels tested useless 
for further study. Furthermore it could not be confidently applied following the 
application of the sensitising agonists if these were resistant to washout. A second index 
of permeabilisation was therefore required, preferably one, which could be applied at the 
end of the protocol and one, which would not be invalidated by the action of the 
sensitising agonists under study. The second index was originally based on the 
hypothesis that permeabilised and unpermeabilised SMCs would respond to Ca^ "^  in the 
MI solutions over separate, distinct [Ca^ ]^ ranges. Hence, a partially permeabilised vessel 
exposed to a [Ca^ "'^ ] sufficient to cause maximum contraction of its permeabilised SMC 
population but no activation of its unpermeabilised SMC population, would show an 
additional increase in tone when it was subsequently exposed to a [Ca^^] that would cause 
maximal activation of both permeabilised and unpermeabilised SMCs. The 2 
concentrations were termed the intra-cellular maximum (imax) and the extra-cellular
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maximum (Umax) respectively, and when force at Cmax (Fcmax) no longer exceeded force at 
im a x  ( F i m a x ) ,  the vcsscl was considered to be fully permeabilised. In practice it was found 
that the two ranges did marginally overlap, but that the contractile resei-ve of the 
unpermeabilised population of SMCs at imax was more than sufficient to distinguish their 
presence at emax (Fig 4.13).
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Figure 4.13 The rationale behind emax index of permeabilisation
CCRCs in permeabilised and unpermeabilised vessels showing the predicted contractile 
reserve (vertical arrow) remaining in unpermeabilised SMCs at pCa 4.55 ( i m a x ) -  Upon exposure to 
a pCa 2.5 (emax) Ml solution this contractile potential is realised, thus reporting the presence of 
any unpermeabiiised SMCs.
Hence in vessels which were incompletely permeabilised the presence of 
unpermeabilised SMCs was clearly observed as an increase in tone following the switch 
fi'om a pCa 4.55 ( im a x )  MI solution to a pCa 2.5 (C m a x )  MI solution. This increase in tone 
was absent in fully permeabilised vessels. This was known as the Cmax index of 
permeabilisation.
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The effect on the signal transduction mechanisms was determined by potency and 
efficacy of the ET-1 induced response in penneabilised vessels at a sub-maximally raised 
tone. This was known as the ET-1 index of signal transduction
4.5.2 Methods
Vessels were set up, noiinalised and their 120mM KCl tension standard response 
obtained as previously described. The following experiments were then performed.
4.5.2.1 Over what range of concentrations does B-escin fully permeabiiise the 
Wistar rat small pulmonary artery?
Following equilibration in a pCa 9.9 MI solution, vessels were bathed in a pCa 5.7 MI 
solution and p-escin added at one of the four following concentrations, 25, 50, 100 or 
200pM. When each vessel reached its individual optimum exposure time it was washed 
in a pCa 9.9 MI solution and allowed to return to baseline. Each vessel was then exposed 
a pCa 4.55 (imax) MI solution until the response stabilised and then the vessel was 
exposed to a pCa 2.5 (emax) MI solution. The procedure was then repeated in fresh 
vessels, however this time the vessels were challenged with IpM ET-1 in a pCa 9.9 MI 
solution (ET-1 index of permeabilisation) prior to perfonning the imax and Cmax 
challenges.
4.5.2.2 What concentration of B-escIn best preserves the receptor coupled signal 
transduction systems?
Vessels were permeabilised as previously described using one of four different 
concentrations of p-escin; 25, 50, 100 or 200pM. Following permeabilisation, vessels 
were washed in a pCa 9.9 MI solution and lOpM A 23187 (30mins incubation) was 
added to permeabiiise the SR to Ca^ ,^ thus preventing agonist induced SR Ca^ "^  release 
which could influence tone. Once the vessels had returned to baseline, they were placed
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in a pCa 6.64 MI solution in order to create a sub-maximal raised tone (-25% of Fimax)- 
Upon stabilisation of the sub-maximal pre-tone, CCRCs to ET-1 (lOnM-lpM) were 
performed. Following the performance of the CCRC the vessels were assessed using the 
Cmax index of permeabilisation to determine the presence of any unpermeabilised SMCs.
4.5.3 Results
4.5.3.1 Over what range of concentrations does B-escin fully permeabiiise the 
Wistar rat small pulmonary artery?
Fcmax was not significantly different between any of the groups when expressed as a 
percentage of each vessels own pre-pemieabilisation 120mM KCl response (all groups 
49-50 ± 2%, n=6 , R>0.05, unpaired ANOVA). However, when the data were expressed 
as a percentage of Fimax, Fcmax was significantly augmented in the 25 pM group (FCmax: 
50, 100, 200pM p-escin; 101 ± 1% of Fimax vs 25pM P-escin; 107 ± 2%, all n=6 , 
P<0.001, unpaired ANOVA) (Fig 4.14).
Vessels permeabilised with 50, 100 or 200pM p-escin showed essentially no response to 
IpM ET-1 in the pCa 9.9 MI. However some vessels permeabilised in 25pM p-escin 
retained the ability to respond to IpM ET-1, producing a significant elevation in tone at 
pCa 9.9 (ET-1 Emax: 50, 100, 200pM p-escin; <1 ± 1% of Fimax vs 25pM p-escin; 5 ± 
2%, n=5-6, P<0.05, unpaired ANOVA). Quantitatively the emax index did not show a 
significant increase in Fcmax in any of the groups following exposure to ET-I (P>0.05, 
n=5-6, unpaired ANOVA). However, qualitatively, vessels from the 25pM p-escin group 
which demonstrated a noticeable response to ET-1 in the pCa 9.9 MI solution also 
produced an Cmax response that was visibly larger than the imax response (Femax: 50, 100, 
200pM P-escin; 101 ± 1% of Fimax vs 25pM P-escin; 105 ± 3%, n = 5-6, R>0.05, 
unpaired ANOVA) (Fig 4.15).
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Figure 4.14 The e a^x index of permeabilisation
Experimental traces showing the course of permeabilisation and the subsequent emax index 
response of; A) a fully permeabilised vessel B) an incompletely permeabilised vessel. C) The 
pCa 2.5 (emax) response (Femax) expressed as a percentage of the pCa 4.55 (imax) response (Fimax) 
for vessels permeabilised at 25, 50, 100 or 200 pM p-escin. (all groups n=6, P<0.01, unpaired 
ANOVA).
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Figure 4.15 The ET-1 index of permeabilisation
Experimental traces showing the ET-1 response of; A) a fully permeabilised vessel B) an 
Incompletely permeabilised vessel In a range of Ml solutions. C) The ET-1 response expressed 
as a percentage of the pCa 4.55 response (Fimax) for vessels permeabilised with 25, 50, 100 or 
200 |iM p-escin. (all groups n=5-6 ,F<0.01, unpaired ANOVA). Also shown is the predicted error 
of a maximal IpM ET-1 response caused by the presence of unpermeabilised SMCs. The error 
is expressed as a % of the pCa 6.64 pre-tone.
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4.S.3.2 What concentration of fi-escin best preserves the receptor coupled signal 
transduction systems?
ET-1 induced a maximum response at IpM in all groups and significantly increased pre­
tone (P/T) in vessels permeabilised with 25, 50 or lOOpM p-escin (25pM p-escin: P/T; 
0,45 ± O.OSmN vs l|aM ET-1 response; 0.68 ± 0.1 OmN, SOpM P-escin; 0.36 ± O.OSmN vs 
0.53 ± 0.12mN, lOOjiM; 0.30 ± 0.04 vs 0.37 ± 0.04 mN, F<0.01, all n=5, paired t-test) 
but not in vessels permeabilised with 200jLiM p-escin (F>0.05, n=5, paired t-test). Neither 
the efficacy nor the potency of the ET-1 response was significantly different between the 
25, 50 or lOOpM P-escin groups. Efficacy data are expressed both as a % of the pCa 6.64 
pre-tone (Emax: 25p,M p-escin; 55 ± 12% of pCa 6.64 P/T vs 50pM; 45 ± 7% vs lOOjaM; 
26 ± 9%, n=5, F>0.05, unpaired ANOVA) and as a % of Fimax (Emax: 25pM P-escin; 13 
± 2% of F i m a x  vs 50pM; 11 ± 2% vs lOOpM; 6  ± 2%, n=5, P>0.05, unpaired ANOVA). 
Potency expressed as pECso values (pECso: 25pM p-escin; 7,10 ± 0.19 vs 50pM; 6.98 ± 
0.11 vs lOOpM; 6.72 ± 0.24, n-5, F>0.05, unpaired ANOVA) (Fig 4.16).
The vessels from all groups were of a comparable internal diameter and replicated 
transmural pressure (P>0.05, unpaired ANOVA), The mean internal diameter and 
replicated transmural pressure of the vessels used in study 4 was 271 ± 11pm and 13.4 ± 
0.3mmHg respectively (n= 6 6  vessels).
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Figure 4.16 The ET-1 signai transduction index
A) Experimental trace showing an ET-1 CCRC in an optimally permeabilised vessel. ET-1 
CCRCs for vessels permeabilised at 25, 50, 100 or 200pM p-escin expressed as a percentage of
B) the pCa 6.64 pre-tone C) the pCa 4.55 response ( F i m a x )  (all groups n=5).
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4.5.4 Application to protocol
25|iM p-escin failed to consistently produce a fully permeabilised preparation, whilst 
200|uM p-escin failed to preserve receptor coupled signal transduction mechanisms. Both 
50 and lOOfxM p-escin fully permeabilised the vessels whilst preserving the signal 
transduction mechanisms. Although the difference in efficacy was not significant 
between 50 and lOOpiM, vessels permeabilised in 50pM P-escin produced a response that 
was most compatible with that observed in unpermeabilised vessels. Therefore all 
subsequent permeabilisation studies were perfoimed at this concentration. The emax index 
of permeabilisation was found to be a useful indicator of the presence of unpermeabilised 
SMCs and was therefore applied at the end of all future permeabilisation experiments as a 
quality control measure.
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4.6 Study 5) “Knocking out” the SR
4.6.1 Background
The final aspect of the protocol development that required investigation was to establish 
whether the SR could still influence [Ca^’*']cyt in response to an agonist in the 
permeabilised preparation. Previous studies (Akopov et a l,  1997;Akopov et al, 
1998;Kitazawa et al, 1989;Evans et al, 1999) had all used the DMSO based ionophore 
A 23187 (lOpM) to irreversibly deplete the SR. In fully permeabilised preparations with 
the SR depleted and extra-cellular [Ca^ ]^ (and hence [Ca^ '^ jcyt) clamped by the EOT A 
based MI solution, any subsequent response to an agonist would have been expected to be 
caused by a change in CaS. However, DMSO may adversely affect the contractile 
apparatus in rat pulmonary arteries (unpublished observations). Furthermore, the obvious 
alternative to this, thapsigargin (which uses a lower [DMSO]), had been shown to cause a 
decrease in the potency of ET-1 in study 3. In light of the evidence suggesting that the 
presence of 5mM ATP in the MI solutions may deplete SR Ca^ ,^ it was considered that 
the SR may not require additional intervention in permeabilised vessels.
4.6.2 Methods
Vessels were set up and permeabilised using 50pM p-escin as previously described
4.6.2.1 Does the SR require additional intervention in permeabilised vessels?
Following permeabilisation, vessels were washed in a pCa 9.9 MI solution and lOpM A
23187, 2|LtM thapsigargin or nothing was added and the vessels allowed to return to 
baseline, whilst the drugs incubated. The vessels pre-treated with thapsigargin, A 23187 
and one with no pre-treatment were then placed in a pCa 6.64 MI solution in order to 
create a sub-maximal tone (-25% of Fimax), whilst a fourth vessel which had underwent
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no additional pre-treatment of the SR was placed in a SOpM K2EGTA based nominally 
Ca^  ^ free 5mM ATP, MI solution to act as a positive control. Upon stabilisation all 
vessels were challenged with 30pM IP3 to trigger SR store release. Following any 
response to IP3, vessels bathed in the 50|uM K2EGTA pCa 9.9 MI solution were washed 
and then exposed to a normal lOmM EGTA pCa 6.64 MI solution to determine what the 
vessels sub-maximal tone (P/T) would have been. Finally, all vessels were exposed to an 
imax (pCa 4.55) MI solution to determine their Fimax-
4.6.3 Results
4.6.3.1 Does the SR require additional intervention in permeabilised vessels?
A 30pM single addition of IP3 (the dominant intra-cellular signal for agonist induced SR
Ca^ "^  release in Wistar rat small pulmonary arteries - see study 2) had essentially no effect 
on vessels incubated with 2pM thapsigargin, lOqM A-23187 or nothing in a pCa 6.64 MI 
solution (IP3 response: all groups; <1 ± 1% of the pCa 6.64 P/T, n=5, P>0.05 unpaired 
ANOVA). This equated to a change in force of <0.25 ± 0.25% (all groups) of the Fimax-
Performing the challenge in the presence of a 50pM EGTA based, nominally Ca^  ^ free 
MI solution yielded a small, transient contraction that was 8  ± 4%, (n=4) of the 
subsequent response to a lOmM EGTA based pCa 6.64 MI solution. This equated to a 
change in force of <2 ± 1% of Fimax- Mean tone at pCa 6.64 was not significantly 
different between any of the groups (P>0.05, unpaired ANOVA) suggesting the 
comparison was valid (Fig 4.17).
The vessels from all groups were of a comparable internal diameter and replicated 
transmural pressure (P>0.05, unpaired ANOVA). The mean internal diameter and 
replicated transmural pressure of the vessels used in study 5 was 287 ± 7pm and 13.2 ± 
0.2mmHg respectively (11= 19 vessels).
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Figure 4.17 Establishing the SR buffering requirement
The response to a single dose addition of SOpM IP3  in vessels bathed in either a 50pM 
(Transparent bars, n=4) or lOmM (Soiid bars, n=5 ail groups) EGTA based Ml solution in the 
presence and absence of 2|iM thapsigargin or 10|llM A 23187. Results expressed as a 
percentage of A) the pCa 6.64 pre-tone and B) pCa 4.55 response (Fimax).
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4.6.4 Application to protocol
The results of study 5 confirmed that the SR of permeabilised vessels did not require 
additional intervention prior to their use in G-protein linked agonist studies performed in 
a pCa 6.64 MI solution.
4.7 Adaptation of the protocol for use with the chronically 
hypoxic rat and the control mouse.
The protocol was found to be compatible for use with the chronically hypoxic Wistar rat 
small pulmonary artery and required no further modification. The protocol was also 
compatible with the mouse C-class intra-pulmonary artery (SPA). In this vessel however 
the optimum concentration of |3-escin was found to be lOpM.
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4.8 Discussion
4.8.1 Study 1) Selecting the optimum tension response standard
Small pulmonary resistance arteries (SPAs) of a similar internal diameter and noimalised
to the equivalent of 12-14mmHg, regularly demonstrate a substantial variation in the 
absolute force they generate in response to a given stimulus (Fig 4.4). In order to 
compare the action of an agonist or other stimuli in these vessels, it is therefore necessary 
to express the response data as a percentage of some quantifiable and repeatable standard. 
Traditionally this has been achieved by depolarising the cell using potassium chloride 
(KCl) at a predetermined concentration to produce a maximum “un-sensitised” 
contraction which can be fully reversed by washout, with no detriment to the vessel.
4.8.1.1 Nominally iso-osmotic KOI depolarising solutions are superior to hyper­
osmotic KCl additions
Hyper-osmotic KCl additions were associated with a 20-30% reduction in F90 and a two 
to four-fold increase in the time to F90 relative to nominally iso-osmotic K^CHgCOO" 
depolarisations. However acetate/chloride substitution was also found to be detrimental to 
the normal contractile responses of the cell during repetitive exposure. This finding was 
consistent with previous reports that inhibition of chloride channels in rat PASMCs has 
been shown to slow the removal of Ca^  ^ from the cytosol following application of 
caffeine and in the absence of extra-cellular Ca^ ,^ significantly increase basal [Ca^ j^cyt 
(Cruickshank et al, 2003).
Based on these findings a nominally iso-osmotic 120mM KCl solution was adopted as the 
protocols tension standard. The data showed that a nominally iso-osmotic KCl solution 
was a fast and reliable standard and had the least deleterious effect on force, rate of force 
production and basal tone despite repetitive and prolonged exposures.
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However, it was noted that the response times of the pulmonary vessels to KCl were far 
slower those reported for systemic resistance vessels (Ghisdal et ai, 2003). A comparison 
of the time course of a nominally iso-osmotic KCl contraction with that of a maximal pCa 
4.55 contraction in optimally permeabilised pulmonary vessels from study 4 found that 
the unpeimeabilised response was ~ 50% slower. This suggested that even when using 
an iso-osmotic KCl solution, some process other than the responsiveness of the 
contractile proteins was limiting the rate of contraction. However this alone was not 
sufficient to explain the substantial difference in the response times between systemic and 
pulmonary vessels. A search of the literature failed to provide a suitable comparison of 
the time courses of pulmonary in vitro and in vivo depolarisation responses. Although the 
extra-lobar pulmonary vessels of the rat are known to be well innervated, sympathetic 
imiervation is absent in the intra-lobar pulmonary arteries (Bradley et al, 1970). 
However, in vitro and in vivo agonist responses to hU-II at 37^C demonstrate a 
comparable time course (5-lOmins) (Deuchar et al, 2005) suggesting the tissue is not 
adversley affected by the in vitro technique. Furthennore the vessels from the current 
study which underwent repeated exposure to iso-osmotic KCl showed no sign of 
deterioration over the course of the experiment, again suggesting the vessels were not 
damaged by the procedure.
4.8.2 Study 2) Investigation into the agonist action of the pCa9.9 Wli 
solution in un-permeabilised vessels
In selecting the bathing solution composition, 3 factors were considered of paramount 
importance: 1) The solution should mimic as closely as practicably possible the normal 
ionic internal environment so that the results were physiologically relevant. 2) It should 
be capable of sustaining the vessels without detriment for extended periods of time; i.e.
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up to 2 hours following permeabilisation. 3) It should not appreciably affect Ca^ "^  
sensitivity.
4.8.2.1 Composition of the Ml solution
The MI solution was an adaptation of that used by Horiuti et al, (1986) which has been 
widely used with a-toxin permeabilised smooth muscle preparations (Horiuti, 
1986;Kitazawa et al, 1989;Himpens et al, 1990;Iizuka et al,  1994;Evans et al, 1999). 
The only major compositional difference was the substitution of acetate for 
methansulphonate. Acetate has been used as the dominant anion in MI solutions in 
studies which have successfully employed p-esein as the permeabilising agent (Akopov 
et al, 1997;Akopov et al, 1998). The MI solution was therefore believed to be a suitable 
replication of the cells internal environment, although this could only be confirmed once 
the penneabilisation stage was reached. However the observation that the MI solution 
consistently induced a bi-phasic contraction in the rat small pulmonary artery was of 
significant concem, especially as no mention had been made of this response previously. 
Hence the main question study 2 was required to address was, did the MI solution affect 
CaS?
4.5.2.2 The Ml solution does not appear to modulate CaS
ATP mediates the contractile response associated with the Ml solution through both 
sarcolemmal Ca^* flux and Ca^  ^store release
The single dose addition studies suggested that 5mM ATP was the only component of the 
MI solution responsible for the bi-phasic response. The rate of fall off between the 
phasic and tonic responses was modified by the MI solution, presumably due to 
acetate/chloride substitution (Cruickshank et al, 2003), but the solution did not 
significantly alter the magnitude of the 5mM ATP responses. 5mM ATP was associated 
with both sarcolemmal Ca^ "^  flux and Ca^  ^ store mobilisation, consistent with the
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activation of both P2Y and P2X receptor subgroups (Pediani et al, 1999;Chootip et al, 
2002). In the permeabilised preparation, P2X activation, which causes sarcolemmal Ca^”^ 
entry (Dubyak & el Moatassim, 1993) but not G-protein activation (Harden et al, 1995), 
would not be of consequence. However P2Y activation, which has been linked to G- 
protein mediated Ca^  ^store release (Pediani et al, 1999) and ROK activation (Sauzeau et 
al, 2000b), further suggested the possibility 5mM ATP modulating CaS in the 
permeabilised preparation.
The phasic response was almost entirely the result of IP3 mediated Ca^  ^ store release, 
whilst the tonic response appeared independent of IP3 production and was not associated 
with caffeine sensitive stores. However the tonic response, was dependent on SR Ca^ ,^ as 
the response was ablated by pre-treatment with thapsigargin. 2 APB has been reported to 
inhibit distinct IP3 pathways with different sensitivity (Kukkonen et al, 2001) thus 
suggesting that the ATP induced Ca^  ^store release associated with the tonic response was 
mediated by a different pathway to the phasic response. These findings where consistent 
with P2 Y2 and P2 Y4 receptor activation. Both subtypes have been reported in rat isolated 
pulmonary vessels and can be activated by ATP (Bogdanov et al,  1998;Chootip et al, 
2002). Additionally, they are G protein coupled receptors that can mediate Ca^  ^ store 
release thi’ough both Gq and Gi proteins (Pediani et al,  1999;Zeng et al,  2003) and of 
greatest concem, both have been shown to cause ROK activation in vascular myocytes 
(Sauzeau et al, 2000b). The possibility of ATP modulating CaS through the ROK 
pathway seemed to be further corroborated by the observation that the tonic response was 
ablated by a single addition of the ROK inhibitor Y27632.
5mM ATP cannot be effectively blocked by pharmacological antagonism
Pharmacological antagonism was not a practical solution to the problem of multiple P2Y
receptor activation by 5mM ATP, as only the P2 Y2 receptor has an effective antagonist.
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Suramin. However Suramin is reported to be a competitive antagonist (Communi et al., 
1999) and as the MI solution contained 5mM ATP, it would not be effective at this 
concentration. Although PPADS and RB2  have been reported to be effective P2 Y4 
antagonists by some investigators, both have also been reported to be ineffective in the rat 
isolated pulmonary artery (Rubino et al, 1999;Chootip et al, 2002).
5mM ATP does not appear to modulate CaS
As pharmacological antagonism was not feasible, it was necessary to determine if 
SmMATP modulated CaS of the preparation. The relative potencies of Ca^ '*' CCRCs 
performed in unpermeabilised vessels suggested that 5mM ATP caused an eight-fold 
increase in sensitivity to extra-cellular Ca^”^ and this was partially, but not entirely 
reversed by the ROK inhibitor Y27632, possibly implying changes in both CaS and 
sarcolemmal Ca^  ^ flux. However, Ca^ "^  CCRCs performed in the absence of ATP also 
suggested a decrease in CaS when performed in the presence of Y27632. Unfortunately 
this aspect of the study had to be abandoned as responses in the presence of Y27632 were 
slowed to such an extent that a single step of the CCRC could take up to 3hours. These 
findings suggested that ROK may have been constitutively active and therefore the shift 
caused by 5mM ATP may have been solely due to enhanced sarcolemmal Ca^ "^  flux 
caused by P2X activation (Chootip et al, 2002). The suspected constitutive activity of 
ROK was corroborated by the single dose addition of Y27632 to unpermeabilised vessels 
with a sub-maximally raised tone in a 0ATP MI solution. Unfortunately the presence of 
5mM ATP in the MI solution prevented the attainment of a stable sub-maximal raised 
tone (presumably due to P2X desensitisation (Chootip et al, 2002)), so a direct 
comparison of the effect of ATP could not be made in this experiment either. However 
when the magnitudes of the shifts caused by Y27632 at pCa 4.55, were compared for the 
5mM ATP Ca^  ^CCRC and the 0ATP sub-maximal tone experiments, they were found to 
be comparable, with both experiments showing a decrease in tone of -50% following
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ROK inhibition. This suggested that ROK was constitutively active in the Wistar rat 
small pulmonary artery but was not substantially modulated by the presence of ATP.
4.8.3 Study 3) Selection of a sensitising agonist as a standard
4.8.3.1 ET-1 is a suitable standard
The efficacy of the ET-1 CCRCs in Krebs buffer demonstrated that ET-1 was capable of 
a causing a contraction greater than the tension standard in these vessels. Repeating the 
CCRCs in depolarised vessels with a clamped extra-cellular [Ca^ ]^ and a negated SR, 
confirmed that ET-1 was indeed capable of modulating tone in the absence of 
sarcolemmal Ca^  ^ flux and Ca^ ''" store release, consistent with its reported ability to 
modulate CaS (Evans et al,  1999). The modulation in tone was found to be ~10-20% of 
the tension standard response, which was somewhat smaller than the effect of ET-1 on 
CaS in the Sprague Dawley rat, which was reported as ~50% of the maximum response 
(Evans et al,  1999). The figuie of 10-20% was arrived at based on the following 
assumptions; The response in the pCa 9.9 MI solution should not have been influenced by 
sarcolemmal flux or Ca^  ^store release (because extra-cellular Ca^  ^was absent and the SR 
had been negated by thapsigargin) hence this would only represent a modulation of CaS, 
but only in those fibres that had some pre-existing level of phosphorylation (Somlyo & 
Somlyo, 2003). The response in the pCa 4.55 MI solution would represent the 
modulation of CaS in all fibres but may have also been augmented by enhanced 
sarcolemmal Ca^  ^ flux. Hence, the true magnitude of the CaS response would lie 
somewhere between these two values.
The data suggested that ET-1 was a viable standard sensitising agonist in the Wistar rat 
small pulmonary arteiy. Based on the studies findings it was predicted that an optimally
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permeabilised prepai'ation should be capable of producing a response to IpM ET-1 with 
an efficacy of 10-20% and a pECso in the range of 10-50nM.
4.8.3.2 A role for ET-1 as an index of permeabiilsation
As pre-treatment with thapsigargin had ablated the tonic response, the effect of ET-1 in 
the pCa 9.9 MI solution had not been expected. The response suggested that there was a 
residual [Ca^ "^ ]cyt in these vessels. This finding was therefore used as a means of 
identifying the presence of populations SMCs that had been resistant to the 
permeabilisation procedure. The response, which occurred in the virtual absence of any 
pre-tone, also suggested it was important to express CaS modulation in relation to the 
maximum post permeabilisation response as well as a percentage of the change in pre­
tone. This was because the magnitude of a CaS response may not be proportional to the 
pre-existing level of tone.
4.8.3.3 ET-1 responses suggest pharmacological blockade of the SR may be 
unnecessary in the permeabilised preparation
The study also found that the presence of 5mM ATP in the MI solution attenuated the 
contribution of store Ca^  ^ release (in response to ET-1) to a level that was 
indistinguishable from that caused by pre-treatment with thapsigargin. Furthermore, the 
potency of the response was increased -seven-fold when Ca^  ^ store depletion was 
achieved solely by 5mM ATP in the MI solution as opposed to also using thapsigargin. 
This suggested that additional pharmacological treatment of the SR might be both 
unnecessary and even counterproductive. As a consequence, the possibility of relying 
solely on the combination of 5mM ATP and lOmM EGTA (in the MI solution) to counter 
agonist induced SR store release, was investigated in study 5.
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4.8.4 Study 4) Selecting the optimum p-escin concentration for 
permeabilisation
4.8.4.1 The variable time method of permeabilisation
The most widely used method of chemical permeabilisation, exposes a vessel to the 
penneabilising agent for a pre-determined, fixed period of time in a pCa 9.9 MI solution 
(lizuka et al,  1994;Akopov et al, 1997;Akopov et al, 1998). However, whilst 
preliminary studies found that this teclmique could produce a functional, permeabilised 
preparation, vessels permeabilised at the same [P-escin] showed marked heterogeneity in 
their ability to respond to the sensitising standard ET-1. Furthermore, the 
penneabilisation indices sometimes showed these vessels to be compromised by a 
population of unpermeabilised SMCs. Hence the tlueshold concentration at which p-escin 
fully penneabilised the preparation was somewhat ill defined. Because of these 
observations, it was decided to adapt the method used by Kitazawa et al, (1989) and 
permeabilise the vessels in a pCa 5.7 MI solution. Ca^  ^ entry, which therefore 
concomitantly occurred as a consequence of the procedure, caused a progressive 
elevation in tone and thus reported on the progression of the permeabilisation. Hence, 
using this teclmique each vessel was believed to be optimally permeabilised. The indices 
of permeabilisation reported the standard error of the e^ax index for vessels permeabilised 
using this technique, was l/ 6 ‘^’ of that associated with the fixed time method.
4.8.4.2 p-escin produces a fuily permeabilised preparation at concentrations 
between 50-200jiiM
The two indices of permeabilisation; the emax index and the ET-1 index, both suggested 
that p-escin consistently produced a fully peimeabilised Wistar rat small pulmonary 
artery at concentrations of between 50 and 200pM. Both indices also suggested that
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whilst some individual vessels could be fully permeabilised by 25|_lM p-escin, this 
concentration could not be relied upon to do so consistently.
Additionally the e^ax index was found to be a reliable means of identifying the presence 
of unpermeabilised SMCs. This index was statistically proven effective for protocols 
where no sensitising agonists were involved and was also considered to be a useful 
indicator for protocols involving sensitising agonists. Hence the emax index was adopted 
as a quality control measure at the end of all future permeabilisation experiments.
4.S.4.3 50pM Is the optimum concentration of p-escIn for the permeabilisation of 
the Wistar rat small pulmonary artery
The ET-1 signal transduction index suggested that their was no significant difference in 
the ET-1 CCRC response of vessels penneabilised with p-escin concentrations between 
25-lOOpM. However as the emax permeabilisation index suggested a concentration of 
25pM could not be relied upon to permeabilise the preparation, it was not considered as a 
viable candidate. Although not significantly different, the mean efficacy and potency of 
the ET-1 response, following permeabilisation with 50pM P-escin was nearly two-fold 
greater than that observed in the lOOpM p-escin group and qualitatively, the responses 
appeared more consistent. Hence based on these findings, 50pM was selected as the 
optimum concentration for p-escin permeabilisation in the Wistar rat small pulmonary 
artery.
4.8.5 Study 5) “Knocking out” the SR
4.8.5.1 The Ml solution adequately buffers agonist Induced Ca^  ^store release
All previous permeabilisation studies to date have relied upon the calcium ionophore, A
23187 to penueabilise and therefore, negate the SR. However the findings of study 3 had 
suggested that the combined presence of 5mM ATP and lOmM EGTA in the MI
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solutions adequately depleted the SR and buffered any residual Ca^ "^  release, without the 
need for pharmacological intervention. This hypothesis was confirmed in study 5 where 
it was shown that a single dose addition of 30pM IP3 did not alter tone in penneabilised 
vessels bathed in the lOmM EGTA based MI solution, regardless of the presence or 
absence of additional pharmacological intervention. The IP3 was active and was shown 
to be capable of mobilising SR Ca^ "^ , as the un-buffered response in the 50pM EGTA 
based MI solution demonstrated. However even this response was substantially smaller 
than expected, further corroborating suspicions that exogenous 5mM ATP was causing 
chronic Ca^  ^store discharge. The advantage of avoiding the “belt and braces” approach 
of negating the SR with a Ca^’*’ ionophore, was that the penneabilised preparation would 
not be exposed to the ionophores’ vehicle, DMSG, which has been found to have 
detrimental effects on the contractile responses of intact small pulmonary arteries 
(unpublished observations). This effect was also witnessed in the current series of 
studies. For example, unpermeabilised vessels bathed in a 5mM ATP MI solution and 
treated with thapsigargin (which is dissolved in DMSO) showed a decrease in the potency 
of their response to ET-1. As a result of these findings the SR received no additional 
pharmacological intervention in future studies.
4.9 The permeabilisation protocol
Based on the combined findings of the protocol development studies, a permeabilisation 
protocol was fomiulated which was found to be appropriate for use in both the control 
and chronically hypoxic Wistar rat small pulmonary artery. The protocol was also found 
to be applicable to the mouse generation intra-lobar (C-class) pulmonary artery, 
however lOpM p-escin was the optimum concentration of the permeabilising agent in 
this vessel (Fig 4.18).
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Figure 4.18 The permeabilisation protocol and the emax index of permeabilisation
Extracts of an experimental trace showing the protocol used to permeabilise and confirm 
permeabilisation, In rat and mouse Intra-pulmonary arteries. 1) Vessel set up and normalisation -  
as described in the general methods. 2) Tension standard response (using a nominally Iso- 
osmotic120mM KCI solution). 3) Introduction of the Ml solution (pCa 9.9) and equilibration of 
response). 4) Permeabilisation (pCa 5.7 Ml solution + p-escin (rat; 50pM, mouse; 10pM). 5) 
Washout and equilibration (pCa 9.9 Ml solution). 6) Specific sensitivity protocol under study (Ca^* 
CCRCs or agonist studies at pCa 6.64). 7) The Omax permeabilisation Index (confirmation of full 
permeabilisation).
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Chapter 5
Results Part II
Calcium Sensitivity Studies in the Control and 
Chronically Hypoxic Wistar rat
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5.1 Introduction
5.1.1 The Chronically hypoxic rat model of pulmonary arterial hypertension
Hypoxia has been defined as a reduction in the oxygen supply to the respiring cells. In
the pulmonary circulation, when alveolar PO2 levels drop below ~70mmHg, a unique 
contractile phenomenon known as hypoxic pulmonary vasoconstriction (HPV) occurs 
(Von Euler & Liljestrand, 1947;Kato & Staub, 1966;Nagasaka et al.  ^ 1984) (See chapter 
1). If the exposure to alveolar hypoxia is chronic, such as during a prolonged high altitude 
sojourn, HPV is accompanied by a vascular remodelling of the small pulmonaiy arteries 
(SPAs) resulting in the development of secondary pulmonary hypertension (SPH) (Hislop 
& Reid, 1976;Smith & Heath, 1977;Herget et al, 1978;Meyrick & Reid, 1978;Meyrick & 
Reid, 1980b;Meyrick & Reid, 1980a;Caldwell & Blatteis, 1983). The mechanisms 
behind the changes are still not fully elucidated but are believed to be mediated by a 
series of influences in addition to sustained HPV, including an imbalance of 
vasoconstrictor/vasodilator factors and altered reactivity of the vasculature to these 
factors (Shimoda et al, 2000). The molecular and cellular adaptations that underlie these 
changes have been found to share similarities with some of the changes that occur in 
pulmonary arterial hypertension (PAH) (see chapter 1), For example, remodelled intra- 
lobar pulmonary arteries isolated from the chronically hypoxic (CH) rat have been 
reported to demonstrate morphological changes such as substantial intimai proliferation, 
medial hypertrophy and adventitial thickening, which remain even after three days of 
recovery in normoxia (Meyrick & Reid, 1980a;Meyrick & Reid, 1980b). Chronic 
hypoxia has also been reported to attenuate endothelium dependant NO relaxation in 
these vessels (Rodman, 1992;Carville et al,, 1993) and increase the constrictor response 
of endogenous agonists such as ET-1 and 5-HT (Eddahibi et al, 1993;MacLean et al, 
1995;Eddahibi et al, 1997;McCulloch et al, 1998). However intimai proliferation
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associated with SPH is polyclonal, whereas in PAH proliferation tends to be monoclonal 
(Lee et al, 1998) and not all studies agree that chronic hypoxia causes intimai 
proliferation (Smith & Heath, 1977). Additionally, there are conflicting reports regarding 
the aforementioned functional changes, some of which, appear to be inconsistent with 
those occurring in PAH. (Bomiet et a l,  2001a;Sauzeau et al, 2003a).
Although the chronically hypoxic rodent is not a perfect model of PAH, it has been 
widely used to elucidate the mechanisms involved in the aetiology of this disease 
(Rabinovitch et al, 1988;Suggett & Barer, 1988;MeCulloch et a l,  1998;MacLean & 
Morecroft, 2001) and its use has undoubtedly contributed to the development of new 
effective therapies for PAH such as the ET-1 antagonist bosentan (Tracleer).
5.1.2 Chronic hypoxia and elevated basal tone
One of the hallmarks of hypoxic PH is the increase in vascular tone. The increase in tone 
is initiated by HPV immediately upon exposure to hypoxia, the sub-acute phase of which 
is thought to be mediated by the Rho kinase (ROK) pathway (Wang et al, 2001;Wang et 
al,  2003). However following exposure to chronic hypoxia, elevated basal tone remains 
long after the hypoxic challenge is withdrawn and there is substantial evidence to suggest 
that it causes the modulation of; receptor expression, ion channel activity and signal 
transduction pathways (Rodman, 1992;Eddahibi et al, 1993;MacLean et al, 
1996b;Shimoda et al,  1999;Chassagne et al,  2000;Bonnet et al, 2001a;Keegan et al, 
2001;Sauzeau et al, 2003b). The effects of these changes may contribute to an increased 
resting [Ca^ J^cyt, which has been reported to be elevated in PASMCs from both 
chronically hypoxic rats and human PAH patients (Shimoda et al, 1999;Yuan et al, 
1998a). However, it has also been suggested that increases in calcium sensitivity (CaS) 
may accompany the elevated [Ca^ j^cyt in PH occurring secondary to chronic hypoxia and
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that responses to agonists may be augmented by this increase in CaS (Shimoda et ah, 
2000;Nagaoka et al, 2004b).
5.1.3 Chronic hypoxia, calcium sensitisation and Rho kinase
In PASMCs obtained from rat intra-lobar pulmonary arteries, CaS was reported to be
augmented following exposure to chronic hypoxia, based on the observation that 
pharmacological blockade of voltage gated channels significantly reduced maximum 
tension induced by ET-1 in control but not hypoxic animals (Shimoda et al, 2000). More 
recently, studies have implicated the ROK pathway with increased CaS in response to 
agonist stimulation. The small GTPase Rho A and its effector ROK have been 
demonstrated to cause increased CaS in a variety of smooth muscle preparations 
including PASMCs (Janssen et al, 200la;Janssen et al, 2001b). Endogenous agonists 
such as ET-1 and PE which exert their influence through G-protein linked receptors have 
been shown to activate this pathway, resulting in increased CaS in systemic arteries 
(Miao et al,  2002;Wingard et al,  2003). Activated ROK phosphorylates the myosin- 
binding sub-unit of MLCP and/or CPI-17 resulting in the inactivation of MLCP (Kimura 
et al, 1996;Feng et al,  1999;Eto et al, 2001). Thus ROK modulates CaS by inhibition of 
MLCP (see chapter 1).
Recent reports from in vivo studies have also suggested a role for the ROK pathway in 
the development of PH secondary to chronic hypoxia. In mice, subcutaneous treatment 
with the ROK inhibitor Y27632 (30mg/kg/day) during exposure to chronic hypoxia 
attenuated RVP, right ventricular hypertrophy and remodelling of the distal pulmonary 
vasculature (Fagan et al, 2004). In other studies, pulmonaiy arterial pressure (PAP) and 
pulmonary vascular resistance (PVR) were virtually normalised in the clironically 
hypoxic rat, by subsequent acute intravenous or oral treatment with Y27632 (Nagaoka et 
al,  2004a;Nagaoka et al, 2004b). Fasudil, another selective inhibitor of ROK has also
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been reported to substantially improve survival in the monocrotaline induced model of 
PH in the rat (Abe et al, 2004). These findings suggest a central role for the ROK 
mediated change CaS in the development of PH.
In contrast however, CaS has been reported to be attenuated in PASMCs isolated from rat 
main (extra-lobar) pulmonary arteries and in arterial ring preparations following exposure 
of the animal to chronic hypoxia (Bonnet et al, 2001a). These findings were based on the 
attenuation of the contractile response to ET-1 and angiotensin II following chronic 
hypoxia, despite no change in the amount of Ca^  ^ mobilised by these agonists as 
determined by indo 1 fluorescence. Consistent with these findings, attenuated contractile 
responses to ET-1, NA and the tliromboxane A2 analogue U46619 have been reported in 
the main pulmonary artery of the chronically hypoxic rat (Bialecki et al, 1998a;Bialecki 
et al, 1998b;Sauzeau et al, 2003a). The attenuation was found to be associated with an 
inhibition of ROK mediated CaS, which was demonstrated by performing Ca^  ^CCRCs in 
the presence and absence of the ROK inhibitor Y27632 and GTPyS in permeabilised 
strips of main pulmonary artery from control and chronically hypoxic rats. These 
findings were supported by RT PCR and Western blot analysis which showed Rho A 
mRNA and RhoA expression to be reduced by 80% in the main pulmonary artery of rats 
following 2 weeks chronic hypoxia (Sauzeau et al, 2003a). The chronic hypoxia induced 
down regulation of Rho A was however prevented by sildenafil, indicating a role for the 
NO/cyclic GMP pathway in the alteration of RhoA/ROK signalling in the main 
pulmonary artery of the chronically hypoxic rat (Sauzeau et al,  2003a;Sauzeau et al, 
2003b). Interestingly, lungs taken from an in vivo mouse study which demonstrated 
increased ROK activity following exposure to chronic hypoxia, found that treatment with 
Y27632 caused an increase in expression of endothelial NOS (NOS III) protein. A 
number of studies in systemic vascular preparations have reported that the NO/cGMP 
mediated pathway and the ROK pathway which both terminate in modulation of MLCP
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activity, are antagonistic to each other (Bolz et al, 2003;Budzyn et al,  2004). However 
the in vivo mouse study also found that conversely, Y27632 reduced NOS III protein in 
control lungs (Fagan et a l,  2004) suggesting that the relationship between the ROK and 
NO pathways may be more complex than first thought.
5.1.4 Aims
The background account suggests that changes in CaS occur in PH secondary to chronic 
hypoxia. However, the nature of these changes remains controversial. The aim of this 
chapter was therefore to determine the role of CaS and the influence of the ROK pathway 
in the regulation of tone in the isolated small pulmonary artery (SPA) of the control and 
chi'onically hypoxic Wistar rat.
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5.2 Methods
5.2.1 Set up
Isolated small pulmonary arteries (D-class) from clu'onically hypoxic and control Wistar 
rats, were set up on the myograph and normalised as described in chapter 2. The right 
ventricular/total ventricular ratio (RV/TV) was used to assess the development of PH (see 
chapter 2). Subsequent to determination of the vessels maximum response to a nominally 
iso-osmotic 120mM KCI solution, the following experiments were performed. During the 
performance of the cumulative concentration response curves (CCRCs) each response 
was allowed to fully stabilise before the next solution exchange. During solution 
exchange, vessels were washed twice with the following solution to minimise the 
possibility of dilution by the previous solution.
5.2.2 Study 1) The effect of chronic hypoxia on basal Ca^^  sensitivity in the 
Wistar rat small pulmonary artery
To determine if CaS was modulated following exposure to clironic hypoxia, Ca^  ^CCRCs 
were performed in permeabilised and unpermeabilised vessels. Unpermeabilised vessels 
were studied in order to gain insight into how much the change in CaS influenced the 
response to extra-cellular Ca^  ^ in these vessels. Small pulmonary arteries from animals 
exposed to chronic hypoxia will be referred to as chronically hypoxic vessels.
5.2.2.1 CCRCs in unpermeabilised smaii puimonary arteries
Age matched control (AM) and chronically hypoxic (CH) vessels were challenged with
the following mock intra-cellular (MI) solutions; pCa; 6.64, 5.70, 5.40, 5.10, 4.55, 4.00, 
3.50, 3.00, 2.50, 2.00, 1.50 in a sequential manner.
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5.2.2.2 CCRCs in 50|llM p-escin permeabilised small pulmonary arteries
Age matched and chronically hypoxic vessels were permeabilised using the method
described in the protocol development. Following permeabilisation the vessels were 
washed in pCa 9.9 MI solution and allowed to return to baseline. Vessels were then 
exposed to the following mock intra-cellular (MI) solutions; pCa; 6.64, 6.17, 5.70, 4.55, 
4.00, 2.50 in a sequential manner.
5.2.3 Study 2) The role of Rho kinase in Ca^  ^sensitivity modulation in the 
chronically hypoxic Wistar rat small pulmonary artery
5.2.3.1 Ca^  ^CCRCs in the presence and absence of the ROK inhibitor Y27632 in 
permeabilised, age matched and chronicaily hypoxic smaii puimonary arteries
Age matched and chronically hypoxic vessels were permeabilised and then allowed to 
equilibrate as in study 1. During this recovery period some of the vessels from both 
groups were incubated with lOpM Y27632 (45 mins). A Ca^ "^  CCRC was then 
performed as in study 5.2.2.2.
5.2.4 Study 3) Confirming the suspected constitutive activity of Rho 
kinase in age matched, Wistar control rat small pulmonary arteries
5.2.4.1 Single dose addition of the ROK inhibitor Y27632 to a sub-maximal raised 
tone in permeabilised, age matched small pulmonary arteries in the presence of 
5mM ATP
Age matched vessels were permeabilised as previously described, then allowed to return 
to baseline in a pCa 9.9 MI solution. Vessels were then exposed to a pCa 6.64 MI 
solution to create a sub-maximal raised pre-tone (-25% of Fimax)- One of each of the 
paired vessels was then treated with a single dose of lOpM Y27632 whilst the remaining 
vessel received a single dose of DMSO equivalent to the concentration present in the
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Y27632 dose. The vessels were then observed until either any response had fully 
stabilised or for 45 mins, whichever was the shorter.
5.2.4.2 Single dose addition of the ROK inhibitor Y27632 (lOpM) to a sub-maximai 
raised tone in unpermeabilised, age matched small puimonary arteries in the 
absence of 5mWi ATP
The response of age matched control vessels to a nominally iso-osmotic 120mM KCI 
solution was determined. Following washout and equilibration the vessels were 
incubated for lOmins with 2pM thapsigargin and then exposed to a 5mM ATP based pCa 
9.9 MI solution to drain the SR. The vessels were then placed in a 0ATP based pCa 9.9 
MI solution, allowed to stabilise and then exposed to a 0ATP pCa 4.55 -  4.00 MI 
solution in order to create a stable raised tone that was -2 5 %  of the maximum tension 
standard response. Following the attainment of a stable raised pre-tone, one of each pair 
of vessels was treated with a single dose of lOpM Y27632 whilst the other vessel of the 
pair received a single dose of DMSO equivalent to the concentration present in the 
Y27632 dose. The vessels were then observed until either any response had fiilly 
stabilised or for 45 minutes, whichever was the shorter.
5.2.5 Quality control assessment
Following the chosen experimental procedures, all permeabilised vessels were challenged 
with the emax index of permeabilisation, to determine the presence of any significant 
population of unpermeabilised SMCs (see chapter 4) Vessels with an Femax response 
which was more than 3% greater than their Fimax response were discarded from the study. 
In vessels partaking in the Ca^  ^CCRCs this was detennined from the CCRC responses.
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5.3 Results
5.3.1 Study 1) The effect of chronic hypoxia on sensitivity in the 
Wistar rat small pulmonary artery
24-
5.3.1.1 CCRCs in unpermeabilised vessels
Neither the efficacy nor the potency of the relationship between extra-cellular Ca
concentration and force production was significantly altered by exposure to 2weeks 
chronic hypoxia (n=7, P>0.05, Mann Whitney test). However, chronically hypoxic 
vessels appeared less sensitive to extra-cellular Ca^ "^  at low concentrations and more 
sensitive at mid to high concentrations causing an increase in the slope of the relationship 
between the [Ca^ "*"] of the MI solution and force (Slope: AM; 0.7 ±0.1 vs CH 1.0 ± 0.1, 
n=7, P<0.05, Mami Whitney test) (Fig 5.1)
100-1
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Figure 5.1 CCRCs in unpermeabilised age matched control and chronically hypoxic 
Wistar rat, small pulmonary arteries
Graph showing CCRCs in unpermeabilised ago matched (AM) (White circles - O) and 
chronically hypoxic (CH) (Black circles - • )  small pulmonary arteries (potency and efficacy 
P>0.05, Hill slope P<0.05, n=7, Mann Whitney test).
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5.3.1.2 CCRCs in 50pM p-escin permeabilised vessels.
As shown in Fig 5.2, cln-onic hypoxia was associated with a small but significant 
decrease CaS (pECgo: AM; 6.33 ± 0.02, n-11 vs CH; 6.24 ± 0.02, n=10, P<0.05, Mann 
Whitney test) which was most pronounced in the lower quartile of the response cuiwe 
(Response at pCa 6.64: AM; 22 ± 1%, of Fimax, n= ll vs CH; 14 ± 2%, n=10, P<0.005, 
Mann Wliitney test). Consistent with these findings, chronically hypoxic vessels also 
demonstrated a small but significant increase in the slope of the relationship between 
cytosolic [Ca^ "^ ] and force (Slope: AM; 1.57 ± 0.08, n= ll vs CH; 1.79 ± 0.1, n=10, 
P<0.05, Mann Whitney test).
The vessels from the age matched and chi'onically hypoxic rats used in both experiments, 
were of comparable internal diameter and replicated transmural pressure (P>0.05, 
unpaired t-tests). Furthermore, there was no difference in the magnitude of the maximal 
responses of the age matched and chronically hypoxic vessel (Unpermeabilised vessels: 
AM; 2.81 ± 0.33mN vs CH; 4.53 ± 1.24mN, n=7) (Penneabilised vessels: AM; 1.85 ± 
0.2mN, n-11 vs CH; 2.20 ± 0.3mN, n=10) (P>0.05, unpaired t-tests). The emax index of 
permeabilisation confirmed the vessels used in the permeabilisation study were fully 
permeabilised (Femax was <0.5 ± 0.5% greater than Fimax in both age matched and 
chronically hypoxic vessels, n=6, P>0.05, Mami Whitney test). The RV/TV was 
significantly larger in the chronically hypoxic vessel group relative to the age matched 
control vessel group and was consistent with the development of PH (P<0.0001, unpaired 
t-test).
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Figure 5.2 The effect of chronic hypoxia on constitutive Ca  ^ sensitivity in the Wistar rat, 
small pulmonary artery
A) Experimental trace of a Ca^  ^ CCRC in a permeabilised age matched (AM) control vessel B) 
Experimental trace of a Ca^  ^ CCRC in a permeabilised vessel following exposure to 2weeks 
chronic hypoxia (CH) C) Graph showing Ca^  ^CCRCs in permeabilised AM (White circles - O) and 
CH (Black circles - •  ) ( ** response at pCa 6.64, n~10-11, P<0.005, Mann Whitney test).
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5.3.2 Study 2) The role of Rho kinase In sensitivity modulation In the 
chronically hypoxic Wistar rat small pulmonary artery.
5.3.2.1 CCRCs In the presence and absence of the ROK Inhibitor Y27632 In 
permeabilised, age matched and chronically hypoxic small pulmonary arteries
Incubation with lOjuM Y27632 caused an attenuation of CaS in age matched control 
vessels. However, this was only significant over the lower quartile of the response 
(pECso: AM; 6.36 ± 0.03 vs AM+Y; 6.30 ± 0.03, P>0.05) (Slope: AM; 1.75 ± 015 vs 
AM+Y; 2.07 ± 0.22, P>0.05) (Response at pCa 6.64: AM; 22 ± 2%, of F w  vs AM + 
Y27632; 11 ± 1%, P<0.01) (All n=5, Mami Whitney tests). The chronically hypoxic 
vessel response was not significantly altered by the Y27632 compound (pEC^o: CH; 6.30 
± 0.03 vs CH4-Y; 6.28 ± 0.02, P>0.05) (Slope: CH; 2.15 ± 0.21 vs CH+Y; 2.11 ± 0.18, 
P>0.05) (Response at pCa 6.64: CH; 12 ± 3% of F w  vs CH + Y27632; 10 ± 2%, 
P>0.05) (All n=5, Mann Whitney tests). Comparison of the tliree attenuated pCa 6.64 
responses (CH, CH + Y27632 and AM + Y27632) found no difference between them 
(n=5, P>0.05, Kruskal Wallis test) (Fig 5.3).
The vessels from the four groups were of comparable internal diameter and replicated 
transmural pressure (P>0.05, unpaired ANOVA). Furthermore, there was no difference 
in the magnitude of the maximal responses of any of the groups (AM; 2,00 ± 0.34mN, vs 
AM+Y; 1.84 ± 0.3 ImN, CH; 1.65 ± 0.42mN, CH + Y; 1.82 ± 0.21, n=5, P>0.05, 
unpaired ANOVA). The emax index of permeabilisation confirmed that all vessels used 
in the study were fully permeabilised (Femax was <1 + 1% greater than Fimax in all groups, 
n=5, P>0.05, Kruskal Wallis test). The RV/TV was significantly larger in the 
chronically hypoxic vessels consistent with the development of PH (H<0.0001, unpaired 
t-test).
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Figure 5.3 The effect of Rho kinase inhibition on constitutive Ca^* sensitivity in small 
pulmonary arteries from control and chronically hypoxic Wistar rats
A) CCRCs in age matched (AM) and chronically hypoxic (CH) vessels in the presence and 
absence of the Rho kinase inhibitor Y27632. B) Bar graph showing the response of AM and CH 
vessels in the presence and absence of Y27632 at pCa 6.64. (All groups n=5, *P<0.01, Mann 
Whitney test).
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5.3.3 Study 3) Confirming the suspected constitutive activity of Rho 
kinase in age matched, Wistar control rat small pulmonary arteries
The results of the previous study suggested that ROK was constitutively active in age
matched control vessels as had previously been noted during the protocol development 
studies. However, it had previously only been possible to make an indirect comparison of 
the effects of exogenous 5mM ATP on this pathway. A stable raised tone in the presence 
of 5mM ATP was now achievable following permeabilisation. Hence, it was now 
possible to compare the effects of exogenous 5mM ATP on ROK.
5.3.3.1 The effect of a single dose addition of the ROK inhibitor Y27632 on a sub- 
maximal raised tone in SOplVI p-escin permeabilised, age matched small pulmonary 
arteries in the presence of 5mM ATP
A single dose of lOpM Y27632 caused a significant decrease in the pCa 6.64 pre-tone 
(P/T; 0.49 ± 0.12mN vs AM + Y; 0.23 ± 0.06, n=6, P<0.05, paired t-test) which was 
absent in the time control (T/C) vessels (P/T; 0.31 ± 0.10 vs AM T/C; 0.30 ± 0.09, n=6, 
P>0.05, paired t-test). When expressed as a percentage of the pre-tone, there was a 
highly significant difference of 51 ± 7% between vessels exposed to the single dose of 
lOpM Y27632 and the time control vessels (AM +Y; -53 ± 6% vs AM T/C; -2 ± 5%, 
n=6, P<0.005, Mami Whitney test) (Fig 5.4). This equated to a decrease that was 11 ± 
1% of F i m a x .
The vessels from the two groups were of comparable internal diameter and replicated 
transmural pressure (P>0.05, unpaired t-test). The mean pre-tone was not significantly 
different between the groups whether expressed in mN (P/T: AM T/C 0.31 ± 0.1 OmN vs 
AM +Y; 0.49 ± 0.12mN, n=6, P>0.05, unpaired t-test) or as a percentage of Fimax (AM 
T/C; 21 ± 2% of Fimax vs AM + Y; 24 ± 2%, n=6, P>0.05, Mann Whitney test). The emax 
index of permeabilisation suggested all vessels used in the study were fully permeabilised
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(FCmax was 1 ± 1% greater than Fimax in both groups, n=6, P>0.05, Wilcoxon matched 
pairs test).
5.3 3.2 The effect of a single dose addition of the ROK inhibitor Y27632 on sub- 
maximal raised tone unpermeabilised, age matched small pulmonary arteries in 
the absence of 5mM ATP
A single dose addition of lOpM Y27632 caused a significant decrease in pCa 4.55-4.00 
pre-tone (P/T; 2.57 ± 0.95mN vs AM + Y; 1.72 ± 0.91, n=5, P<0.05, paired t-test) which 
was absent in the time control (T/C) vessels (P/T; 2.62 ± 2.21 vs AM T/C; 2.62 ± 2.21, 
n=3, f  >0.05, paired t-test). When expressed as a percentage of the pre-tone, there was a 
significant mean difference of 47 ± 16% between vessels exposed to the lOpM Y27632 
bolus and the time control vessels (AM +Y; -47 ± 12%, n=5 vs AM T/C; -0.2 ± 0.2%, 
n=3, P<0.05, Mann Whitney test) (Fig 5.4). This equated to a decrease that was 14 + 4 % 
of the 120mM KCI tension standard.
The vessels from the two groups were of comparable internal diameter and replicated 
transmural pressure (P>0.05, unpaired t-test). The mean pre-tone (expressed as a 
percentage of the maximum response to iso-osmotic 120mM KCI) was not significantly 
different between the groups (AM T/C 35 ± 9%, n=3 vs AM +Y; 30 ± 7%, n=5, P>0.05, 
Mann Whitney test).
5.3.3.S Comparison of the effect of a single addition of lOpM Y27632 to 
permeabilised and unpermeabilised small pulmonary arteries with a sub- 
maximally raised pre-tone
The reduction in tone caused by the single dose addition of lOjuM Y27632 to either 
permeabilised vessels (P/V) in the presence of 5mM ATP or unpermeabilised vessels 
(U/V) in the absence of ATP was of a comparable magnitude when expressed either as a 
percentage of the reduction in pre-tone (P/V; -51 + 7% of P/T, n=6 vs U/V; -47 ± 16%,
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n=5) (Fig 5.4) or as a percentage of the vessels own maximum response (P/V; 11 ± 1% of 
Fimax, n=6 vs U/V; 14 ± 4% of the 120mM KCI tension standard, n=5).
The vessels from the two groups were of comparable internal diameter and replicated 
transmural pressure (P>0.05, unpaired t-test). The mean pre-tones (expressed as a 
percentage of Fimax in P/V or the 120mM iso-osmotic KCI tension standard in U/V) were 
also of comparable magnitudes (P/T: P/V; 24 ± 2%, n=6 vs U/V; 30 ± 7%, n=5).
The mean internal diameter and replicated transmural pressure of the vessels used in this 
study was 285 ± 9pm and 13.4 ± 0.3mmHg respectively (n=75vessels/42 rats). The mean 
RV/TV ratio was follows: Age matched controls; 0.232 ± 0.004, n=27. Chronically 
hypoxic rats; 0.348 ± 0.009, n=15.
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Figure 5.4 The constitutive activity of Rho kinase is not altered by exogenous 5mlVI ATP
A) Experimental traces showing the effect of a single dose addition of the Rho kinase inhibitor 
Y27632 in permeabiiised age matched vessels in the presence of 5mM ATP and unpermeabilised 
age matched vessels in the absence of exogenous ATP. Time control (T/C) responses treated 
with the vehicie DMSO are on the left for comparison. B) Bar chart showing the relative reduction 
in pre-tone caused by Y27632 or the vehicle DMSO; in permeabilised vesseis in the presence of 
5mM ATP (n=6) and unpermeabilised vessels in the absence of exogenous ATP (n=5).
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5.4 Discussion
5.4.1 Unpermeabilised chronicaily hypoxic Wistar rat small pulmonary 
arteries do not show an obvious change in their sensitivity to extra-cellular 
Ca^+
The CCRCs performed in unpermeabilised vessels did not suggest a substantial 
difference in the response to extra-cellular [Ca^ "^ ], although the greater slope of the 
relationship between the [Ca^ "^ ] of the MI solution and force suggested that chronically 
hypoxic vessels may have been slightly less sensitive to extra-cellular Ca^  ^ at 
concentrations up lOpM. Although this could have been due to a reduction in 
sarcolemmal Ca^ "^  conductance, this has not been reported in these vessels, in fact Ca^’*' 
conductance has been reported to be enhanced in PAECs following exposure to chronic 
hypoxia (Fantozzi et al, 2003).
5.4.2 sensitivity is attenuated in the p-escin permeabilised chronically 
hypoxic Wistar rat small pulmonary artery in the absence of a functional 
endothelium
In permeabilised small pulmonary arteries, clironic hypoxia was associated with a small 
but significant decrease in CaS which was most pronounced in the lower quartile of the 
response. At a [Ca^ '^ jcyt of 230iiM, which lies within the normal range for G-protein 
agonist induced tonic contraction, exposure to 2weeks chronic hypoxia reduced basal 
CaS by just over 40% relative to control vessels. [Ca^ '^ jcyt during the tonic phase of ET-1 
induced contraction in smooth muscle cells has been reported at ~ 200nM (Scliroeder et 
al, 2000). Incubation with the ROK inhibitor Y27632 reduced the CaS of control vessels 
to levels similar to that observed in the clironically hypoxic vessels, but did not further 
attenuate CaS in the hypoxic vessels. These findings suggest that in p-escin 
penneabilised vessels, ROK is constitutively active in control vessels but that its activity
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may be reduced in rats exposed to 2weeks chronic hypoxia. The data are consistent with 
the reported loss of the CaS response to GTPyS in the rat, penneabilised main (extra- 
lobar) pulmonary artery following 2weeks chronic hypoxia (Sauzeau et al, 2003a), The 
same group also found that Rho A expression was attenuated by 80% in these vessels and 
that Rho A expression in whole lung preparations (indicative of intra-lobar pulmonary 
arteries) was decreased by 30%. Non linear regression found the effects of chronic 
hypoxia and ROK inhibition were most pronounced between ~30-300nM suggesting 
physiological relevance.
5.4.3 Rho kinase is constitutiveiy active in the control Wistar rat smaii 
puimonary artery
The constitutive activity of ROK was further coiToborated in both permeabilised and 
unpermeabilised vessels by the addition of a single dose of Y27632 to vessels with a sub- 
maximally raised tone. In both conditions, inliibition of ROK caused a 50% reduction in 
the pre-constricted tone, which was entirely consistent with the 50% attenuation caused 
by ROK inhibition during the permeabilised control vessel Ca^  ^ CCRC at a [Ca^ '^ Jcyt of 
230nM. Constitutive activity of the ROK pathway has also been reported in resistance 
arteries from hamster gracilis muscle (Bolz et al, 2003) and in rat small mesenteric 
arteries, where it is thought to be involved in maintaining basal tone (VanBavel et al, 
2001), However, the concentration of Y27632 used (lOpM), has been reported to cause 
partial inhibition of PKCg (Eto et al, 2001) and therefore the possibility of atypical PKC 
involvement in constitutive CaS cannot be ruled out.
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5.4.4 Exogenous 5mM ATP does not modulate Rho kinase activity in the 
Wistar rat small pulmonary artery
As the response in the permeabilised vessels was performed in the presence of exogenous 
5mM ATP and the response in the unpermeabilised vessels in the absence of exogenous 
ATP, the comparable results also suggested that ROK mediated CaS was not noticeably 
modified by the presence 5mM ATP in the MI solution. This was a question, which had 
been posed during the protocol development but could not be satisfactorily answered with 
the initial experiments described in chapter 4.
5.4.5 Chronic hypoxia changes the activity of the Rho kinase and nitric 
oxide/cGMP pathways
Whilst the findings are generally consistent with those previously described in the only 
other permeabilisation study, they are in direct opposition to the in vivo evidence. One 
common thread that links the previous in vivo and in vitro permeabilisation studies is the 
relationship that has been reported between ROK, NOS HI and CaS. Inhibition of ROK 
has been shown to augment NOS III in endothelial cells (Bivalacqua et al, 2004). Thus 
it is possible that the in vivo effects of Y27632 were not simply due to its effects on the 
ROK sensitisation pathway in smooth muscle cells, but also by preventing ROK located 
within endothelial cells from inhibiting NOS III. This would be consistent with a report 
that NOS III protein was substantially increased in hypoxic mouse lungs which had been 
treated with Y27632 (Fagan et al, 2004) and that down regulation of NOS III in human 
PAECS exposed to hypoxia was prevented by ROK inhibition (Takemoto et al, 2002). 
Interestingly Sauzeau et al, (2003a) reported that oral treatment with sildenafil a PDE 5 
inhibitor, which prevents cGMP (NO 2"^  messenger) breakdown, substantially attenuated 
right ventricular hypertrophy and prevented vascular remodelling in rats exposed to 
2weeks chronic hypoxia, but that subsequent administration of Y27632 had no effect. 
Studies have now shown that NO causes relaxation by reducing CaS as well as by
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reducing [Ca^ '^ ]cyt and that in systemic resistance arteries the decrease in CaS may be the 
dominant mechanism (Bolz et al, 2003;Soloviev et al, 2004). This pathway exerts its 
influence on MLCP and there is evidence that in smooth muscle the NO/cGMP and ROK 
pathways antagonise one another by their opposing actions on MLCP (Budzyn et al, 
2004;Bolz et al, 2003). It seems reasonable given the finding that acute hypoxia inhibits 
MLCP tlirough ROK (Wang et al, 2003) to hypothesise that in chronic hypoxia, CaS 
would increase in smooth muscle cells as decreased activity of the NO/cGMP pathway 
would leave the constitutive activity and/or hypoxic stimulation of ROK unopposed. 
However decreased NO/PKG signalling has been shown to result in a strong decrease in 
RhoA mRNA in both rat and human systemic arteries (Sauzeau et al, 2003b). Hence, 
whilst hypoxia may increase the activity of ROK in smooth muscle cells by decreasing 
NO/cGMP antagonism, it may paradoxically decrease Rho A expression.
The finding by Sauzeau et ah, (2003a) that Rho A expression was also substantially 
down-regulated in rat pulmonary arteries following 2weeks clironic hypoxia, may explain 
the discrepancies between the in vivo dosing studies and the in vitro permeabilisation 
study. For example, Y27632 could prevent the increased activation of ROK and hence 
prevent an increase in CaS during the onset of hypoxia, but would paradoxically also 
have no effect in untreated fully adapted chronically hypoxic animals if subsequent 
negative feedback had down regulated Rho A expression to a point which prevented 
significant ROK activation. Unfortunately the immediate normalisation of PVR 
following intravenous administration of Y27632 in clironically hypoxic rats after their 
return to normoxia reported by Nagaoka et al,  (2004b), suggested the ROK pathway was 
still strongly involved in the elevated vasomotor tone even after 3-4weeks. In fact the 
magnitude of the response reported by Nagaoka et al, (2004b) suggest that ROK 
mediated Ca^’*' sensitisation is entirely responsible for the elevated PVR and hence PAP 
of chronic hypoxia induced PH in the rat. However one variable that may require further
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consideration and could provide a possible explanation for the discrepancies is the length 
of exposure to chronic hypoxia. Interestingly, all of the studies which have shown a 
decrease in CaS in rats, have used a 2 week exposure to clironic hypoxia (Sauzeau et al, 
2003b;Sauzeau et al, 2003a;Bonnet et al, 2001a) where as those studies suggesting an 
increase in CaS have used a 3-4 week exposure period (McMurtry et al,  2003;Nagaoka 
et al,  2004a;Nagaoka et al,  2004b). The exposure period to hypoxia has previously been 
reported to modulate the sensitivity of response to ET-1, with a decrease in potency 
occurring after 2weeks exposure to clnronic hypoxia, but returning towards nonnal 
following 3-4 weeks exposure (Bialecki et al,  1998a;Bialecki et al,  1998b).
5.4.6 How does the loss of endothelial function affect the interpretation of 
the present study?
It was also considered that the loss of the endothelium may explain the discrepancy 
between the similar results of the present and the previous in vitro permeabilisation study 
and the diametrically opposite responses of the in vivo study by Nagaoka et al., (2004). 
The permeabilisation studies almost certainly result in the destruction of the endothelium 
(Laher et al, 1995) and therefore only report on the constitutive activity of the sensitising 
pathways. However, the ability of GTPyS to increase CaS in the permeabilised control 
vessels but not in those exposed to 2weeks chronic hypoxia (Sauzeau et al, 2003a) is 
contrary to the loss of the endothelium or some endothelium derived activating factor 
being responsible for the discrepancy. In conjunction with the RT PCR reports, this 
supports the down regulation of Rho A rather than a functional uncoupling of the 
mechanism due to the permeabilisation procedure or exposure to clironic hypoxia.
Interestingly, it was observed during the protocol development, that the IpM ET-1 
response was not changed in contol and chronically hypoxic vessels following 
pemieabilisation, and both were compatible. In fact, ET-1 was still capable of increasing
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CaS to some extent following incubation with Y27632, suggesting ET-1 does not exert its 
effects on CaS solely through the ROK pathway. These findings are consistent with 
reports that ET-1 is staurosporine sensitive (Bialecki et al, 1998a;Bialecki et al, 1998b) 
and therefore its effect on CaS may well be, at least partly mediated through PKC. It was 
also reported, that although the maximum response to ET-1 in unpermeabilised vessels 
was attenuated following 2weeks chronic hypoxia, the staurosporine sensitive component 
of the response was substantially augmented (Bialecki et al, 1998a). Hence in the Wistar 
rat small pulmonary artery, whilst chronic hypoxia may attenuate the constitutive activity 
of ROK it does not necessarily prevent agonists from increasing CaS.
5.5 Conclusion
The findings of the present study suggest that in the Wistar rat small pulmonary artery, a 
basal sensitisation of the contractile apparatus exists in the absence of any external 
influence and that it is mediated by constitutive activity of ROK. 2weeks chronic 
hypoxia was found to attenuate the basal CaS, but did not prevent subsequent agonist 
induced Ca^ "^  sensitisation, which may have been mediated by an alternative pathway 
(e.g. PKC). Further studies in control and chronically hypoxic small pulmonary arteries 
in the presence of GTPyS, and the analysis of RhoA expression, would determine if the 
potential for agonist induced sensitisation was attenuated in this pathway and confirm 
whether the attenuated CaS was associated with down regulation of Rlio A expression. 
Additionally, performing; 1) agonist CCRCs at 230nM Ca^ "^ , and 2) Ca^  ^ CCRCs in the 
presence of an optimal concentration of the agonist, in permeabilised control and 
chronically hypoxic vessels would determine if chionic hypoxia modulates the contractile 
response to these agonists through changes in the CaS component of the response.
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Chapter 6
Results Part II
iii. The role of Calcium Sensitivity in the 5-HT 
hypothesis of Puimonary Arterial Hypertension
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6.1 Introduction
6.1.1 Chronic hypoxia causes increased 5-HT mediated contraction in the 
Wistar rat small pulmonary artery
Serotonin (5-HT) has been widely reported as a pulmonary vasoconstrictor and co­
mitogen and a number of studies have implicated it with the remodelling and 
vasoconstriction associated with pulmonary hypertension (PH) secondary to chronic 
hypoxia (CH) (MacLean et al, 1996b;Eddahibi et al, 1997;Keegan et al, 2001;Murdoch 
et al, 2003). A review of the postulated role of 5-HT in the development of pulmonary 
arterial hypertension (PAH) was presented in the general introduction (chapter 1).
5-HT induced vasoconstriction in the control Wistar rat, small pulmonary artery (SPA) is 
of low efficacy and potency and is mediated through the 5-HT2a receptor, although the 5- 
HTib receptor is present. However, in the clironically hypoxic rat, there is a marked 
increase in the contractile response to 5-HT and this is at least partly due to an increase in 
5-HTiB receptor mediated vasoconstriction (MacLean et a l,  1996b). It has been 
demonstrated however that in control rats, responses to 5 carboxaniidotryptamine (5-CT), 
a non selective 5-HTi receptor agonist, can be potentiated by elevated basal tone induced 
by ET-1 activation of the Gq-coupled receptor and further potentiated by NOS III 
inhibition using L-NAME. The responses of control vessels were so augmented by these 
conditions that they where not significantly different from responses in chronically 
hypoxic vessels. However these conditions did not further augment the increased 
constriction induced by clironic hypoxia (MacLean & Morecroft, 2001). The 
phenomenon was reported to be due synergistic interactions between the Gq-coupled 
receptors (i.e. stimulated by ET-1) and Gi-coupled receptors (i.e. stimulated by 5-HT/5- 
CT), however the synergy was not thought to be simply the result of an elevation of intra­
cellular Ca^ .^ ET-1 is known to increase CaS in these vessels (Evans et al, 1999) and
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inhibition of the NO/cGMP pathway has been shown to augment the ability of Rho 
kinase to increase CaS (Sauzeau et al,  2003a). Hence, it raises the question of whether 
the reported synergy in the control rat and the augmented response in the chronically 
hypoxic rat, are linked to an ability of 5-HT to increase CaS. 5-HT has been shown to 
increase CaS in ovine, porcine, bovine, rat and human systemic arteries through 
activation of Rho kinase (ROK) (Akopov et al, 1998;Shimokawa et al, 1999;Weber & 
Webb, 2001;Kandabashi et al,  2002;Nishikawa et al, 2003) and this response has also 
been shown to be increased in some pathological states such as systemic hypertension 
(Weber & Webb, 2001). Although 5-HT has not yet been demonstrated to increase CaS 
in any pulmonary vessels its mitogenic action has been shown to be blocked by 5 -H T ib /id  
antagonists and the ROK inhibitor Y27632 clearly suggesting this pathway can be 
activated by its presence (Liu et al, 2004).
6.1.2 The 5-HT transporter (5-HTT) and its role in PH
The 5-HT transporter (5-HTT) has also been linked to the aetiology of PAH, although its 
role is still controversial (see chapterl). In summary, both an increase (Eddahibi et al, 
1999) and decrease (Jeffery et al, 2000;Hoshikawa et al,  2003;MacLean et al, 2004) in 
5-HTT expression have been reported following chronic hypoxia. In transgenic mice that 
over-express the 5-HTT, RVP was elevated three-fold but that there was no evidence of 
right ventricular hypertrophy or vascular remodelling. However following 2weeks 
chronic hypoxia, both right ventricular hypertrophy and vascular remodelling were 
significantly greater than in hypoxic controls despite 5-HTT expression being 
significantly reduced (MacLean et al, 2004). These findings suggested that an increase 
in 5-HTT expression/activity might augment vasoconstriction prior to the onset of 
vascular remodelling. If this was so it could provide valuable insight into the aetiology of 
PAH. Conversely however, it was observed that 5-HTT over-expression substantially
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reduced the potency but not efficacy of the contractile response to 5-HT in the small 
pulmonary artery of the mouse (unpublished observations). Hence in vitro, 5-HTT over- 
expression reduced the contractile activity to 5-HT, presumably by reducing local 5-HT 
concentrations around the 5-HT receptors, but in vivo appeared to increase overall 
contractile activity. This raised the possibility that over-expression of the 5-HTT could 
somehow result in an increase CaS.
6.1.3 Aims
Presently there are no reports of the influence of 5-HT receptor activation or the effect of 
the 5-HTT on CaS in the pulmonary circulation. The aims of this study were therefore 
two-fold: 1) To determine if 5-HT receptor activation can modulate CaS in the Wistar rat 
small pulmonary artery. 2) To determine if over-expression of the 5-HTT causes an 
increase in the CaS of the C57BL/6xCBA mouse small pulmonary artery.
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6.2 Methods
6.2.1 Set up
Small pulmonary arteries (D-class vessels) from chi'onically hypoxic (CH) and age 
matched (AM) control Wistar rats and generation intra-lobar small pulmonary arteries 
(C-class vessels) from C57BL/6xCBA transgenic (TG) and wild type (WT) control mice 
were harvested, set up on the myograph and normalised as described in the general 
methods. Permeabilisation studies were performed at 24®C, whilst general phannacology 
experiments were performed at 37°C (see chapter 2). Rat and mouse vessels were 
permeabilised with 50pM and lOpM p-escin respectively (see chapter 4). The right 
ventricular/total ventricular ratio (RV/TV) was used to assess the development of PH (see 
chapter 2). Subsequent to detennination of the vessels maximum response to a nominally 
iso-osmotic 120mM KCl solution (permeabilisation studies) or a 50mM hyper-osmotic 
KCl addition (general pharmacology), the following experiments were performed.
6.2.2 Study 1) The effect of 5-HT receptor agonists on sensitivity in 
the age matched control and chronically hypoxic Wistar rat, permeabilised 
small pulmonary artery at sub-maximai tone (pCa 6.64)
Permeabilised age matched control and chronically hypoxic vessels were sub-maximally 
constricted in a pCa 6.64 MI solution. When this pre-agonist addition, tone (pre-tone) 
had stabilised, a single dose of lOOpM 5-HT, 5-CT, aMe 5-HT or CP 94253 was added 
and the response observed until it had stabilised. A second dose of 320pM 5-HT, 5-CT, 
aMe 5-HT or CP 94253 was then added and the response observed until it had stabilised. 
5-CT is a non-selective 5-HTi receptor agonist, whilst CP 94253 is a selective 5-HTm 
receptor agonist. aMe 5-HT is a selective 5 -HT2 receptor agonist. Two concentrations of
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each agonist were used as bi phasic responses were observed during initial experiments 
(Fig 6.1).
CD
500s
320uM 5-CT
pCa 6.64
Figure 6.1 Experimental trace showing a bl-phasic response to a single dose of 5CT
This exceptional response implied that 5-HT and 5-CT could activate more than one 5-HT 
receptor subtype. Because of this, preliminary CCRCs to 5-HT and 5-CT were performed at pCa 
6.64 (not shown). These suggested that the maximum constrictor action to 5-HT/5-CT occurred 
at lOOpM and the maximum dilator action at 320pM.
6.2.3 Study 2) Effect of over-expression of the 5-HT transporter on 
sensitivity in the C57BL/6xCBA mouse intra-lobar pulmonary artery
6.2.3.1 Permeabilisation studies
Penneabilised wild type (WT) and transgenic (TG) vessels were exposed to the following 
stepwise increases in free Ca^’*'concentration pCa; 9.9, 7.12, 6.64, 6.16, 5.7, 4.55, 4.0, 2.5. 
Each increase was performed by a solution exchange, where the previous MI solution 
was drained and the vessel washed twice in the following solution. The response was 
then allowed to stabilise before the next solution exchange was performed.
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6.2.3.2 General pharmacology studies
Following the determination of the response to 50mM KCl, cumulative concentration 
response curves (CCRCs) to 5-HT (InM -  O.lmM) were performed in the presence and 
absence of the 5-HTT inhibitor citalopram (0.1 pM) in unpenneabilised wild type and 
transgenic vessels. Vessels not pre-treated with citalopram were then thoroughly washed 
and allowed to return to baseline once more before a CCRC to ET-1 (IpM -  IpM) was 
performed.
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6.3 Results
6.3.1 Study 1) Effect of 5-HT agonists on Ca^  ^ sensitivity in permeabilised 
age matched control and chronic hypoxic Wistar rat small pulmonary 
arteries
6.3.1.1 Effect of 5-HT on sensitivity at pCa 6.64 in age matched control 
vessels
5-HT, a  me 5-HT and 5-CT all failed to significantly modulate CaS at either lOOpM or 
320pM doses (n-6 , all groups, P>0.05, paired t-test). However 3/6 vessels challenged 
with 5-HT and 3/6 vessels challenged with 5-CT did demonstrate a limited modulation of 
CaS. In these vessels 5-HT and 5-CT, caused a small increase in tone at lOOpM which 
was then either sustained (1 / 6  vessels) or followed by a slightly larger decrease in tone at 
320pM (2/6 vessels) (Fig 6.2).
lOOpM CP 94253 did not significantly modulate CaS, however 320pM CP 94253 caused 
a substantial reduction in pre-tone (P/T) of 65 ± 11% (P/T; 0.43 ± 0.09mN vs 320pM; 
0.16 ± 0.05mN, n=6 ), which was significant and observed in all vessels tested (P<0.01, 
paired t-test) (Fig 6.3 and fig 6.4). This equated to 18 ± 4% of F im a x -
6.3.1.2 Effect of 5-HT on sensitivity at pCa 6.64 in chronically hypoxic 
vessels
2  weeks chronic hypoxia did not significantly alter any of the responses observed from 
that observed in control vessels (n=5, all groups, P>0.05, unpaired t-tests). 320pM CP 
94253 caused a reduction of the pre-tone (P/T) by 45 ± 8 % (P/T; 0.40 ± 0.09mN vs 
320pM; 0.23 ± 0.06mN, n=5, P<0.05, paired t-test) (Fig 6.3). This equated to 9 ± 2% of
F im a x *
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Comparison of the age matched control and chronically hypoxic, CP 94253 responses 
when standardised to their paired Fimax suggested the clironically hypoxic response was 
attenuated relative to the control response, however this was not significant (AM; 18 ± 
4% of Fimax n= 6  vs CH; 9 ± 2%, n=5, P>0.05, unpaired t-test) (Fig 6.4). The response 
was compared in this manner so that the change in CaS could be expressed against a 
constant rather than the pCa 6.64 pre-tone, which itself can be modulated by hypoxia as 
was shown in chapter 5.
Mean pre-tone was not significantly different between the any of the age matched control 
groups (n=6 , P>0.05, unpaired ANOVA) or the chronically hypoxic groups (n=5, 
P>0.05, unpaired ANOVA) either expressed in mN or as a percentage of F im a x -  
However, the pre-tone of the age matched control groups was significantly larger than the 
pCa 6.64 pre-tone of the clironically hypoxic groups (AM; 27 ± 2% n=24/6 vs CH; 21 ± 
1 %, n=20/5, P<0.05, unpaired t-test) consistent with the reduction in constitutive CaS 
reported in chapter 5. Vessels form all groups were of comparable internal diameter and 
replicated transmural pressure (n=5-6, P>0.05, unpaired ANOVA). The mean vessel size 
and replicated transmural pressure was 268 ± 5pm and 13.4 ± 0.2mmHg respectively 
(n=44 vessels/11 rats). In completely umesponsive vessels, exposure to IpM ET-1 
caused a significant, 51 ± 5% increase in mean pre-tone (n=8 , P<0.05, paired t-test) 
suggesting the integrity of the signal transduction system was preserved in both age 
matched and chi'onically hypoxic non-responsive vessels. The Cmax index of 
permeabilisation, suggested all the vessels were fully permeabilised (Fcmax; 1 ± 1 % 
greater than Fimax, all groups n=5-6, P>0.05, paired t-test). The RV/TV ratio was 
significantly larger in the chronically hypoxic group consistent with the development of 
PH (AM; 0.233 ± 0.006 vs CH; 0.363 ± 0.013, n=5-6, P<0.0001, unpaired t-test).
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Figure 6.2 Experimental traces showing the effect of 5-HT on Ca^  ^ sensitivity in the Wistar 
rat, small pulmonary artery
A) The typical response to 5-HT, 5CT or aMe 5-HT in age matched control and chronically 
hypoxic vessels. B) Some individual vessels demonstrated the ability to modulate CaS in either 
a bi-phasic or mono-phasic manner to 5-HT or 5-CT but not aMe 5-HT.
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Figure 6.3 The effect of 5-HT agonists on Ca^  ^ sensitivity in the age matched control and 
chronically hypoxic Wistar rat small pulmonary artery
The effect of single dose additions of 5-HT, aMe 5-HT, 5-CT and CP 94253 on CaS at pCa 6.64 
in the A) age matched control rat SPA (n=6, *P<0.01, paired t-test) and B) chronically hypoxic rat 
SPA (n=5, *P<0.05, paired t-test).
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Figure 6.4 The effect of the selective 5-HTib receptor agonist CP 94253 on sensitivity 
in the Wistar rat small pulmonary artery
A) Experimental trace showing a strong response to CP 94253 in an age matched (AM) control 
vessel B) An apparently attenuated response to CP 94253 in a chronically hypoxic (CH) vessel C) 
Bar graph comparing the desensitisation causes by 320pM CP 94253 in AM and CH vessels, 
normalised as a percentage Fimax (pCa 4.55 response). The mean attenuation was not significant 
(n=5-6, P>0.05, unpaired t-test)
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6.3.2 Study 2) Effect of over-expression of the 5-HT transporter on 
sensitivity in the C57BL/6xCBA mouse intra-lobar pulmonary artery
6.3.2.1 Permeabilisation studies
sensitivity was not significantly different between wild type (WT) and transgenic
(TG) mice which over express the 5-HTT at any point on the Ca^ "^  CCRC curve (pEC^o 
values, WT; 6.17 ± 0.02, n=9 vs TG; 6,15 ± 0.02, n - 8 , P>0.05, unpaired t-test) (Fig 6.5).
The vessels from the two groups were of comparable internal diameter and replicated 
transmural pressure (n=8-9, P>0.05, unpaired t-tests). The emax index of 
penneabilisation, suggested all the vessels were fully permeabilised (Fe,nax; < 1  ± 1 % 
greater than Fimax, n=8-9, P>0.05, paired t-test). The RV/TV ratio was not significantly 
different between the wild type and transgenic groups (WT; 0.240 ± 0.004, n=9 vs TG; 
0.242 ± 0.008, n=8 , R>0.05, unpaired t-test) and was not indicative of PH, however all 
transgenic animals were confirmed to over-express 5-HTT by PCR of tail tips.
G.3.2.2 General pharmacology studies
Over-expression of the 5-HTT caused a marked reduction in the potency (pECso: WT; 
7.16 ± 0.08, n~5 vs TG; 5.66 ± 0.05, n=4, P<0.0001, unpaired t-test) but not the efficacy 
(n=4-5, P>0.05 unpaired t-test) of the 5-HT response when compared to wild type 
controls. This effect was substantially but not entirely reversed by incubation with 
0.1 pM citalopram (pECgo: TG; 5.66 ± 0.05, n=4 vs TG +0.1 pM Cit; 6.71 ± 0.07, n=5, 
P<0.0001 unpaired t-test) (pEC50: WT control; 7.16 ± 0.08 vs TG +0.1 pM Cit; 6.71 + 
0.07, n=5, P<0.005 unpaired t-test), however citalopram had no effect whatsoever on the 
wild type response (n=5, P>0.05, unpaired t-test) (Fig 6 .6 ).
The response to ET-1 was not significantly changed with regard to either potency or 
efficacy by over-expression of the 5-HTT (n=4-5, P>0.05 unpaired t-tests) (Fig 6 .6 ).
199
RV/TV data was not obtained as hearts were used in alternative studies, however 5-HTT 
over-expression was confirmed in transgenic animals by PCR of tail tips.
Mean internal diameter and replicated transmural pressure, were not significantly 
different between any of the groups (n=4-5, P>0.05, unpaired ANOVA). The mean vessel 
size and replicated transmural pressure of the mouse vessels used in the permeabilisation 
and phannacology studies was 527 ± 13pm and 13.9 ± 0.2mmHg respectively (n=36 
vessels/27 mice).
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Figure 6.5 The effect of 5-HTT over-expression on sensitivity in the permeabilised 
C57BL/6xCBA mouse intra-lobar pulmonary artery
Experimental traces of Ca^  ^ CCRCs performed in A) Wild type (WT) control mice and B) 
transgenic (TG) mice over-expressing the 5-HTT. C) Graph comparing the Ca^  ^ CCRCs for 
permeabilised WT and TG mouse intra-lobar pulmonary arteries (n=8-9, P>0.05, unpaired t-test). 
Inset shows the right ventricular/total ventricular (RV/TV) ratio (n=8-9, P>0.05 unpaired t-test).
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Figure 6.6 The effect of 5-HTT over-expression on 5-HT and ET-1 pharmacology in the 
isolated unpermeabilised C57BL/6xCBA mouse intra-lobar pulmonary artery
A) 5-HT CCRCs in the wild type (WT) and transgenic (TG) mouse in the presence and absence 
of 0.1 uM citalopram (n=4-5,**P<0.005, ***P<0.0001, unpaired t-test) B) ET-1 CCRCs in the WT 
and TG mouse (n=4-5, P>0.05, unpaired t-test).
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6.4 Discussion
6.4.1 The effect of 5-HT agonists on CaS in the normal and chronically 
hypoxic Wistar rat small pulmonary artery
6.4.1.1 5-HT does not modulate CaS In the rat small pulmonary artery
The data suggest that in p-ecin permeabilised, normal or chronically hypoxic Wistar rat,
small pulmonaiy arteries, 5-HT does not significantly affect CaS, The findings were 
therefore not consistent with increased CaS mediating the enhanced contractile response 
to 5-HT in the unpermeabilised chronically hypoxic rat small pulmonary artery. However 
5-HT did modulate CaS to a limited extent at very high concentrations (100-320pM) in 
some individual vessels (Fig 6.2). These responses were therefore examined using 
selective and non-selective 5-HT receptor agonists in an attempt to separate the 
individual components of the small bi-phasic response and hence determine if two or 
more response signals were opposing one another. In a disease state such as PAH, it is 
possible that selective expression of a single receptor subtype could occur thus favouring 
one of the prospective components (MacLean et a l, 1996b;Keegan et a l, 2001). This 
could unmask an enlianced ability to modulate CaS, as might have occurred in the 
previously reported synergistic responses between 5-CT and ET-1 in unpenneabilised 
vessels (MacLean & Morecroft, 2001).
6.4.1.2 Activation of the 5-HTib/d receptor decreases CaS In the rat small 
pulmonary artery
The mono and bi-phasic responses observed in a small number of vessels challenged with 
either 5-HT or the non-selective 5-HT,/5-HT? receptor agonist 5-CT, were indicative of 
an ability to both increase and decrease CaS in these vessels through either the 5-HT, or 
5-HT? receptors. Interestingly, vessels fi'om the same animal tended to behave in a 
similar manner to 5-HT and 5-CT, but showed no response whatsoever to the 5-HT]
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receptor agonist aMe 5-HT suggesting 5-HT] receptors have no influence CaS even at 
supra maximal concentration. The findings suggest the responses were therefore limited 
to the 5HT,b, 5-HTiD and/or 5-HTv receptors. As the 5-HT? receptor has not yet been 
identified in the rat pulmonary artery it was considered that the response was most likely 
mediated through the 5-HTm/m receptor. The selective 5-HTm receptor agonist CP 
94253 did not influence CaS at concentrations less than lOOpM but caused a substantial 
decrease at 320pM (P<0.01), in all vessels tested, reducing tone to a level similar to that 
reported by the action of the ROK inhibitor Y 27632 in chapter 5.
In vessels which had been exposed to 2weeks chronic hypoxia, the effect of CP 94253 
appeared to be attenuated by -  50% when the responses were normalised to their paired 
Fimax response but this was not significant (P>0,05). Chronic hypoxia is reported to 
increase expression of the 5-HTis in the rat (MacLean et a l, 1996b) and therefore one 
may expect its ability to decrease CaS to be augmented under these conditions. However, 
the findings of chapter 5 (and the comparative levels of pre-tone in the present study) 
suggest that chronic hypoxia down-regulates constitutive CaS in P-escin permeabilised, 
rat small pulmonary arteries. Therefore if the pathway which mediates the CaS response 
to CP 94253 was down-regulated by exposure to 2weeks chronic hypoxia, the potential of 
the 5-HTIB to cause desensitisation might have been limited despite its increased 
expression. Although CP 94253 is a specific 5-HTm receptor agonist, at the 
concentrations required to cause the reported desensitisation response its specificity 
would be doubtful, and its action can therefore only be narrowed to either the 5-HTm or 
5-HTm receptor.
Due to time constraints, the present study did not determine which receptor subtype was 
responsible for the small increase in CaS that was observed in some vessels. However, 
when considered with the augmented desensitisation observed in the presence of CP
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94253, it did raise the possibility that 5-HT and 5-CT were capable of substantial 
modulation of CaS at very high concentrations, but that 2  opposing actions mediated 
through different receptor subtypes may typically resulted in no net change of CaS. This 
would require the use of specific 5HTm and 5-HTm antagonists in the presence of 5-HT 
or 5-CT to determine if a significant increase in CaS can be unmasked under these 
conditions.
6.4.2 The effect of over-expression of the 5-HTT on CaS in the 
C57BL/6xCBA mouse small pulmonary artery
Over-expression of the 5-HTT had no effect on the Ca^  ^CCRCs in permeabilised mouse 
vessels suggesting basal CaS was completely unaffected. This was consistent with the 
results of the ET-1 general pharmacology experiment in unpermeabilised mouse vessels, 
which found the response to be unchanged by 5-HTT over-expression. In contrast, the 
potency of the 5-HT CCRC contractile response in unpermeabilised vessels was 
attenuated some thirty-fold by over-expression of the 5-HTT. This attenuation was 
substantially although not entirely, reversed by citalopram. Citalopram has only trivial 
effects on CaS (unpublished study, not shown) and therefore its effect was believed to be 
due to its action as a selective serotonin re-uptake inliibitor (Wanstall et a l, 2003). 
Hence it is hypothesised that 5-HTT over-expression caused a localised reduction in 5- 
HT concentration around the 5-HT cell surface receptors, which was virtually reversed by 
citalopram. The findings of this study are therefore contrary to over-expression of the 5- 
HTT causing and elevation in PAP through an increase in CaS of the contractile 
apparatus. Furthermore over-expression of 5-HTT did not cause an increase in the 
overall contractile responsiveness to 5-HT or ET-1 and therefore the enhanced PAP 
associated with 5-HTT over-expression cannot be explained by the findings of this study.
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6.4.3 Conclusion
The findings of this study are not consistent with 5-HT mediating a change in CaS in the 
control or chronically hypoxic rat, or 5-HTT over-expression modulating CaS in the 
mouse. However, selective activation of the 5-HTib receptor demonstrated that CaS can 
be modulated by selective 5-HT agonists.
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Chapter 7
General conclusion
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7.1 Conclusion
7.1.1 Re-statement of aims
The initial aims of this thesis were: 1) To determine the role of human iirotensin II (hU- 
II) in the regulation of pulmonaiy vascular tone and whether hU-II could be involved in 
the aetiology of pulmonary arterial hypertension (PAH). 2) To determine the role of Ca^ "^  
sensitivity (CaS) in the regulation of pulmonary vascular tone and to determine whether 
modulations in CaS could be involved in the aetiology of PAH. The two areas chosen for 
study where pulmonary hypertension (PH) secondary to chronic hypoxia and the 5-HT 
system.
7.1.2 hU-ll and the regulation of pulmonary arterial tone
hU-II was found to be a potent but low efficacy vasoconstrictor of normal rat, extra-lobar 
and 1 st generation intra-lobar pulmonary arteries but had no action in any mouse or 
human vessels tested. The constrictor response was generally not augmented in rat 
models of PAH. The findings of this thesis are therefore not consistent with a role for hU- 
II in the aetiology of PAH.
7.1.3 Ca^  ^sensitivity and the regulation of pulmonary arterial tone
A permeabilisation protocol was successfully developed, which permitted the study of the
phenomenon of Ca^  ^sensitisation in the Wistar rat small pulmonary artery. The protocol 
consistently yielded fully permeabilised small pulmonary arteries with intact 2 "^  
messenger systems. Furthermore the maximum contractile response of the permeabilised 
preparations was typically seven-fold greater than previously had been reported (Evans et 
a l, 1999).
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Rho kinase was found to be constitutively active in normal rat small pulmonary arteries 
resulting in an enhanced level of CaS in these vessels, which was subsequently attenuated 
following 2weeks chronic hypoxia. This finding suggested that changes in constitutive 
CaS occur in the chronically hypoxic rat model of PAH and warrant fiirther investigation, 
especially with regard to the exposure period to hypoxia.
5-HT did not modulate CaS in the normal or chronically hypoxic rat small pulmonary 
artery. Therefore the reported enhanced contractile responses to 5-HT following 2weeks 
exposure to chronic hypoxia are not mediated through an increase in CaS. However 
activation of the 5-HTmm receptor using the selective agonist CP did significantly 
attenuate CaS suggesting further investigation using selective antagonists is warranted. 
Over-expression of the 5-HT transporter (5-HTT) was not foimd to modulate CaS in the 
mouse small pulmonary artery. Pharmacological studies in the mouse, suggested the 
effect of the 5-HTT on the 5-HT vasoconstrictor profile, was primarily mediated by its 
impact on local 5-HT concentrations around the cell surface receptors.
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Appendix
Health and Safety assessment
Questionnaire on the Use of Human Tissues in Research
Name o f  Research Group P u lm o n a r y  v a s c u l a r  
Group Leader P r o f .  MR M acL ean
Senior Technician M rs L y n n  L a u g h l in ,
Laboratory Location L a b  5 0 1  WMB
1 Docs your laboratory carry out experiments with human tissues? Yes
1 r e s e c t e d  hu m an  l u n g :  p u l m o n a r y  a r t e r i e s / a i r w a y s
2 h u m a n  a b d o m in a l  a r t e r i e s
2 Do you have any stored human tissue? Yes
3 Do you have any plans to work with human tissues? Yes
If you have answered Yes to any o f the above questions, please answer also the remaining 
questions. Otherwise thi^ section o f  the form can be disregarded,
4 Has everyone in your group read the new guidelines and received
appropriate instruction in the use, storage and disposal o f  human tissues? Yes
5 If  the answer to Q4 is No, then please indicate when you plan to carry out
the training and have the forms confirming that this has taken place completed.
Date.
6 Please indicate specifically where you have human tissues stored and the nature 
o f  the tissue stored.
L i q u i d  N i t r o g e n  s t o r a g e ;  p u l m o n a r y  a r t e r i e s
7 Please indicate how you intend to dispose o f  tissue once your investigations
are complete. T i s s u e  i s  d o u b l e - b a g g e d  a n d  t r a n s p o r t e d  t o  t h e  
B i o h a z a r d  b i n  a t  t h e  W e s t e r n  I n f i r m a r y  G la s g o w  f o r  i n c i n e r a t i o n .  A  
f u l l  r e c o r d  i s  k e p t  i n  t h e  l a b o r a t o r y .
Full details o f the type o f tissue, the method o f disposal and the date o f disposal must be kept by the research group leader and should be fonwrded to Paul Phillips.
8 Please provide documentary evidence (photocopies) that the appropriate ethical 
perm issions have been obtained.
A t t a c h e d :
-  W e s t  E t h i c s  C o m m it te e  a p p r o v a l  (0 0 ^ 3 7 )  f o r  i n g u i n a l  h e r n i a
b i o p s i e s  ( f o r  p r o v i s i o n  o f  a b d o m i n a l  a r t e r i e s )
~ W e s t  E t h i c s  c o m m i t t e e  a p p r o v e d  p a t i e n t  c o n s e n t  f o r m  f o r  u s e  o f
r e s e c t e d  l u n g  t i s s u e .
Com pleted by:: D a te :............
H;\Docs\jny mfoVHuman tissue questionnaire FEB 01.doc
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West Glasgow Hospitals ethics committee approval
West Glasgow Hospitals
PART OF THE NORTH GLASGOW UNIVERSITY HOSPITALS NHS TRUST
Our Ref; 
Your Ref:
AHT
Please reply to: Mrs A H Torrie
SECRETARY - WEST ETHICS COMMITTEE
18 April, 2000
■ Dr Colin Berry 
MRC Clinical Training Fellow 
Department of Medicine 
Western Infirmary
WEST ETHICS COMMITTEE 
Western Infirmary 
Dumbarton Road 
Glasgow G11 6NT
Direct Line: 211 6238 
Fax: 211 1920
Dear Colin, 
00/37(2) Dr C Berry et al - An investigation of the vasopressor effect of 
urotensin compared with other known vasoconstrictor molecules in 
human resistance arteries In healthy volunteers.
The Committee at the meeting held today ratified Chairman’s approval but wished to draw to 
your attention that the protocol submitted contains an error i.e. that the biopsies will not be gluteal, 
they are in fact inguinal hernia biopsies. The amendment should come back to the secretary for filing. 
This study now has fiill and unqualfied Ethics Committee approval.
Please note that the approval contained in this letter is valid for all sites which form part of the North 
Glasgow Trust. If however, this research is to be carried out at sites within the North Glasgow Trust 
other than the one covered by this letter, then a covering letter signed by the person responsible for the 
research on that site, should be sent listing names, titles and addresses of all collaborating researchers. 
A copy of this approval letter should be passed to them.
It should be noted that although Ethics Committee approval has been granted, Trust Management 
approval is still required. This should be obtained through the Research and Development Office at 
Gartnavel General Hospital (tel: 211 0115).
Kind regards.
Yours sincerely.
V
Andrea H Torrie
SECRETARY - WEST ETHICS COMMITTEE
Incorporating the W estern  Infirmary, G artnavel General Hospital,
The G la sg o w  H o m o eo p a th ic  Hospital, Drum chapel Hospital and Blawarlhili Hospital
211
Patient consent form
West Glasgow Hospitals
DEPARTMENT OF CARDIOTHORACÏC SURGERY
CONSENT FORM FOR PERÎvnSSION TO USE RESECTED LUNG TISSUE 
FOR RESEARCH PURPOSES IN PATIENTS UNDERGOING LUNG
OPERATIONS
As it will have been explained to you, you are about to undergo an operation to 
remove all, or part of, your lung. Doctors in the Pathology Department will perform a 
number of tests on the tissue that is removed during the operation. This will allow 
your surgeon to give you a diagnosis and prognosis and guide you if any other 
treatment is required. Once they have completed their examination, the tissue is 
normally discarded.
Because we are constantly engaged in research ourselves and in collaboration with 
others, we are seeking your permission to use some of this tissue that is normally 
discarded. This would be used in a number of ongoing projects designed to investigate 
cancer and in detailing the anatomy & physiology of the blood vessels within the 
lung.
If you wish your resected tissues to be used in this way, the following guarantees will 
be given:
• No tissue will be removed apart from what is deemed necessary for your 
operation as decided by your surgeon,
• Sampling of tissue will not prejudice in any way the results of your operation 
or affect the ability of the pathologist to produce an accurate report.
• Samples used for research will be removed firom tissue that would normally be 
discarded.
• In cases of cancer research, small samples may be frozen and stored to allow 
tests to be done at a future date.
Should you not wish tissues'to be removed, this will not affect your treatment in any 
way.
ncorporating th e  W estern  Infirmary, G artnavel G en era l H ospital,
‘h e  G la sg o w  H o m o e o p a th ic  Hospital, D rum chapel H ospital and  BlawarlhiliTtospital
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Details of the current research projects and the project leaders are to be found below. 
The ultimate responsibility rests however with your surgeon to whom all queries 
should be addressed.
The pharmacology of endogenous vasOactive factors In human pulmonary arteries. 
Supervisor: Professor M MacLean, University of Glasgow
Molecular markers of chemosensitivity in non-small cell lung cancer.
Supervisor: Professor R Brown, Beatson Institute
The physiology of human pulmonary vasculature.
Supervisor: Dr. AJ Peacock, Western'Infirmary, Glasgow.
These projects have been approved by the Research Sc Ethics Committee for North 
Glasgow Hospitals University Trust.
CONSENT
I,.................................................... consent to the use of any tissues removed from me
during my lung operation to be used for the purposes of research, I have read the 
notes above and understand them. I appreciate that under certain circumstance it may 
be necessary to store some tissue samples for analysis at a later date.
Patient signature; ...................     Date:
Surgeon’s name: .............................................
Surgeon’s signature:  ...........................   Date:
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Guidelines for the use of human tissue
Use of Human Tissue -Prof.M MacLean % Lab
1- All tissue that enters the lab must be logged in the Human Tissue Log Book;
# Date
#Age
#Organ
#Dlsease Type
#Hospltal of origin
#Reference number
2“ Date and name of person who collected tissue must be recorded on sheet on wall.
3- Photocopy of concent form must be placed in folder in drawer that contains Log book.
4- Gloves must be worn at all times,however they must be removed before handling other 
equipment.
5- When using the microscope the handles must be covered in nesco film for adjustment.
6- Work area must be covered in benchcote.all instruments,tissues cottonbuds must be 
contained on benchkote.
7“ All waste must be placed in the yellow waste bags which should be taped next to work
area.The waste should be taken that day to the Hospitial for disposal and the person 
responsible sign the^disposal sheet.
8" All instruments used must be decontaminated for 45-60minutes but no longer in Virkon 
Soln 10% in Water, A designated tub has been labelled for this use.Plastlc containers 
used for transport must be soaked in the same soln overnight before being placed in wash 
tub.
9- Lab worker who do not follow above guide lines will not be allowed to work with Human 
tissue.
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